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A B S T R A C T
Background
Allergic rhinitis is a common condition affecting both adults and children. Patients experience symptoms of nasal obstruction, rhinor-
rhoea, sneezing and nasal itching, which may affect their quality of life.
Nasal irrigation with saline (salty water), also known as nasal douching, washing or lavage, is a procedure that rinses the nasal cavity
with isotonic or hypertonic saline solutions. It can be performed with low positive pressure from a spray, pump or squirt bottle, with a
nebuliser or with gravity-based pressure in which the person instils saline into one nostril and allows it to drain out of the other. Saline
solutions are available over the counter and can be used alone or as an adjunct to other therapies.
Objectives
To evaluate the effects of nasal saline irrigation in people with allergic rhinitis.
Search methods
The Cochrane ENT Information Specialist searched the ENTTrials Register; CENTRAL; OvidMEDLINE; Ovid Embase; CINAHL;
Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. The date of the search was 23
November 2017.
Selection criteria
Randomised controlled trials (RCTs) comparing nasal saline irrigation, delivered by any means and with any volume, tonicity and
alkalinity, with (a) no nasal saline irrigation or (b) other pharmacological treatments in adults and children with allergic rhinitis. We
included studies comparing nasal saline versus no saline, where all participants also received pharmacological treatment (intranasal
corticosteroids or oral antihistamines).
Data collection and analysis
We used the standard methodological procedures expected by Cochrane. Primary outcomes were patient-reported disease severity and a
common adverse effect - epistaxis. Secondary outcomes were disease-specific health-related quality of life (HRQL), individual symptom
scores, general HRQL, the adverse effects of local irritation or discomfort, ear symptoms (pain or pressure) and nasal endoscopy scores.
We used GRADE to assess the quality of the evidence for each outcome; this is indicated in italics.
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Main results
We included 14 studies (747 participants). The studies included children (seven studies, 499 participants) and adults (seven studies, 248
participants). No studies reported outcomes beyond three months follow-up. Saline volumes ranged from ’very low’ to ’high’ volume.
Where stated, studies used either hypertonic or isotonic saline solution.
Nasal saline versus no saline treatment
All seven studies (112 adults; 332 children) evaluating this comparison used different scoring systems for patient-reported disease
severity, so we pooled the data using the standardised mean difference (SMD). Saline irrigation may improve patient-reported disease
severity compared with no saline at up to four weeks (SMD -1.32, 95% confidence interval (CI) -1.84 to -0.81; 407 participants;
6 studies; low quality) and between four weeks and three months (SMD -1.44, 95% CI -2.39 to -0.48; 167 participants; 5 studies;
low quality). Although the evidence was low quality the SMD values at both time points are considered large effect sizes. Subgroup
analysis showed the improvement in both adults and children. Subgroup analyses for volume and tonicity were inconclusive due to
heterogeneity.
Two studies reported methods for recording adverse effects and five studies mentioned them. Two studies (240 children) reported no
adverse effects (epistaxis or local discomfort) in either group and three only reported no adverse effects in the saline group.
One study (48 children) reported disease-specific HRQL using a modified RCQ-36 scale. It was uncertain whether there was a
difference between the groups at any of the specified time points (very low quality). No other secondary outcomes were reported.
Nasal saline versus no saline with adjuvant use of intranasal steroids or oral antihistamines
Three studies (40 adults; 79 children) compared saline with intranasal steroids versus intranasal steroids alone; one study (14 adults)
compared saline with oral antihistamines versus oral antihistamines alone. It is uncertain if there is a difference in patient-reported
disease severity at up to four weeks (SMD -0.60, 95% CI -1.34 to 0.15; 32 participants; 2 studies; very low quality) or from four
weeks to three months (SMD -0.32, 95% CI -0.85 to 0.21; 58 participants; 2 studies; very low quality). Although none of the studies
reported methods for recording adverse effects, three mentioned them: one study (40 adults; adjuvant intranasal steroids) reported no
adverse effects (epistaxis or local discomfort) in either group; the other two only reported no adverse effects in the saline group.
It is uncertain if saline irrigation in addition to pharmacological treatment improved disease-specific HRQL at four weeks to three
months, compared with pharmacological treatment alone (SMD -1.26, 95% CI -2.47 to -0.05; 54 participants; 2 studies; very low
quality). No other secondary outcomes were reported.
Nasal saline versus intranasal steroids
It is uncertain if there was a difference in patient-reported disease severity between nasal saline and intranasal steroids at up to four
weeks (MD 1.06, 95% CI -1.65 to 3.77; 14 participants; 1 study), or between four weeks and three months (SMD 1.26, 95% CI -0.92
to 3.43; 97 participants; 3 studies), or indisease-specific HRQL between four weeks and three months (SMD 0.01, 95% CI -0.73
to 0.75; 83 participants; 2 studies). Only one study reported methods for recording adverse effects although three studies mentioned
them. One (21 participants) reported two withdrawals due to adverse effects but did not describe these or state which group. Three
studies reported no adverse effects (epistaxis or local discomfort) with saline, although one study reported that 27% of participants
experienced local discomfort with steroid use. No other secondary outcomes were reported.
Authors’ conclusions
Saline irrigation may reduce patient-reported disease severity compared with no saline irrigation at up to three months in both adults
and children with allergic rhinitis, with no reported adverse effects. No data were available for any outcomes beyond three months.
The overall quality of evidence was low or very low. The included studies were generally small and used a range of different outcome
measures to report disease severity scores, with unclear validation. This review did not include direct comparisons of saline types (e.g.
different volume, tonicity).
Since saline irrigation could provide a cheap, safe and acceptable alternative to intranasal steroids and antihistamines further high-
quality, adequately powered research in this area is warranted.
P L A I N L A N G U A G E S U M M A R Y
Nasal saline for allergic rhinitis
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Background
Allergic rhinitis is inflammation (swelling and/or irritation) of the inside of the nose caused by allergies. It is common in both children
and adults. Allergic rhinitis can be intermittent (fewer than four days per week, or four weeks per year) or persistent (more than four
days per week, or four weeks per year). The allergy can be caused by many different things but common allergens (things causing allergy)
are: grass or tree pollen, mould, dust mites or animal dander (tiny flakes of skin). People with allergic rhinitis experience symptoms
(nasal obstruction, runny nose, nasal itching and sneezing) that may affect their quality of life.
Nasal saline irrigation (also known as nasal douche, wash or lavage) is a procedure that rinses the nasal cavity with saline (salt water)
solutions. How saline works is not fully understood but it is probably through making the mucus (snot) thinner, making it easier to
remove and also removing some of the allergens from the nose that cause irritation. Nasal saline irrigation can be performed with sprays,
pumps or squirt bottles. Saline solutions can be isotonic (the same concentration of salt that is found in the body - 0.9% NaCl) or
hypertonic (more salty than found in the body - more than 0.9% NaCl). Although saline irrigation is thought to be safe there have
been reports of epistaxis (nosebleeds) and irritation or discomfort in the nose and ears. This therapy is available without prescription
and can be used alone or as an add-on to other pharmacological treatment for allergic rhinitis, such as intranasal (in the nose) steroids
and oral antihistamines).
Search date
The evidence is up to date to November 2017.
Study characteristics
We found 14 studies with a total of 747 participants (260 adults; 487 children). The volume of saline used in the studies varied: five
studies used ’very low’ volumes (nasal sprays providing less than 5 mL saline per nostril per application), two studies used low-volume
(between 5 and 59 mL saline per nostril per application introduced with a syringe) and four studies used high-volume solutions (more
than 60 mL per nostril per application). Eight studies used hypertonic saline, five used isotonic saline and three studies did not provide
this information. Two studies used two different types of saline solutions.
Study funding sources
Seven studies did not say how they were funded. The other seven were funded either by the investigators’ department or research grants
from regional or national government. No studies were funded by pharmaceutical companies.
Key results
Nasal saline irrigation compared with no saline irrigation
Nasal saline irrigation may have benefits in both adults and children in relieving the symptoms of allergic rhinitis compared to no saline
irrigation and it is unlikely to be associated with adverse effects. It is not possible to tell from this review whether there is a difference
between the different volumes and concentrations of saline solution.
Adding nasal saline irrigation onto ’pharmacological’ allergic rhinitis treatment
It is uncertain whether adding nasal saline irrigation to pharmacological treatment (intranasal steroids or oral antihistamines) helps to
improve the symptoms of allergic rhinitis compared to using pharmacological treatments alone. The use of nasal saline irrigation is
unlikely to be associated with adverse effects.
Nasal saline irrigation compared to ’pharmacological’ allergic rhinitis treatment
There is not enough evidence to know whether nasal saline irrigation is better, worse or the same as using intranasal steroids. No studies
reporting the outcomes we were interested in compared nasal saline irrigation with oral antihistamines.
Quality of evidence
The overall quality of evidence for nasal saline irrigation compared with no saline treatment was eitherlow quality (our confidence in
the effect estimate is limited: the true effect may be substantially different from the estimate of the effect) or very low quality (we have
very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect). This was
because the studies were mostly very small and used different methods to measure the same outcome. Since saline irrigation could
provide a cheap, safe and acceptable alternative to intranasal steroids and antihistamines further high-quality studies are needed.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Saline versus no saline treatment for allergic rhinitis
Patient or population: allergic rhinit is
Setting: secondary care
Intervention: saline
Comparison: no saline treatment
Outcomes Relative effect
(95% CI)
Anticipated absolute effects∗ (95% CI) Certainty of the evidence
(GRADE)
What happens
Without saline With saline Difference
Disease severity score
(up to 4 weeks)
Assessed with: various
instruments
Follow-up: range 1
week to 4 weeks
of part icipants: 407
(322 children; 85
adults)
(6 RCTs) 2
- - - SMD 1.32 lower
(1.84 lower to 0.81 lower)
⊕⊕©©
LOW 1
Saline irrigat ion may im-
prove the pat ient-reported
disease severity compared
with no saline treatment in
both children and adults.
The mean dif ference in dis-
ease severity score was
1.32 standard deviat ions
lower (1.84 to 0.81 lower)
with saline compared to
no saline. This translates
into a decrease of approxi-
mately 1.97 points (1.21 to
2.74) on a 0- to 10-point
VAS for nasal symptoms
(lower = better)
Disease severity score
(4 weeks to 6 months)
Assessed with: various
instruments
Follow-up: range 6
weeks to 8 weeks
of part icipants: 167
- - - SMD 1.44 lower
(2.39 lower to 0.48 lower)
⊕⊕©©
LOW 1
Saline irrigat ion may im-
prove the pat ient-reported
disease severity compared
with no saline treatment in
both children and adults.
The mean dif ference in dis-
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(102 children; 65
adults)
(5 RCTs) 2
ease severity score was
1.44 standard deviat ions
lower (2.39 to 0.489 lower)
with saline compared to
no saline. This translates
into a decrease of approxi-
mately 2.98 points (0.99 to
5.98) on a 0- to 10-point
VAS for nasal symptoms
(lower = better)
Individual symptom
scores - not measured
- - No studies measured this
outcome.
Epistaxis
Follow-up: range 4
weeks to 6 weeks
of part icipants: 240
(all children)
(2 RCTs)
Not pooled Study populat ion ⊕⊕©©
LOW 3
2 studies (240 children) re-
ported no adverse ef fects
in either arm. Both studies
included only children
0% Not pooled Not pooled
Disease-specif ic HRQL
Assessed with: RCQ-36
quality of lif e quest ion-
naire
Scale f rom: 0 to 140,
lower = better
Follow-up: 4 weeks
of part icipants: 42 (all
children)
(1 RCT)
- The mean disease spe-
cif ic HRQL - Up to 4
weeks without saline
was 19.26
- MD 3.32 lower
(11.35 lower to 4.71 higher)
⊕©©©
VERY LOW 4
It is uncertain whether
saline improves the dis-
ease-specif ic quality of lif e
at 4 weeks, compared with
no saline, because the qual-
ity of the evidence is very
low. The study included
only children
Disease-specif ic HRQL
- 4 weeks to 6 months
Assessed with: RCQ-36
Scale f rom: 0 to 140
follow-up: 6 weeks
of part icipants: 42 (all
- The mean disease spe-
cif ic HRQL - 4 weeks to
6 months without saline
was 15.94
- MD 2.06 lower
(8.38 lower to 4.26 higher)
⊕©©©
VERY LOW 4
It is uncertain whether
saline improves the dis-
ease-specif ic quality of lif e
at 6 weeks, compared with
no saline, because the qual-
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children)
(1 RCT)
ity of the evidence is very
low. The study included
only children
Other adverse ef fects:
local irritat ion
Follow-up: range 4
weeks to 6 weeks
of part icipants: 240
(all children)
(2 RCTs)
Not pooled Study populat ion ⊕⊕©©
LOW 3
2 studies (240 children) re-
ported no adverse ef fects
in either arm. 3 further stud-
ies (68 children; 44 adults)
reported no adverse ef fects
in the saline arm. There is
no information for the con-
trol arm0% Not pooled Not pooled
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; HRQL: health-related quality of lif e;MD: mean dif ference; RCQ-36: Thai rhinoconjunct ivit is quality of lif e scale; RCT: randomised controlled trial; SMD:
standardised mean dif ference; VAS: visual analogue scale
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Low-quality evidence. Downgraded by one level due to risk of bias (all of the studies used dif ferent scales for which the
validat ion is unknown). Downgraded by one level due to inconsistency (there is stat ist ical heterogeneity within the results
possibly due to the variat ions in tonicity, volume and method of applicat ion of saline used).
2Dif ferent instruments were used to assess the disease severity score. A summary of these can be found in Table 2.
3Low-quality evidence. Downgraded by two levels due to risk of bias (the report ing of the adverse outcomes was very poor
and it was unclear whether the adverse ef fects were systematically sought).
4Very low-quality evidence. Downgraded by two levels for risk of bias (results came f rom one study using an instrument for
which the validat ion status is unknown with a high risk of performance and detect ion bias). Downgraded by one level for
imprecision (the results are imprecise due to the small sample size and the conf idence intervals are very wide).
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B A C K G R O U N D
Description of the condition
According to the Allergic Rhinitis and its Impact on Asthma
(ARIA) guidelines (ARIA 2008), allergic rhinitis is defined clini-
cally by nasal hypersensitivity symptoms induced by an immuno-
logically mediated (most often IgE-dependent) inflammation of
the nasal mucous membranes after exposure to an offending aller-
gen. Common allergic triggers include house dust mites, pollens
(from trees, grasses, shrubs and weeds), animal dander or fungi,
which occur naturally in the environment. In addition, allergic
rhinitis can be caused by triggers to which a person is exposed in
the course of their work (occupational exposure). These may in-
clude vegetable proteins, enzymes and chemicals (BSACI 2017).
Symptoms of allergic rhinitis may include nasal obstruction
(blockage or congestion), rhinorrhoea (which can be anterior lead-
ing tonasal discharge, or posterior leading to post-nasal drip), nasal
itching and sneezing (ARIA 2008). In addition to nasal symptoms,
some people with allergic rhinitis also report eye symptoms (wa-
tering, redness, itching) and ear symptoms such as pain, pressure
or feeling of fullness; however, aural (ear) symptoms have also been
reported as an adverse effect of nasal saline irrigation (Chusakul
2013). There is evidence that people with allergic rhinitis may
experience decreased quality of life due to issues such as loss of
sleep, secondary daytime fatigue, impaired school and work per-
formance, decreased cognitive functioning and decreased long-
term productivity (Schoenwetter 2004).
Allergic rhinitis is commonly classified into ’intermittent’ and ’per-
sistent’ disease. Intermittent allergic rhinitis is diagnosed when
symptoms are present for less than four days per week or for
less than four weeks. Persistent allergic rhinitis is diagnosed when
symptoms are present more frequently than four days per week
and for at least four consecutive weeks (ARIA 2008). The presence
of intermittent or persistent disease may be related to the type of
allergic triggers for allergic rhinitis, for example intermittent aller-
gic rhinitis may be linked to the release of a certain type of tree
pollen (such as elm tree pollen) occurring once a year for a period
of a few weeks.
Prior to 2001, allergic rhinitis was classified into ’seasonal’, ’peren-
nial’ and ’occupational’, based on the time of exposure. Seasonal
allergic rhinitis was used to define mainly ’outdoor’ allergens such
as tree pollens, which were not present consistently throughout
the year, whereas the term ’perennial’ allergic rhinitis was used
for ’indoor’ allergens where exposure was thought to be consis-
tent throughout the year. The ARIA 2001 guidelines attempted to
make the classification more useful in the real world by introduc-
ing the terms ’intermittent’ and ’persistent’ to classify the disease.
The previous classification had been felt to be inadequate as it was
noted that in certain situations a seasonal allergen may occur year
round (e.g. grass pollen allergy in Southern California) or symp-
toms of perennial allergy may not always be present all year round
(e.g. in the Mediterranean area where levels of house dust mite
allergen are low in the summer). Thus the change to intermittent
and persistent was made (ARIA 2001).
The ARIA guidelines further classify allergic rhinitis into ’mild’
and ’moderate/severe’ depending on the person’s severity of symp-
toms and the impact of the condition on their quality of life.
Moderate/severe allergic rhinitis is diagnosed when one or more
of the following items are present: sleep disturbance; impairment
of daily activities, leisure or sport; impairment of school or work;
or troublesome symptoms (ARIA 2008).
The diagnosis of allergic rhinitis is based upon clinical symptoms
combined with laboratory studies demonstrating the presence of
allergen-specific IgE in the skin (skin prick test) or blood (serum
IgE). A review of epidemiological studies estimated that 10% to
15% of adults have allergic rhinitis based on both the presence of
symptoms and a positive skin prick test (Mims 2014). However,
the number is higher when people reporting either just symptoms
(up to 34%) or a positive skin prick test (up to 53.9%, testing 10
allergens) are considered (Mims 2014). There are a wide range of
estimates for the prevalence of allergic rhinitis in children (10% to
40%). These differences in estimates may be attributable to both
the geographical location of the study, the method of diagnosis
used (whether a skin prick test was completed or whether the
diagnosis was based on symptoms), or both (Mims 2014).
Traditionally there has appeared to be a higher prevalence of al-
lergic rhinitis in countries with a ’western lifestyle’ (USA and Eu-
rope), where reported prevalence rates vary between 10%and 30%
(ARIA 2008). For areas outside these regions, Katelaris et al com-
pleted a review of global prevalence studies, which identified a
great diversity in the prevalence estimates of allergic rhinitis both
between and within countries (Katelaris 2012). The review con-
cluded that “the prevalence of allergic rhinitis is increasing and
its adverse impact on the quality of life of affected individuals is
increasingly recognised” (Katelaris 2012). The increase in preva-
lence has been hypothesised as being due to increasing urbanisa-
tion and modification of lifestyles, which has led to reduced expo-
sure to environmental allergens during early childhood resulting
in a weaker immune system and consequent development of aller-
gies, commonly known as the ’hygiene hypothesis’ (ARIA 2008).
There is a well-established link between allergic rhinitis and
asthma. A literature review identified that 40% of patients with
allergic rhinitis had asthma (Kim 2008). The proportion of pa-
tients with asthma reporting symptoms of allergic rhinitis ranged
from 30% to 80%. This connection is perhaps unsurprising as
both allergic rhinitis and asthma are based on shared physiologi-
cal immune responses to an identified foreign substance (allergen)
(Kim 2008).
Treatment options for allergic rhinitis include allergen avoidance,
pharmacological therapy and immunotherapy. Pharmacological
therapies include various classes of medications, including anti-
histamines, intranasal corticosteroids and anti-leukotrienes (ARIA
2008). Nasal saline has been used as a ’natural’ remedy for cen-
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turies and recent Cochrane Reviews have evaluated its efficacy
as a potential treatment or adjunct to pharmacological treatment
for chronic rhinosinusitis and upper respiratory tract infections
(Chong 2016; King 2015).
Description of the intervention
Saline can be deposited in the nasal cavity in various forms, includ-
ing sprays, drops, nebulisers and irrigations. The volume of nasal
saline from sprays and nebulisers can vary greatly. These can be
very low-volume devices (< 5 mL per nostril) through to squeeze
bottles and Neti pots, which are usually high-volume devices (> 60
mL). While nasal saline sprays reach the nasal cavity adequately,
there is some evidence to suggest that high pressure and volume
saline is more effective in penetrating the adjacent sinus cavities
(Wormald 2004).
The saline solutions available are hypotonic (with a concentration
of less than 0.9% NaCl), physiologic (with a concentration of
0.9% NaCl) and hypertonic (with a concentration of greater than
0.9% NaCl). There is some evidence in other conditions that
the tonicity of the saline solution alters its efficacy (Berjis 2011;
Rabago 2005). In addition, the pH of saline solutions has been
investigated and there is some evidence that solutions buffered
with sodiumbicarbonate (increased alkalinity)may have an impact
on the nasal symptoms of people with allergic rhinitis (Chusakul
2013).
How the intervention might work
The physiological mechanisms underlying any benefit of the use of
nasal saline are not fully understood but it is commonly proposed
that the primary mechanism of action is mechanical (Barham
2015). This may include clearance of mucus (saline thins mucus
and helps to clear it out) (Elkins 2011), and removal of airborne al-
lergens and inflammation mediators such as histamine (Georgitis
1994). There is some evidence to suggest that at some concentra-
tions nasal saline may improve ciliary beat function (Bonnomet
2016) and mucociliary function (Hermelingmeier 2012). Adverse
effects of nasal saline irrigation are thought to be rare and generally
mild but may include ear fullness, stinging of the nasal mucosa
and epistaxis (nosebleed) (Khianey 2012).
Why it is important to do this review
Allergic rhinitis is a highly prevalent condition in adults and chil-
dren, with a large impact on patients and high healthcare costs:
both direct, from the cost of repeat healthcare visits and of chronic
medical therapy, and indirect, via absenteeism and lost productiv-
ity (Schoenwetter 2004).
PreviousCochrane Reviews have demonstrated some possible ben-
efit of saline in adults with chronic rhinosinusitis (Chong 2016)
and in people with upper respiratory tract infections (King 2015).
The two most recent systematic reviews identified on the use of
nasal saline in allergic rhinitis had latest search dates of 2010
(Hermelingmeier 2012) and December 2011 (Khianey 2012).
Khianey 2012 limited their inclusion criteria to studies published
in English and also included studies in populations with a range
of different sinonasal conditions including upper respiratory tract
infection and chronic rhinosinusitis. Hermelingmeier 2012 spec-
ified the population as people with seasonal or perennial allergic
rhinitis. This review looked at prospective trials (including before
and after studies) and only included studies published in English
or German. Both reviews identified potential benefits for people
in terms of symptom improvement and found that saline irriga-
tion was well tolerated, but both reviews highlighted the need for
further research in this area in order for definitive conclusions to
be drawn. This review will include recently published studies and
we will apply no restriction with regard to language of publication.
O B J E C T I V E S
To evaluate the effects of nasal saline irrigation in people with
allergic rhinitis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included studies with the following design characteristics:
• randomised controlled trials, including cluster-randomised
trials and quasi-randomised trials, and cross-over trials if the data
from the first phase were available;
• participants were followed up for at least two weeks.
We excluded studies with the following design characteristics:
• randomised participants by side of nose (within-patient
controlled) because it is difficult to ensure that the effects of any
of the interventions considered can be localised; or
• perioperative studies, where the sole purpose of the study
was to investigate the effect of nasal saline irrigation on surgical
outcomes.
Types of participants
Patients (adults and children) with clinical symptoms character-
istic of allergic rhinitis with a positive radioallergosorbent test
(RAST) or skin prick test (SPT).
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We excluded studies that included a majority (more than 50%)
of participants with:
• non-allergic rhinitis;
• chronic rhinosinusitis;
• acute sinusitis;
• cystic fibrosis;
• immunotherapy started within the prior year;
• any alteration of allergic rhinitis-specific pharmacotherapy
(antihistamines, intranasal corticosteroids, anti-leukotrienes)
during the trial;
• aspirin-exacerbated respiratory disease;
• surgery for turbinate reduction within three months prior
to study.
Had we found a study that included a mixed group of partici-
pants, we would have excluded it if more than 50% of the par-
ticipants met the ’excluded’ population criteria above, unless the
study reported the results for the different populations separately.
Similarly, if there had been a study where more than 50% of the
people had allergic rhinitis we would have included the study but,
where possible, we would only have used the results for the popu-
lation with allergic rhinitis providing the randomisation had been
stratified.
Types of interventions
The use of saline, as an active treatment, delivered to the nose by
any means (douche, irrigation, pulsed, spray or nebuliser).
Tonicity:we included all concentrations of saline. ’Hypotonic’ was
defined as a concentration of less than 0.9% NaCl, ’physiologic’
as 0.9% NaCl and ’hypertonic’ as greater than 0.9% NaCl.
Volume: we included all volumes of saline treatments. ’Very low-
volume’ related to misting sprays or other delivery methods where
the volume of application is likely to be less than 5 mL per nostril
per application. ’Low-volume’ was defined as between 5 mL and
59 mL per nostril per application. ’High-volume’ was defined as
a volume of 60 mL or greater per nostril per application.
We included studies investigating ’buffered’ saline solutions where
the aim was to adjust the pH of the solution. We excluded studies
that used formulations of saline solution that contained other ad-
ditives, such as xylitol, antibacterials and surfactants. We also ex-
cluded studies using other formulations, such as lactated Ringer’s
solution.
There was no minimum duration of treatment.
Comparisons
The main comparison pairs were:
• nasal saline versus no saline irrigation;
• nasal saline plus pharmacological treatment versus
pharmacological treatment alone.
Other possible comparison pairs included:
• nasal saline versus pharmacological treatment.
The term ’pharmacological treatment’ refers to commonly ac-
cepted treatments for allergic rhinitis such as oral antihistamines
and intranasal corticosteroids, as recommended by internationally
accepted treatment guidelines, such as the ARIA guidelines (ARIA
2008).
Types of outcome measures
We analysed the following outcomes in the review, but we did not
use them as a basis for including or excluding studies.
Primary outcomes
• Disease severity, as measured by patient-reported symptom
score (such as the Total Nasal Symptom Score (TNSS)
questionnaire and visual analogue scales (VAS)).
• Significant local adverse effects: epistaxis.
Secondary outcomes
• Disease-specific health-related quality of life, using validated
disease-specific health-related quality of life scores, such as the
Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ),
Mini Rhinoconjunctivitis Quality of Life Questionnaire
(MiniRQLQ) and Rhinitis Symptom Utility Index (RSUI).
• Individual symptom scores for the following symptoms:
◦ anterior rhinorrhoea (runny nose): where a study
reports ’rhinorrhoea’ as the outcome, in the absence of a
definition within the paper we assumed that this measured
anterior rhinorrhoea. Where the authors reported a combined
outcome for anterior and posterior rhinorrhoea and we were not
able to obtain individual results, we recorded this as a combined
’anterior and posterior rhinorrhoea’ category;
◦ posterior rhinorrhoea (post-nasal drip);
◦ nasal blockage or congestion or obstruction;
◦ nasal itching;
◦ sneezing.
• Generic health-related quality of life, using validated
generic quality of life scores, such as the SF-36, EQ-5D and
other well-validated instruments.
• Any other local adverse effects: local irritation, discomfort.
• Aural symptoms: ear pain, pressure or feeling of fullness.
• Endoscopic score (e.g. Lund-Mackay/Lund-Kennedy).
As both short-term and long-term effects are important we evalu-
ated efficacy outcomes at the following time points:
• up to four weeks from the start of treatment (particularly
relevant for intermittent allergic rhinitis);
• from four weeks to six months;
• from six months to 12 months; and
• at more than 12 months (particularly relevant for persistent
allergic rhinitis).
Where a study reported data for an outcome atmore than one time
point, we included the data for the longest of each of the four time
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points above. For example, if a study reported outcomes at one
week, three weeks and 12 weeks from the start of treatment, we
used the three-week results (for the up to four weeks time point)
and the 12-week results (for the four weeks to six months time
point). We paid attention during the analysis to the prevention of
’double counting’ of studies when presenting summary results.
For adverse effects, we analysed data from the longest time periods
available.
Search methods for identification of studies
The Cochrane ENT Information Specialist conducted systematic
searches for randomised controlled trials and controlled clinical
trials. There were no language, publication year or publication
status restrictions. The date of the search was 23 November 2017.
Electronic searches
The Information Specialist searched:
• the Cochrane ENT Trials Register (searched via CRS Web
23 November 2017);
• the Cochrane Register of Controlled Trials (CENTRAL)
(searched via CRS Web 23 November 2017);
• Epub Ahead of Print, In-Process & Other Non-Indexed
Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)
(1946 to 23 November 2017);
• Ovid EMBASE (1974 to 23 November 2017);
• Ovid CAB Abstracts (1910 to 23 November 2017);
• EBSCO CINAHL (1982 to 23 November 2017);
• Ovid AMED (1985 to 23 November 2017);
• LILACS, lilacs.bvsalud.org (searched 23 November 2017);
• KoreaMed (searched via Google Scholar 23 November
2017);
• IndMed, www.indmed.nic.in (searched 23 November
2017);
• PakMediNet, www.pakmedinet.com (searched 23
November 2017);
• Web of Knowledge, Web of Science (1945 to 23 November
2017);
• ClinicalTrials.gov (searched via the Cochrane Register of
Studies 23 November 2017);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP), www.who.int/ictrp (searched
23 November 2017).
The Information Specialist modelled subject strategies for
databases on the search strategy designed for CENTRAL. Where
appropriate, theywere combined with subject strategy adaptations
of the highly sensitive search strategy designed by Cochrane for
identifying randomised controlled trials and controlled clinical tri-
als (as described in theCochraneHandbook for Systematic Reviews of
Interventions Version 5.1.0, Box 6.4.b. (Handbook 2011). Search
strategies for major databases including CENTRAL are provided
in Appendix 1.
Searching other resources
We scanned the reference lists of identified publications for ad-
ditional trials and contacted trial authors where necessary. In ad-
dition, the Information Specialist searched Ovid MEDLINE and
theCochrane Library to retrieve existing systematic reviews relevant
to this systematic review, so that we could scan their reference lists
for additional trials. The Information Specialist also ran non-sys-
tematic searches of Google Scholar to retrieve grey literature and
other sources of potential trials.
Data collection and analysis
Selection of studies
At least two review authors (KH, SG, KS, GS) independently
screened all titles and abstracts of the studies obtained from the
database searches to identify potentially relevant studies. Two re-
view authors (KH, CP) evaluated the full text of each potentially
relevant study to determine whether it met the inclusion and ex-
clusion criteria for this review.
We resolved any differences by discussion and consensus, with
the involvement of a third author for clinical and/methodological
input had it been necessary.
Data extraction and management
Two review authors (KH and KS) independently extracted data
from each study using a standardised data collection form (see
Appendix 2). Whenever a study had more than one publication,
we retrieved all publications to ensure complete extraction of data.
Where there were discrepancies in the data extracted by different
review authors, we checked these against the original reports and
we resolved differences by discussion and consensus, with the in-
volvement of a third author or a methodologist where necessary.
We contacted the original study authors for clarification or for
missing data whenever required. If we found differences between
publications of a study, we contacted the original authors for clar-
ification. We used data from the main paper(s) where no further
information was found.
We included key characteristics of the studies, such as study design,
setting, sample size, population and how outcomes were defined
or collected in the studies. In addition, we also collected baseline
information on prognostic factors or effect modifiers. For this
review, this included:
• age of participants;
• intermittent or persistent allergic rhinitis;
• type of allergic trigger (e.g. mites, pollens, animals, etc.);
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• severity of allergic rhinitis (’mild’ or ’moderate/severe’ as
defined in ARIA 2008).
For the outcomes of interest to the review, we extracted the find-
ings of the studies on an available case analysis basis; i.e. we in-
cluded data from all participants available at the time points based
on the treatment randomised whenever possible, irrespective of
compliance or whether participants had received the treatment as
planned.
In addition to extracting prespecified information about study
characteristics and aspects of methodology relevant to risk of bias,
we extracted the following summary statistics for each trial and
each outcome:
• For continuous data: the mean values, standard deviations
and number of participants for each treatment group. Where
endpoint data were not available, we extracted the values for
change from baseline. We analysed data from measurement
scales such as RQLQ as continuous data.
• For binary data: the numbers of participants experiencing
an effect and the number of participants assessed at the time
point.
• For ordinal scale data: if the data appeared to be
approximately normally distributed or if the analysis that the
investigators performed suggested parametric tests were
appropriate, then we treated the outcome measures as
continuous data. If data had been available, we would have
converted into binary data.
We prespecified the time points of interest for the outcomes in this
review (Types of outcome measures). While studies had reported
data atmultiple time points, we only extracted the longest available
data within the time points of interest. For example, if a study
reported data at one, two and four weeks, we only extracted and
analysed the data for the four-week follow-up.
Extracting data from figures
Where values for primary or secondary outcomes were shown as
figures within the paper we contacted the study authors to try to
obtain the raw values. When the raw values were not provided,
we extracted information from the graphs using an online data ex-
traction tool (http://arohatgi.info/WebPlotDigitizer/app/), using
the best quality version of the relevant figures available.
Assessment of risk of bias in included studies
KH and KS undertook assessment of the risk of bias of the in-
cluded studies independently, with the following taken into con-
sideration, as guided by theCochrane Handbook for Systematic Re-
views of Interventions (Handbook 2011):
• sequence generation;
• allocation concealment;
• blinding;
• incomplete outcome data;
• selective outcome reporting; and
• other sources of bias.
We used the Cochrane ’Risk of bias’ tool in RevMan 5.3 (RevMan
2014), which involves describing each of these domains as reported
in the trial and then assigning a judgement about the adequacy of
each entry: ’low’, ’high’ or ’unclear’ risk of bias.
Measures of treatment effect
We summarised the effects of dichotomous outcomes (e.g. pro-
portion of participants with symptom resolution) as risk ratios
(RR) with 95% confidence intervals (CIs). For the key outcomes
that were presented in the ’Summary of findings’ tables, we also
expressed the results as absolute numbers based on the pooled re-
sults and compared to the assumed risk.We would have calculated
the number needed to treat to benefit (NNTB) using the pooled
results had it made sense to do so. The assumed baseline risk would
typically be either (a) the median of the risks of the control groups
in the included studies, this being used to represent a ’medium-
risk population’ or, alternatively, (b) the average risk of the control
groups in the included studies used to represent the ’study pop-
ulation’ (Handbook 2011). Had a large number of studies been
available, and where appropriate, we would have also presented
additional data based on the assumed baseline risk in (c) a low-
risk population and (d) a high-risk population.
For continuous outcomes, we expressed treatment effects as amean
difference (MD) with standard deviation (SD). When different
scales were used to measure the same outcome we used the stan-
dardised mean difference (SMD), and we provided a clinical in-
terpretation of the SMD values.
Unit of analysis issues
This review did not use data from phase II of cross-over studies or
from studies where the participant was not the unit of randomisa-
tion, i.e. studies where the side of the nose (right versus left) was
randomised.
If we had found cluster-randomised trials, we would have analysed
these according to the methods in section 16.3.3 of the Cochrane
Handbook for Systematic Reviews of Interventions (Handbook
2011).
Dealing with missing data
We contacted study authors via email whenever the outcome of
interest was not reported if the methods of the study suggest that
the outcome had been measured. We did the same if not all data
required for meta-analysis were reported, unless the missing data
were standard deviations. When standard deviation data were not
available we approximated these using the standard estimation
methods from P values, standard errors or 95% CIs if these were
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reported, as detailed in the Cochrane Handbook for Systematic Re-
views of Interventions (Handbook 2011). Had it been impossible
to estimate these, we would have contacted the study authors.
Apart from imputations for missing standard deviations, we did
not conduct any other imputations. We extracted and analysed
data for all outcomes using the available case analysis method.
Assessment of heterogeneity
We assessed clinical heterogeneity (which may be present even in
the absence of statistical heterogeneity) by examining the included
trials for potential differences between studies in the types of par-
ticipants recruited (including age of participants), interventions
or controls used and the outcomes measured.
We assessed statistical heterogeneity by visually inspecting the for-
est plots and by considering the Chi² test (with a significance
level set at P < 0.10) and the I² statistic, which calculates the
percentage of variability that is due to heterogeneity rather than
chance, with I² values over 50% suggesting substantial heterogene-
ity (Handbook 2011).
Assessment of reporting biases
We assessed reporting bias as between-study publication bias and
within-study outcome reporting bias.
Outcome reporting bias (within-study reporting bias)
We assessed within-study reporting bias by comparing the out-
comes reported in the published report against the study protocol,
whenever this could be obtained. If the protocol was not available,
we compared the outcomes reported to those listed in themethods
section. If results are mentioned but not reported adequately in a
way that allows analysis (e.g. the report only mentions whether the
results were statistically significant or not), bias in a meta-analysis
is likely to occur. We tried to find further information from the
study authors. If no further information was obtained, we noted
this as being a ’high’ risk of bias. Where there was insufficient in-
formation to judge the risk of bias we noted this as an ’unclear’
risk of bias (Handbook 2011).
Publication bias (between-study reporting bias)
We had planned to create funnel plots if sufficient studies (more
than 10) were available for an outcome. If we had observed asym-
metry of the funnel plot, we had planned to conduct more formal
investigation using the methods proposed by Egger 1997.
Data synthesis
We conducted all meta-analyses using Review Manager 5.3
(RevMan 2014). For dichotomous data, we analysed treatment
differences as a risk ratio (RR) calculated using the Mantel-Haen-
szel methods. We would have analysed time-to-event data using
the generic inverse variance method.
For continuous outcomes, if all the data were from the same scale,
we pooled mean values obtained at follow-up with the change
in outcomes (i.e. difference between pre- versus post-treatment
values) and reported this as a MD. However, if the SMD had to
be used as an effect measure, we would not have pooled change
and endpoint data.
When statistical heterogeneity is low, random-effects versus fixed-
effect methods yield trivial differences in treatment effects. How-
ever, when statistical heterogeneity is high, the random-effects
method provides a more conservative estimate of the difference.
Subgroup analysis and investigation of heterogeneity
Where data were available, we conducted some subgroup analy-
ses regardless of whether statistical heterogeneity was observed, as
these were widely suspected to be potential effect modifiers. For
this review, this included the following.
• Volume of saline delivery (e.g. ’very low’, ’low’ and ’high’
volume). There is evidence of a difference in effectiveness
between high- and low-volume saline irrigation in people with
chronic sinonasal symptoms (Pynnonen 2007).
• Tonicity of saline solution (hypertonic, isotonic and
hypotonic solutions). There is some evidence in other conditions
that tonicity may have an effect on the efficacy of nasal saline
(Berjis 2011; Rabago 2005).
• Alkalinity of saline solution. There is evidence that
increased alkalinity of the saline solution improves some nasal
symptoms (Chusakul 2013).
• Participant age (children, adults or mixed population).
There may be differences in physiology that are unknown and
compliance and volumes may well be quite different in the
paediatric population compared to adults.
We initially planned to present the main analyses of this review
according to the volume of saline delivery, however we changed
this to present the initial analyses subgrouped by age during the
process of the review (Differences between protocol and review).
We presented all other subgroup analysis results in tables and as
forest plots.
In addition to the subgroups above, we had planned to conduct
the following subgroup analyses in the presence of statistical het-
erogeneity:
• method of delivery (e.g. nebuliser, spray, irrigation);
• duration of treatment;
• frequency of allergic rhinitis symptoms (e.g. intermittent or
persistent as defined by ARIA 2008), where an older study using
the ’seasonal’ and ’perennial’ classification was used, we would
have interpreted ’seasonal’ as ’intermittent’ and ’perennial’ as
’persistent’ allergic rhinitis unless there was specific information
in the paper that would make this inappropriate;
• severity of symptoms (mild, moderate/severe as defined by
ARIA 2008).
12Saline irrigation for allergic rhinitis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
When studies had a mixed group of participants, we had planned
to analyse the study as one of the subgroups (rather than as a
mixed group) if more than 80% of the participants belong to one
category. For example, if 81% of participants were over 18, we
would have analysed the study as though the participants were
adults.
Sensitivity analysis
We had planned to carry out sensitivity analyses to determine
whether the findings were robust to the decisions made in the
course of identifying, screening and analysing the trials. We had
planned to conduct sensitivity analysis for the following factors,
whenever possible:
• impact of model chosen: fixed-effect versus random-effects
model;
• risk of bias of included studies: evaluating the impact of
missing data on the results of the studies due to participant
attrition, to determine whether the missing outcome data for the
participants in the trial could have influenced the results of the
review;
• how outcomes were measured: we planned to investigate
the impact of including data where the validity of the
measurement instrument used was unclear.
If any of these investigations had found a difference in the size of
the effect or heterogeneity, we would have mentioned this in the
Effects of interventions section.
GRADE and ’Summary of findings’ table
Using the GRADE approach, at least two review authors (KH,
KS) independently rated the overall quality of evidence using the
GDT tool (http://www.guidelinedevelopment.org/) for the main
comparison pairs listed in the Types of interventions section. The
quality of evidence reflects the extent to which we are confident
that an estimate of effect is correct and we applied this in the inter-
pretation of results. There are four possible ratings: high, moder-
ate, low and very low. A rating of high quality of evidence implies
that we are confident in our estimate of effect and that further
research is very unlikely to change our confidence in the estimate
of effect. A rating of very low quality implies that any estimate of
effect obtained is very uncertain.
TheGRADE approach rates evidence fromRCTs that do not have
serious limitations as high quality. However, several factors can
lead to the downgrading of the evidence to moderate, low or very
low. The degree of downgrading is determined by the seriousness
of these factors:
• study limitations (risk of bias);
• inconsistency;
• indirectness of evidence;
• imprecision; and
• publication bias.
We included a ’Summary of findings’ table, constructed ac-
cording to the recommendations described in Chapter 10 of
the Cochrane Handbook for Systematic Reviews of Interventions
(Handbook 2011). We included the following outcomes in the
’Summary of findings’ table: patient-reported disease severity
score, individual symptom scores, significant adverse effects (epis-
taxis), disease-specific health-related quality of life and other ad-
verse effects (local irritation/discomfort).
R E S U L T S
Description of studies
Results of the search
The searches retrieved a total of 1402 references after removal of
duplicates. We identified three additional references from other
sources. We screened the titles and abstracts and subsequently re-
moved 1319 references. We assessed 86 full texts for eligibility of
which we excluded 66 references; we excluded 31 of these refer-
ences (29 studies) with reasons recorded in the review (Excluded
studies).
We included 16 references (14 studies). We did not identify any
ongoing studies. There are four references awaiting assessment (see
below).
A flow chart of study retrieval and selection is provided in Figure
1.
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Figure 1. Study flow diagram.
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Included studies
All of the 14 studies (16 references) included were parallel-group
randomised controlled trials (RCTs). Two studies were described
as ’single-blinded’ whereas the remaining 12 were non-blinded
studies. All except one were single-centre studies. Seven studies
included two treatment arms and seven included three treatment
arms. The range of follow-up varied from 7 days to 12 weeks.
Full details can be found in the Characteristics of included studies
table.
Setting
The studies came from five countries: six were conducted in Italy
(Di Berardino 2017; Garavello 2003; Garavello 2005; Garavello
2010; Marchisio 2012; Rogkakou 2005), five in China (Chen
2014; Li 2009; Lin 2017; Ning 2011; Wu 2014), and one in each
in Thailand (Chairattananon 2013), Turkey (Yasar 2013) and the
USA (Cordray 2005).
The setting of the studies is not clearly describedwithin the papers.
We assumed that most studies recruited their participants from
secondary care but one study was conducted in family practices
(primary care) (Cordray 2005), and four other studies were very
unclear about the setting (Di Berardino 2017; Garavello 2005; Li
2009; Wu 2014).
Population
A total of 747participantswere involved in the studies. The sample
size of the studies ranged from 14 to 160 participants. Only one
study included more than 100 participants and the median study
size was 46 participants.
Age
Seven studies included only children (Chairattananon 2013; Chen
2014; Garavello 2003; Garavello 2005; Li 2009; Marchisio 2012;
Yasar 2013). Six of these reported the mean age, which ranged
from 6 to 11 years. The median of the mean ages was 9.4 years.
Only one study included children of less than five years (Chen
2014).
Seven studies only included adults (Cordray 2005; Di Berardino
2017; Garavello 2010; Lin 2017; Ning 2011; Rogkakou 2005;
Wu 2014). Five studies reported the mean ages of the participants
and these ranged from 24 to 47 years. The median of the mean
ages was 33.9 years.
Sex
Thirteen of the 14 included studies included both males and fe-
males. The proportion of males in the studies ranged from 39%
to 62%. One study included only pregnant women (Garavello
2010).
Diagnosis
Eleven studies diagnosed participants with allergic rhinitis and two
specified that included participants had allergic rhinoconjunctivi-
tis (Di Berardino 2017; Garavello 2005). Lin 2017 only included
participants with allergic rhinitis and chronic cough (lasting for
eight weeks or more).
Five studies stated (or it could be interpreted) that they included
participants with persistent allergic rhinitis, and six included par-
ticipants with seasonal allergic rhinitis. Further details of the type
and severity of allergic rhinitis, and the allergen type, for partici-
pants included in the studies are shown in Table 1.
Interventions
Saline solution
Details of the tonicity, volume and method of administration of
the saline solution are provided in Table 1.
In summary:
• Eight studies used hypertonic saline and five studies used
isotonic (’normal’) saline. Three studies did not provide any
information about tonicity.
• Five studies used very low-volume saline, two used low-
volume saline and four used high-volume saline. Three studies
did not provide information on the volume.
• Five studies allowed oral antihistamines to be used as rescue
medication when needed (Chairattananon 2013; Di Berardino
2017; Garavello 2005; Garavello 2010; Marchisio 2012).
Chairattananon 2013 stated that pseudoephedrine was also
prescribed as rescue medication.
• The duration of treatment ranged from seven days to three
months.
Comparisons
Saline versus no saline treatment
Seven studies compared nasal saline irrigation with no saline treat-
ment (Chairattananon 2013; Di Berardino 2017; Garavello 2003;
Garavello 2005; Garavello 2010; Marchisio 2012; Ning 2011).
15Saline irrigation for allergic rhinitis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Marchisio 2012 was a three-arm study that compared two differ-
ent types of nasal saline (hypertonic and isotonic saline) with no
saline treatment.
Saline plus pharmacological treatment versus
pharmacological treatment alone
Three studies included arms where both nasal saline irrigation
and intranasal corticosteroidswere given. The intranasal steroids
given were budesonide nasal spray in Li 2009 (256µg/day for four
weeks, 128 µg/day for four weeks and 64 µg/day for four weeks)
and Wu 2014 (128 µg/day for three months); and fluticasone
proportionate nasal spray in Chen 2014 (200 µg/day for four
weeks, 100 µg/day for four weeks and 50 µg/day for four weeks).
It was not explicitly stated in any of the studies in which order the
saline and steroid treatments were given.
One study used an oral antihistamine (10 mg/day cetirizine) in
addition to saline irrigation for four weeks (Rogkakou 2005).
Saline versus intranasal corticosteroids
Seven studies compared nasal saline irrigation with intranasal
steroid treatment. Intranasal steroids were:
• budesonide (three studies; Li 2009; Ning 2011; Wu 2014);
• fluticasone propionate (two studies; Chen 2014; Lin 2017);
• mometasone furoate (one study; Yasar 2013);
• aqueous triamcinolone (one study; Cordray 2005).
We considered the doses for these treatments to be within the nor-
mal clinical range and details can be found in the Characteristics
of included studies table.
Saline versus intranasal antihistamines
One study compared saline irrigation with intranasal antihis-
tamines (two puffs of azelastine in each nostril per day (1 puff
= 0.14 mg)) for eight weeks. This study did not report any of
the primary or secondary outcomes defined in the review (Yasar
2013).
Outcomes
One study did not report any relevant outcomes as the aim of the
study was to measure nasal cavity volumes using acoustic rhinom-
etry (Yasar 2013).
Primary outcomes
Disease severity, as measured by patient-reported symptom
score
Twelve studies reported a patient-reported disease severity score.
These scores differed greatly in the method of reporting from
combined visual analogue scales for all symptoms, to individual
scales for up to 10 symptoms. The summary scores were also all
constructed differently. Only one paper reported validation of the
scales that they used (Lin 2017). A summary of the scales used is
in Table 2.
Significant local adverse effects: epistaxis
Adverse effects were not well reported in the studies. Only four
studies specifically mentioned in their methods section that ad-
verse effects would be routinely reported (Chairattananon 2013;
Garavello 2005; Garavello 2010; Lin 2017). Of the 10 studies that
mentioned adverse effects in their results section, six only reported
on the nasal saline irrigation group (Chairattananon 2013; Chen
2014; Garavello 2005; Garavello 2010; Li 2009;Marchisio 2012),
and three reported on adverse effects in both study arms (Garavello
2003; Lin 2017; Wu 2014). The remaining study indicated that
there were withdrawals due to adverse effects but it was not clear
to which groups the participants were allocated (Cordray 2005).
Secondary outcomes
Disease-specific health-related quality of life
Five studies measured disease-specific health-related quality of life.
Two studies used the Rhinoconjunctivitis Quality of Life Ques-
tionnaire (RQLQ) (Cordray 2005; Wu 2014), although the stud-
ies constructed the overall score in a different way. Lin 2017 used
themini-RQLQ, a shortened version of the full RQLQ,Rogkakou
2005 used the Rhinasthma® questionnaire and Chairattananon
2013 used a questionnaire specific to Thai allergic rhinocon-
junctivitis patients (RCQ-36). Further details of each scale can
be found in the study-specific section of the Characteristics of
included studies table.
Individual symptom scores
No studies reported individual symptom scores.
Generic health-related quality of life
No studies measured generic health-related quality of life.
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Any other local adverse effects: local irritation, discomfort
See the section above on significant local adverse effects.
Aural symptoms: ear pain, pressure or feeling of fullness
No studies specifically mentioned aural symptoms as either a
symptom of allergic rhinitis or as an adverse effect of treatment.
Endoscopic score
Only Marchisio 2012 reported the use of an endoscopy score as
an outcome. This study graded the turbinate swelling on a range
of 0 to 3 and reported the change at four weeks from baseline in
the proportion of children with moderate to severe swelling of the
turbinate.
Excluded studies
We formally excluded 29 studies (31 papers) that most closely
matched the inclusion criteria (Characteristics of excluded
studies).
Population
We excluded four studies as they investigated the use of saline
irrigation inpeoplewith chronic rhinosinusitis, not allergic rhinitis
(Bachmann 2000; Heatley 2001; Rabago 2002; Shoseyov 1998).
In addition, we excluded one study as despite including people
with allergic rhinitis, the condition was diagnosed by symptoms
and not using one of the diagnostic tests specified in our inclusion
criteria (Chowdary 2017).
Intervention
We excluded four studies due to the wrong intervention. Two
studies used thermal water rather than saline (Barbieri 2002;Mora
2002), one compared saline against a non-standard treatment for
allergic rhinitis (Luffa Operculate) (NCT01248325 2010) and
one used tap water, rather than saline (Xiong 2014).
Study design
We excluded five studies because the study design was a single arm
with no comparison group (Barberi 2016a; Barberi 2016b; Jan
2013; Nguyen 2014; Tomooka 2000).
Comparisons of saline studies
We excluded 15 studies (17 references) due to the comparison
being between different saline solutions, rather than a comparison
of saline with no saline treatment or pharmacological treatment for
allergic rhinitis (ChiCTR-INR-16009778 2016; Chusakul 2012;
DelGiudice 2011; Lin 2014;Malizia 2017;NCT01326247 2011;
NCT02729012 2016; Polasek 1987; Satdhabudha 2012; Singh
2016; TCTR20150923001 2015; TCTR20160120001 2016;
TCTR20160913003 2016; Ural 2009; Valencia Chavez 2015).
Awaiting assessment studies
There are four studies awaiting assessment. One study is awaiting
translation (Krcmova 2011). Three studies were published as ab-
stracts only and the full-text papers, or further information, could
not be obtained despite attempts to contact the study authors
(Hausfeld 2007; Lee 2017; Manole 2013). See Characteristics of
studies awaiting classification.
Risk of bias in included studies
See Figure 2 for a ’Risk of bias’ graph (our judgements about
each risk of bias item presented as percentages across all included
studies) and Figure 3 for a ’Risk of bias’ summary (our judgements
about each risk of bias item for each included study).
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Random sequence generation
We assessed four studies as high risk of bias for random sequence
generation.
• Chen 2014 did not mention the methods of randomisation
in the paper and we noted that there was unequal distribution
between the groups and very limited information about the
baseline characteristics of the population included by allocated
group.
• Li 2009 describes the participants as “randomised” in the
abstract but uses the word “divided” in the methods section with
no further details. In addition, there was a lack of information
about baseline characteristics.
• In Yasar 2013 it is unclear whether the participants were
randomised to study groups as the paper states that the
participants were “classified” into three groups. Although
baseline characteristics for age and gender were given and did not
differ between groups, other baseline characteristics were not
provided.
• Cordray 2005 states that the study was “randomised” but
no methods are described and it is not even clear how many were
randomised to each group. The paper also lacked baseline
characteristics for the groups.
We assessed two studies as having unclear risk of bias as the papers
indicated that the participants were “randomised” but no details
of the methods are presented (Ning 2011; Wu 2014).
We assessed the remaining eight studies as at low risk of bias for
random sequence generation.
Allocation concealment
One study had a high risk of allocation concealment bias, as there
were an unequal number of participants in each arm and no base-
line characteristics are provided so there is a concern that the inves-
tigators may have known the group to which they were allocating
participants (Li 2009).
There were 10 studies that did not provide any information about
the methods used to ensure that the investigators allocating par-
ticipants to the groups could not influence the allocation and we
assessed these as having unclear risk of bias (Chairattananon 2013;
Chen 2014; Cordray 2005; Di Berardino 2017; Marchisio 2012;
Ning 2011; Rogkakou 2005; Wu 2014; Yasar 2013).
The remaining three studies were at low risk of allocation conceal-
ment bias.
Blinding
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Blinding of participants and personnel
We judged all of the studies to be at high risk of bias. Thirteen
studies were non-blinded and many of these compared saline with
no saline treatment so there were practical issues that meant blind-
ing of participants would not have been possible. Cordray 2005
describes their study in the abstract as “single-blinded” but does
not provide details of which aspect of the trial this relates to as
the three different trial arms had different regimens: the saline was
given three times daily whereas the steroid was given once daily
and no placebo is mentioned. We assessed this as insufficient pro-
tection from participants and personnel from knowing the treat-
ment group to which they were allocated.
Blinding of outcome assessors
We assessed all of the included studies to be at high risk of bias.
None of the studies mentioned that the outcome assessors were
blinded to treatment group. As most of the outcomes were partic-
ipant-reported, and the participants were not blinded, blinding of
outcome assessors was not possible.
Incomplete outcome data
We assessed two studies to be at high risk of attrition bias due
to a rate of withdrawal above 25%. In Cordray 2005, 29% of
participants withdrew but the authors did not provide any reasons
for withdrawals or state whether there were differences between
groups. Marchisio 2012 noted that 25% of the participants in the
no saline treatment groupdidnot complete the study.The dropout
rate was imbalanced between the groups although reasons were
provided. More people dropped out of the no saline treatment
group because of the use of rescue medications.
One study was at unclear risk of bias as although no withdrawals
were mentioned the paper did not provide enough information
to determine whether all the participants included in the study
completed (Chen 2014).
We assessed the remaining 11 studies as at low risk of bias.
Selective reporting
We assessed three studies as at high risk of reporting bias. Chen
2014 had incomplete reporting of outcomes in the paper. Cordray
2005 was the only study that reported withdrawals due to adverse
effects, yet failed to provide information about the nature of the
effects or in which treatment groups they occurred. Rogkakou
2005 failed to report any measures of variation for their results.
One study was at unclear risk of selective reporting bias (
Chairattananon 2013). One outcome was mentioned in the re-
sults section (use of antibiotics) but was not identified in themeth-
ods section. In addition, there was some confusion between the
published abstract and the draft full paper (provided by personal
communication with the authors) regarding which quality of life
instrument was used.
We assessed the remaining 10 studies as at low risk of selective
reporting as, despite not having a protocol available, all of the
outcomes mentioned in their methods sections were reported in
the results.
Other potential sources of bias
Use of non-validated instruments
We assessed three studies as at low risk of bias. In Lin 2017, ref-
erences were provided for the papers reporting validation of the
different outcomes. Yasar 2013 did not report any relevant out-
comes. In Cordray 2005, the only outcome of relevance that was
reported had been measured using a validated scale.
We assessed the remaining 11 studies as at unclear risk of bias be-
cause they did not mention the validation of the instruments used
to measure the patient-reported disease severity score. In addition,
Wu 2014 and Chairattananon 2013 appeared to use variations of
validated health-related quality of life scales but did not discuss
the impact that this may have had on the results.
Other bias
A general lack of information provided in two papers led to them
being assessed as having unclear risk of other bias (Chen 2014;
Cordray 2005).
We identified no other sources of bias in the remaining 12 studies.
Funding sources
Funding was mentioned in seven studies. Two studies reported
that no external financial support was received (Di Berardino
2017; Yasar 2013). Five studies received funding from national
or regional governmental funds (Chen 2014; Li 2009; Lin 2017;
Ning 2011; Wu 2014).
No information was provided about funding in the remaining
seven studies.
Declarations of interest
Four studies made a declaration in the paper that none of the
authors had conflicts of interest (Di Berardino 2017; Lin 2017;
Marchisio 2012; Yasar 2013). None of the 10 remaining studies
provide any declarations of interest.
Effects of interventions
See: Summary of findings for the main comparison Saline
versus no saline treatment for allergic rhinitis; Summary of
findings 2 Saline irrigation plus pharmacological treatment versus
pharmacological treatment alone for allergic rhinitis
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Comparison 1. Saline versus no saline treatment
Seven studies (444 participants) compared saline treatment with
no saline treatment. Four used hypertonic saline (Di Berardino
2017; Garavello 2003; Garavello 2005; Garavello 2010) and one
used isotonic solution (Chairattananon 2013). One study did not
provide details of tonicity (Ning 2011). One study included two
saline groups, one using isotonic saline and one using hypertonic
saline (Marchisio 2012); for the initial analyses we combined these
saline groups.
1.1. Disease severity, as measured by patient-reported
symptom score
All seven studies presented data for disease severity using a number
of different scales; a summary can be found in Table 2.
One study asked participants to rate their “overall nasal symp-
toms” on a 0 to 10 visual analogue scale (lower score = WORSE
symptoms) (Chairattananon 2013).
Five of the remaining six studies asked participants to measure the
same symptoms: rhinorrhoea, nasal blockage, nasal itching and
sneezing (Di Berardino 2017; Garavello 2003; Garavello 2010;
Marchisio 2012; Ning 2011). One study recorded different symp-
toms (nasal discharge, nasal blockage, eye redness, eye itching)
(Garavello 2005).
Due to the differences in the scales used, we used a standardised
mean difference (SMD) in the analysis.
Up to four weeks
Six studies reported results at up to four weeks. The results showed
that people using saline irrigation had lower symptom scores than
people in the no saline treatment group (SMD -1.32, 95% confi-
dence interval (CI) -1.84 to -0.81; 407 participants; 6 studies; I2
= 75%) (Analysis 1.1). Due to the statistical heterogeneity iden-
tified, we used a random-effects model. The heterogeneity was
driven mainly by the large apparent effect in Garavello 2010. Re-
moving this study reduced the heterogeneity to a low level and the
result still significantly favoured the use of saline irrigation. This
SMD represents a large effect size and translates into a decrease
of approximately 1.97 points (1.21 to 2.74) on a 0- to 10-point
visual analogue scale for nasal symptoms (lower = better) (low-
quality evidence).
Subgroup analysis results show that both children (SMD -1.07,
95% CI -1.39 to -0.74; 322 participants; 4 studies; I2 = 25%)
and adults (SMD -2.06, 95% CI -3.80 to -0.32; 85 participants;
2 studies; I2 = 90%) reported improved symptoms with saline
compared to no saline. There was no evidence of a difference
between the age subgroups.
Four weeks to six months
Five studies reported results at between six and eight weeks. The
results showed that people using saline irrigation had lower symp-
tom scores than people in the no saline group (SMD -1.44, 95%
CI -2.39 to -0.48; 167 participants; 5 studies; I2 = 86%) (Analysis
1.2). We used a random-effects model due to the presence of sta-
tistical heterogeneity. The heterogeneity did not reduce after re-
moving Garavello 2010 and the result still significantly favoured
the use of saline irrigation. This SMD represents a large effect size
and translates into a decrease of approximately 2.98 points (0.99
to 5.98) on a 0- to 10-point visual analogue scale for nasal symp-
toms (lower = better) (low-quality evidence).
Subgroup analysis show that both children (SMD -1.06, 95% CI
-2.13 to 0.01; 102 participants; 3 studies; I2 = 83%) and adults
(SMD -2.02, 95% CI -3.79 to -0.25; 65 participants; 2 studies; I
2 = 87%) reported improved symptoms with saline compared to
no saline, but there was no evidence of a difference between the
subgroups for the different ages.
1.2. Significant local adverse effects: epistaxis
Three studies reported methods for collecting information about
adverse effects in their methods section (Chairattananon 2013;
Garavello 2005; Garavello 2010). Five studies made a statement
about adverse effects in their results section. Of these, two stud-
ies (240 children) reported that there were no adverse effects in
either of the treatment groups although epistaxis was not specifi-
cally mentioned as being sought (low-quality evidence) (Garavello
2003;Marchisio 2012). The remaining three studies only provided
information that no adverse effects were reported in the saline
treatment arm (Chairattananon 2013; Garavello 2003; Marchisio
2012).
1.3. Disease-specific health-related quality of life
One study (Chairattananon 2013; 42 children) reported disease-
specific health-related quality of life using the Thai Rhinoconjunc-
tivitis Quality of Life scale (RCQ-36). This questionnaire has 36
items each measured on a 0 to 4 scale, however only 35 items were
used in this study (range 0 to 140), higher score = worse quality
of life.
Up to four weeks
It is uncertain whether there is an improvement in disease-spe-
cific quality of life with saline irrigation compared with no saline
treatment at four weeks in children (mean difference (MD) -3.32,
95% CI -11.35 to 4.71; 42 participants; 1 study) (Analysis 1.3)
(very low-quality evidence).
Four weeks to six months
It is uncertain whether there is an improvement in disease-spe-
cific quality of life with saline irrigation compared with no saline
treatment at eight weeks in children (MD -2.06, 95% CI -8.38
to 4.26; 42 participants; 1 study) (Analysis 1.3) (very low-quality
evidence).
21Saline irrigation for allergic rhinitis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1.4. Individual symptom scores
No studies reported symptom scores for the individual symptoms
of anterior rhinorrhoea (runny nose), posterior rhinorrhoea (post-
nasal drip), nasal blockage/congestion/obstruction, nasal itching
or sneezing.
1.5. Generic health-related quality of life
No studies reported generic health-related quality of life.
1.6. Any other local adverse effects: local irritation,
discomfort
Five studies made a statement about adverse effects. Two studies
(240 children) reported that no adverse effects were experienced in
either of the treatment groups (Garavello 2003; Marchisio 2012),
although it is unclear whether the specific adverse effects of local
irritation and discomfort were sought (low-quality evidence).
The remaining three studies (68 children, 44 adults) reported that
there were no adverse effects in the ’active’ treatment group (i.e.
saline irrigation) although again it is unclear whether the specific
adverse effects of local irritation and discomfort were sought (
Chairattananon 2013; Garavello 2005; Garavello 2010).
1.7. Aural symptoms: ear pain, pressure or feeling of fullness
No studies reported aural symptoms.
1.8. Endoscopic score (e.g. Lund-Mackay/Lund-Kennedy)
No studies reported endoscopy scores (for example, Lund-Mackay
or Lund-Kennedy).
One study (220 children) reported the change from baseline at
four weeks in the proportion of children with moderate to severe
swelling of the turbinates. The group using hypertonic saline ir-
rigation showed a significant reduction in the percentage of chil-
dren with moderate to severe turbinate swelling (-31.2%, 95% CI
-16.5% to -46.0%), whereas the groups using isotonic saline and
no saline irrigation both showed a non-significant reduction in the
proportion of children with moderate to severe turbinate swelling
(-5.1%, 95% CI -9.9% to 19.9% and -5.0%, 95% CI -11.9% to
21.9%, respectively) (Marchisio 2012).
Subgroup analysis
We stated in the protocol that analyses would be completed with
regards to the volume, tonicity and alkalinity of the solution, ir-
respective of statistical heterogeneity. The only outcome that had
enough data to be included in the subgroup analysis was that of
patient-reported disease severity. It should be noted that there is
statistical heterogeneity within these results, which is probably due
to the different scoring systems used and so all of the results must
be treated with caution.
Volume
When we classified the results into volume subgroups, all of the
saline volume categories showed improvement in patient-reported
disease severity compared with no saline treatment at up to four
weeks:
• Very low-volume saline (less than 5 mL/nostril per
application): SMD -0.96, 95% CI -1.39 to -0.52; 100
participants; 3 studies; I2 = 5%.
• Low-volume saline (between 5 mL and 60 mL/nostril per
application): SMD -2.07, 95% CI -3.73 to -0.42; 265
participants; 2 studies; I2 = 92%.
• High-volume saline (more than 60 mL/nostril per
application): SMD -0.92, 95% CI -1.56 to -0.28; 42
participants; 1 study.
See Analysis 4.1.
The results for four weeks to six months (range of follow-up six
to eight weeks) were as follows:
• Very low-volume saline (less than 5 mL/nostril per
application): SMD -1.33, 95% CI -2.22 to -0.44; 80
participants; 3 studies; I2 = 67%.
• Low-volume saline (between 5 mL and 60 mL/nostril per
application): SMD -2.91, 95% CI -3.77 to -2.05; 45
participants; 1 study.
• High-volume saline (more than 60 mL/nostril per
application): SMD -0.41, 95% CI -1.02 to 0.21; 42 participants;
1 study.
See Analysis 4.2.
The tests for subgroup differences did not indicate statistical dif-
ferences between the subgroups at either time point.
Tonicity
For this subgroup analysiswe separated out the results for the three-
arm trial comparing two different saline solutions (hypertonic and
isotonic saline) with no saline treatment (Marchisio 2012), but we
split the denominator in the no saline treatment group between
the comparisons in the two separate groups to ensure that people
in the no saline treatment group were not counted twice.
When we classified the results into tonicity subgroups, all of the
saline tonicity categories showed improvement in patient-reported
disease severity compared with no saline treatment at up to four
weeks:
• Isotonic or ’normal’ saline (0.9%): SMD -0.82, 95% CI -
1.18 to -0.47; 152 participants; 2 studies; I2 = 0%.
• Hypertonic saline (> 0.9%): SMD -1.72, 95% CI -2.62 to -
0.82; 255 participants; 5 studies; I2 = 87%.
See Analysis 5.1.
The results for between four weeks and six months (range of
follow-up six to eight weeks) were as follows:
• Isotonic or ’normal’ saline (0.9%): SMD -0.41, 95% CI -
1.02 to 0.21; 42 participants; 1 study.
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• Hypertonic saline (> 0.9%): SMD -1.91, 95% CI -3.14 to -
0.68; 105 participants; 3 studies; I2 = 84%.
See Analysis 5.2.
In both instances the effect size for treatment with hypertonic
solution was greater than with normal saline. The tests for sub-
group differences did not indicate statistical differences at up to
four weeks, but did suggest that there may have been a difference
at between four weeks and six months (P = 0.03, I2 = 78.3%).
However, it can seen that there is considerable heterogeneity in
the results of the group using hypertonic saline.
Alkalinity
The alkalinity of solutions was not well reported in the studies and
so it was not possible to undertake this subgroup analysis.
No further subgroup analyses were undertaken.
Comparison 2. Adding saline irrigation to
pharmacological treatment
Three studies (119 participants) compared saline irrigation with
intranasal steroids against intranasal steroids alone. One study (14
adults) compared saline irrigation with oral antihistamine against
oral antihistamines alone.
2.1. Disease severity, as measured by patient-reported
symptom score
Four studies reported this outcome (Chen 2014; Li 2009;
Rogkakou 2005; Wu 2014). Chen 2014 did not present sufficient
data in the paper to use in the meta-analysis and no response was
received after we attempted to contact the author, so only narrative
results are presented. Each of the studies included in the meta-
analysis used different scoring mechanisms and included different
symptoms (Table 2):
• Li 2009 and Chen 2014: reported four symptoms each
measured on a four-point scale (0 to 3 scale, 0 = no symptoms).
The sum of the scores gave a total score (total range 0 to 12).
• Rogkakou 2005: reported eight symptoms each measured
on a four-point scale (0 to 3, 0 = no symptoms). The sum of the
symptom scores was calculated (total range 0 to 24).
• Wu 2014: reported 10 symptoms each measured on a 0 to
10 visual analogue scale (VAS) (0 = least symptoms). These
scores were averaged to give a final range of 0 to 10.
Up to four weeks
Two studies (18 children, 14 adults) reported patient-reported dis-
ease severity at up to four weeks. In one study all participants also
used oral antihistamines (Rogkakou 2005), and in the other study
all participants also used intranasal steroids (Li 2009). It is uncer-
tain whether saline irrigation in addition to pharmacological treat-
ment (oral antihistamines or intranasal steroids) improved symp-
tom scores at four weeks compared with pharmacological treat-
ment alone (SMD -0.60, 95% CI -1.34 to 0.15; 32 participants;
2 studies; I2 = 0%) (Analysis 2.1)(very low-quality evidence).
Chen 2014 reported higher mean values for disease severity (more
severe symptoms) in the intranasal steroid group (4.16, 17 chil-
dren), compared with the group receiving saline and intranasal
steroids (3.26, 26 children) at four weeks using an instrument with
a total range of 0 to 12. The authors reported that there was a
significant difference between groups (P < 0.05) but they did not
provide information on the variance of the results and no response
was received from the author after a request for further informa-
tion.
Four weeks to six months
Two studies (18 children; 40 adults) in which all participants also
used intranasal steroids reported patient-reported diease severity
at three months (Li 2009;Wu 2014). It is uncertain whether saline
irrigation in addition to intranasal steroids improved symptom
scores at three months compared with pharmacological treatment
alone (SMD -0.32, 95% CI -0.85 to 0.21; 58 participants; 2
studies; I2 = 0%) (Analysis 2.2) (very low-quality evidence).
Chen 2014 reported higher mean values for disease severity (more
severe symptoms) in the intranasal steroid group (4.27, 17 chil-
dren) compared with the group receiving saline and intranasal
steroids (3.37, 26 children) at three months using an instrument
with a total range of 0 to 12.
2.2. Significant local adverse effects: epistaxis
None of the studies specifically mentioned how adverse effects
would be sought in their study methods; nor did they mention
epistaxis as an adverse effect. Three studies made statements about
adverse effects. One study (40 adults) indicated that “all [treat-
ments were]tolerated well, none [of the participants] had adverse
events” (Wu2014) and the other two studies (62 children) reported
that nasal irrigation with saline was well accepted in all patients
and no adverse effects were reported in the saline group (Chen
2014; Li 2009) (very low-quality evidence).
2.3. Disease-specific health-related quality of life
Two studies including only adults measured disease-specific
health-related quality of life at between four weeks and three
months.
Rogkakou 2005, where all participants also used oral antihis-
tamines, used the Rhinasthma quality of life instrument (range 0
to 100, lower = better quality of life) at four weeks.We present the
results for the ’global impact’, which is a synthetic score covering
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the entire questionnaire. Standard deviations for the results were
not presented and so we imputed these from the P values.
Wu 2014, where all participants also used intranasal steroids, used
the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)
(unclear range, lower = better quality of life) at three months.
Due to these differences, we used the SMD in the analysis.
Four weeks to six months
It is uncertain whether saline irrigation in addition to pharmaco-
logical treatment (oral antihistamines or intranasal steroids) im-
proved health-related quality of life at four weeks to three months
compared with pharmacological treatment alone (SMD -1.26,
95%CI -2.47 to -0.05; 54 adult participants; 2 studies; I2 = 63%).
We used a random-effects model due to statistical heterogeneity
(Analysis 2.3) (very low-quality evidence).
2.4. Individual symptom scores
No studies reported symptom scores for the individual symptoms
of anterior rhinorrhoea (runny nose), posterior rhinorrhoea (post-
nasal drip), nasal blockage/congestion/obstruction, nasal itching
or sneezing.
2.5. Generic health-related quality of life
No studies reported generic health-related quality of life.
2.6. Any other local adverse effects: local irritation,
discomfort
None of the studies specifically mentioned local irritation or dis-
comfort as an adverse effect. Two studies made statements about
adverse effects. One (40 adults) indicated that “all [treatments
were]tolerated well, none [of the participants] had adverse events”
(Wu 2014) and the other (18 children) stated that “Nasal irriga-
tion with saline was well accepted in all patients and no adverse effect
was reported” (Li 2009) (very low-quality evidence).
2.7. Aural symptoms: ear pain, pressure or feeling of fullness
No studies reported aural symptoms of ear pain, pressure or feeling
of fullness.
2.8. Endoscopic score (e.g. Lund-Mackay/Lund-Kennedy)
No studies reported endoscopic scores.
Comparison 3. Saline versus intranasal steroids
Seven studies (89 children, 129 adults) compared saline nasal ir-
rigation with intranasal steroids (Chen 2014; Cordray 2005; Li
2009; Lin 2017; Ning 2011; Wu 2014; Yasar 2013), although
Yasar 2013 (40 children) did not report any of the primary or
secondary outcomes for this review.
One study included two saline arms (hypertonic and normal
saline) (Cordray 2005), for which we combined the results for
these analyses.
3.1. Disease severity, as measured by patient-reported
symptom score
Five studies measured disease severity using a patient-reported
symptom score (Chen 2014; Li 2009; Lin 2017 Ning 2011; Wu
2014).
Two of these studies could not be included in the quantitative
results: Chen 2014 did not present sufficient data in the paper to
be used in the meta-analysis and no response was received after we
attempted to contact the author, therefore only narrative results
are presented. Ning 2011 used median values and interquartile
ranges to describe the results in the intranasal steroid arm, and
means with standard deviations in the arm receiving saline.
Each of the three studies included in the quantitative results used
different scales, which are summarised in Table 2.
• Li 2009: Four symptoms: sneezing/itching, rhinorrhoea,
nasal congestion and postnasal drip/snorting, each measured on
a four-point scale (0 to 3 scale, 0 = no symptom). The sum of the
scores gave a total score (total range 0 to 12).
• Lin 2017: Four symptoms: nasal obstruction, rhinorrhoea,
sneezing and nasal pruritis, measured as a ”total nasal score“ on a
visual analogue scale (0 to 10).
• Wu 2014: Ten symptoms: nasal obstruction, itching,
sneezing, nasal discharge, eye itching, eye swelling, tearing, eye
pain, coughing and difficulty breathing, each measured on a 0 to
10 visual analogue scale (VAS) (0 = least symptoms). These
scores were averaged to give a final range of 0 to 10.
Due to these differences, when we performed meta-analyses that
included more than one study we used the SMD.
Up to four weeks
One study (14 children) presented results for symptom severity. It
is uncertain whether there is a difference in symptom severity score
between the intranasal steroid and the saline irrigation groups at
four weeks (MD 1.06, 95% CI -1.65 to 3.77) (Analysis 3.1).
Chen 2014 reported higher mean values for disease severity (more
severe symptoms) in the saline group (5.44, 18 children) compared
with the intranasal steroid group (4.11, 17 children) at four weeks
using an instrument with a total range of 0 to 12.
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Four weeks to six months
Three studies (83 adults, 14 children) showed that intranasal
steroids may improve patient-reported symptom scores compared
with saline irrigation at four weeks to three months (SMD 1.26,
95% CI -0.92 to 3.43; 97 participants; three studies; I2 = 95%).
We used a random-effects model due to unexplained heterogene-
ity (Analysis 3.2).
Chen 2014 reported higher mean values for disease severity (more
severe symptoms) in the saline group (6.58, 18 children) compared
with the intranasal steroid group (4.27, 17 children) at 12 weeks
using an instrument with a total range of 0 to 12.
3.2. Significant local adverse effects: epistaxis
One study reported the recording of adverse effects in their meth-
ods section although epistaxis was not specifically mentioned as
being sought or identified in any of the studies. Of the five studies
that mentioned adverse effects in their results, Cordray 2005 (21
adults) reported that two participants withdrew from the study
due to adverse effects but they did not provide further informa-
tion as to the nature of the effects or to which groups the par-
ticipants were allocated. Wu 2014 (38 adults) mentioned that all
treatments were ”well tolerated“ and Lin 2017 (45 adults) reported
that none of the saline irrigation group experienced adverse effects
but that 27.3% of the intranasal steroid group reported adverse
effects (although none were reported as epistaxis). The remaining
two studies only noted that there were no adverse effects in the
saline irrigation group; there was no information for the groups
allocated to intranasal steroids (Chen 2014; Li 2009).
3.3. Disease-specific health-related quality of life
Two studies reported disease-specific health-related quality of life:
• Wu 2014: used the Rhinoconjunctivitis Quality of Life
Questionnaire (RQLQ) (unclear range, lower = better quality of
life).
• Lin 2017: used the mini-RQLQ, a shortened version of the
RQLQ tool (0 to 84, lower = better quality of life).
Due to these differences, when we performed meta-analyses that
included more than one study we used the SMD.
Four weeks to six months
Two studies (83 adults) indicated that it is uncertain whether there
is a difference in disease-specific quality of life between the saline
irrigation and intranasal steroid groups at three months (SMD
0.01, 95% CI -0.73 to 0.75; 83 participants; 2 studies; I2 = 65%).
We used a random-effects model due to heterogeneity (Analysis
3.3).
3.4. Individual symptom scores
No studies reported symptom scores for the individual symptoms
of anterior rhinorrhoea (runny nose), posterior rhinorrhoea (post-
nasal drip), nasal blockage/congestion/obstruction, nasal itching
or sneezing.
3.5. Generic health-related quality of life
No studies reported generic health-related quality of life.
3.6. Any other local adverse effects: local irritation,
discomfort
See section 3.2 above. Only Lin 2017 (45 adults) specifically men-
tioned local irritation or discomfort, where 6/22 (27.3%) of partic-
ipants using intranasal steroids reported pharyngitis (sore throat)
compared to no reports in the group using saline treatment (risk
ratio (RR) 0.07, 95% CI 0.00 to 1.24) (Analysis 3.4).
3.7. Aural symptoms: ear pain, pressure or feeling of fullness
No studies reported aural symptoms of ear pain, pressure or feeling
of fullness.
3.8. Endoscopic score (e.g. Lund-Mackay/Lund-Kennedy)
No studies reported endoscopic scores.
Comparison 4. Saline versus intranasal antihistamines
One study (40 children) compared saline irrigation with intranasal
antihistamines but did not report any of the primary or secondary
outcomes of this review (Yasar 2013).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Nasal saline plus pharmacological treatment versus pharmacological treatment alone for allergic rhinitis
Patient or population: allergic rhinit is
Setting: secondary care
Intervention: saline plus pharmacological treatment (intranasal steroids or oral ant ihistamines)
Comparison: pharmacological treatment alone
Outcomes Relative effect
(95% CI)
Anticipated absolute effects∗ (95% CI) Certainty of the evidence
(GRADE)
What happens
Without saline With saline Difference
Disease severity score
(up to 4 weeks)
Assessed with: various
instruments used
Follow-up: 4 weeks
of part icipants: 32 (18
children; 14 adults)
(2 RCTs)1
- - - SMD 0.6 lower
(1.34 lower to 0.15 higher)
⊕©©©
VERY LOW 2
It is uncertain whether
saline in addit ion to phar-
macological treatment (an-
t ihistamines or steroids)
improves pat ient-reported
severity scores at 4 weeks,
compared with pharmaco-
logical treatment alone
Disease severity score
(4 weeks to 6 months)
Assessed with: various
instruments used
Follow-up: 3 months
of part icipants: 58 (18
children; 40 adults)
(2 RCTs) 1
- - - SMD 0.32 lower
(0.85 lower to 0.21 higher)
⊕©©©
VERY LOW 2
It is uncertain whether
saline in addit ion to phar-
macological treatment (an-
t ihistamines or steroids)
improves pat ient-reported
severity scores at 3 months,
compared with pharmaco-
logical treatment alone
Individual symptom
scores - not measured
- - No studies measured this
outcome.
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Adverse ef fects - epis-
taxis
of part icipants: 58 (2
RCTs)
(18 children; 40 adults)
Three studies made statements about adverse ef fects. One study (40 adults) indicated that
‘‘all [treatments were] tolerated well, none [of the participants] had adverse events’’ (Wu 2014) and the
other two studies (62 children) reported that nasal irrigat ion with saline was well accepted
in all pat ients and no adverse ef fect was reported with the use of saline (Li 2009).
⊕©©©
VERY LOW 3
It is uncertain whether there
is a dif ference in adverse ef -
fects between the groups.
None of the studies specif -
ically mentioned epistaxis
as an adverse ef fect
Health-related quality
of lif e (4 weeks to 6
months)
Assessed with: various
instruments
of part icipants: 54 (all
adults)
(2 RCTs)4
- - - SMD 1.26 lower
(2.47 lower to 0.05 lower)
⊕©©©
VERY LOW 5
It
is uncertain whether saline
in addit ion to pharmaco-
logical treatment (ant ihis-
tamines or steroids) im-
proves health-related qual-
ity of lif e at 4 weeks to
6 months, compared with
pharmacological treatment
alone
Other adverse ef fects:
local irritat ion
Follow-up: range 4
weeks to 6 weeks
of part icipants: 58 (18
children;40 adults)
(2 RCTs)
None of the studies specif ically mentioned local irritat ion as an adverse ef fect. Two studies
made statements about adverse ef fects. One study (40 adults) indicated that ‘‘all [treatments
were] tolerated well, none [of the participants] had adverse events’’ (Wu 2014) and the other (18
children) that ‘‘Nasal irrigation with saline was well accepted in all patients and no adverse effect was
reported” (Li 2009).
⊕©©©
VERY LOW 3
It is uncertain whether there
is a dif ference in adverse
ef fects between the groups
as no adverse ef fects were
reported
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; RCT: randomised controlled trial; SMD: standardised mean dif ference
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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1Dif ferent instruments were used to assess the disease severity score. A summary of these can be found in Table 2.
2 Very low-quality evidence. Downgraded by two levels due to risk of bias (studies were generally poorly conducted with a
high risk of bias; the validat ion status of the symptom severity scores used is unknown). Downgraded by one level due to
imprecision (the results are imprecise with small sample sizes and wide conf idence intervals).
3Very low-quality evidence. Downgraded by two levels due to risk of bias (studies were generally poorly conducted with a high
risk of bias and it is unclear whether adverse ef fects were systemically reported). Downgraded by one level due to imprecision
(very small sample size).
4Rogkakou 2005 used the ’Global Impact ’ score for the Rhinasthma quality of lif e instrument. Wu 2014 used the Rhinocon-
junct ivit is Quality of Life Quest ionnaire (RQLQ) but the range of possible scores is not reported.
5Very low-quality evidence. Downgraded by two levels due to risk of bias (studies were generally poorly conducted with a high
risk of bias; it is unclear whether the instruments used were validated and the scale in one remains unknown). Downgraded by
one level due to inconsistency (there is signif icant stat ist ical heterogeneity between the results). Downgraded by one level
due to imprecision (sample size is very small and so the conf idence intervals are very wide).
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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D I S C U S S I O N
Summary of main results
This review includes seven studies comparing nasal saline irriga-
tion with no saline treatment where no background pharmaco-
logical treatment was used (Summary of findings for the main
comparison), and four studies comparing saline irrigation with no
saline treatment where all participants used pharmacological treat-
ment for allergic rhinitis (intranasal steroids: three studies; oral
antihistamines: one study) (Summary of findings 2).
Seven studies compared nasal saline irrigation against intranasal
steroid treatment.One study compared saline irrigation against in-
tranasal antihistamines but no relevant outcomes were presented.
Saline versus no saline treatment (no background
treatment)
There may be an improvement in patient-reported disease severity
with saline irrigation compared to no saline treatment at up to
four weeks and at up to eight weeks (low-quality evidence). It is
uncertain whether there are differences between the saline and no
saline groups with respect to disease-specific health-related quality
of life at up to four weeks and at eight weeks (very low-quality
evidence). Of the five studies that made statements about adverse
effects, no adverse effects were reported in either the saline arms
(five studies) or no saline arms (two studies) (low-quality evidence).
No other prespecified outcomes were reported.
Subgroup analysis for volume indicated that all of the volumes
of saline irrigation may have reduced patient symptom severity
but there was significant heterogeneity within the results. With
respect to tonicity, the effect size for treatment with hypertonic
solution was greater than with normal saline, although there was
considerable heterogeneity in the results.
Saline plus pharmacological treatment versus
pharmacological treatment alone (intranasal steroids
or oral antihistamines)
It is uncertain whether there are differences between saline irri-
gation and no saline treatment, when used alongside pharmaco-
logical treatment, in patient-reported disease severity or disease-
specific health-related quality of life (very low-quality evidence). No
adverse effects were reported. No other outcomes were reported.
Saline versus intranasal steroids
It is uncertain whether there are differences between saline and
intranasal steroid treatment for any of the outcomes reported. The
quality of the evidence is very low.
Overall completeness and applicability of
evidence
The evidence included studies in both children and adults, in-
cluding a study in pregnant women. The included saline solutions
varied greatly with respect to the volume and tonicity of saline and
are likely to be representative of the solutions available in practice.
Adverse effects were not well reported in the included studies. In
many studies the methods section did not detail how adverse ef-
fects would be defined or recorded, and in many the results just
included one statement indicating that ’no adverse effects were
reported’. There have been adverse effects reported in other pop-
ulations using nasal saline irrigation. Cochrane Reviews investi-
gating the use of nasal saline irrigation in people with other con-
ditions have noted the adverse effects of epistaxis and local irri-
tation/discomfort (Chong 2016; King 2015). The author team
have identified that in addition to nasal symptoms, people with
allergic rhinitis using saline irrigation may also complain of aural
symptoms, which could influence their adherence.
The maximum duration of treatment in the studies was three
months and so it is not known whether the efficacy in reducing
symptoms ismaintained over a longer period, or if there are longer-
term adverse effects that were not reported in the studies.
Quality of the evidence
The quality of the evidence for the outcomes as assessed with
GRADE is low or very low. The studies were generally small with
poor description of methodology. The lack of information about
the validation of instruments used to assess patient-reported dis-
ease severity limited our confidence in the results. It is likely that
the variety of different saline interventions used within the studies
(volumes, tonicity, duration of treatment), and differences in the
disease severity scores, resulted in the heterogeneity observed in
the results.
Potential biases in the review process
Four of the studies were conducted in China, two of which re-
quired translation fromChinese. There may have been other stud-
ies published in the Chinese literature that were not identified
through our searches.
For the comparison of saline irrigation with no saline treatment,
this review did not look at the number of people who required
the use of rescue medication during the study, although a num-
ber of studies did state that rescue medication (usually oral an-
tihistamines) was allowed. If there was a variation between the
two treatment groups with regards to the number requiring res-
cue medication this may have had an impact on the effect sizes
reported, although this is likely to increase the effect size for saline
irrigation compared to no saline treatment. Future updates could
consider taking this into account; for example, theChairattananon
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study used a combined ’nasal symptom and medication’ score,
which helped to account for this (Chairattananon 2013).
We did not include studies using saline as a ’placebo’ treatment
in comparison to ’active’ allergic rhinitis treatments (such as in-
tranasal steroids). In these studies, which are looking primarily at
the efficacy and safety of the ’active’ treatment, the characteristics
of the saline placebo are often poorly reported. In addition, the
saline placebo is often mixed with other excipients to more closely
mimic the active intervention.
Agreements and disagreements with other
studies or reviews
Comparison with systematic reviews looking at nasal
saline irrigation for allergic rhinitis
We found two systematic reviews. Each included both randomised
and non-randomised clinical trials (e.g. before-after studies). The
conclusions of the reviews did not contradict the findings of our
review:
• Hermelingmeier 2012: ”Saline nasal irrigation (SNI) using
isotonic solution can be recommended as complementary therapy in
AR. It is well tolerated, inexpensive, easy to use, and there is no
evidence showing that regular, daily SNI adversely affects the
patient’s health or causes unexpected side effects.“
• Khianey 2012: ”Overall, the data appear to demonstrate some
small clinical benefit to nasal saline irrigation. Nasal saline
irrigation is well tolerated, with minimal side effects. Further
definitive studies are needed to optimize efficacy.“
Comparison with Cochrane Reviews looking at nasal
saline irrigation for other populations
We found two Cochrane Reviews investigating the use of nasal
saline irrigation in other populations. Both highlighted the low
quality of the evidence as a limiting factor in drawing conclusions.
• Chong 2016 investigated nasal saline irrigation in people
with chronic rhinosinusitis. The authors only found two studies
with very different populations, methods of nasal irrigation and
comparisons. They found that the quality of evidence was very
low and that it was difficult to draw conclusions.
• King 2015 examined the use of nasal saline irrigation in
people with upper respiratory tract infections (URTIs). They
concluded: ”Nasal saline irrigation possibly has benefits for relieving
the symptoms of acute URTIs. However, the included trials were
generally too small and had a high risk of bias, reducing confidence
in the evidence supporting this.“
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
For people with allergic rhinitis
There is low-quality evidence that nasal saline irrigation may have
benefits in both adults and children in relieving symptoms of al-
lergic rhinitis compared to no saline treatment. The use of nasal
saline irrigation is unlikely to be associated with adverse effects.
It is unclear which is the best type of saline irrigation to use with
respect to volume, strength and how often to use it.
For clinicians
There is low-quality evidence that using saline irrigation may re-
duce patient-reported disease severity compared with no saline
treatment at up to four weeks and between four weeks and three
months in both adults and children. The reporting of adverse ef-
fects in the studies was very poor but no studies reported adverse
effects with the use of saline. This review did not look at direct
comparisons of saline type (e.g. volume, tonicity and frequency of
administration). No longer-term outcomes (after three months)
were identified. There is a lack of evidence to compare saline irri-
gation to pharmacological treatments.
For funders
Although saline may be an effective treatment for reducing symp-
toms of allergic rhinitis (low-quality evidence), there is generally a
lack of information about its use. Further research is needed: this
may include both systematic reviews comparing types of saline
(volume, tonicity, frequency of administration), as we excluded 15
studies from this review that made these comparisons, and well-
conducted primary trials (see Implications for research).
Implications for research
Evidence
As of November 2017, we have identified 14 studies that inves-
tigated the use of nasal saline irrigation in allergic rhinitis. The
studies were generally small (median sample size = 46 participants)
and poorly reported. The evidence identified indicates that there
may be benefits in terms of patient-reported disease severity when
compared with no saline treatment but the range of unvalidated
instruments used, along with heterogeneity in the study character-
istics, made it difficult to draw definite conclusions. The reporting
of adverse effects was very poor in the studies.
We consider that more research on the use of nasal saline in allergic
rhinitis is very important. We propose that the following aspects
should be considered when designing trials:
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Population
• Separate trials should be completed in children and in
adults as the setting for recruitment and the outcomes are likely
to be different.
◦ Children should be recruited from secondary care
clinics where better diagnostic testing is available and
recruitment is likely to be easier.
◦ Adults could be recruited into large, multicentre,
primary care trials, although appropriate diagnosis testing
should be a prerequisite.
• Trials should be adequately powered and imbalances in
prognostic factors (for example, allergen type) must be
accounted for in the statistical analysis.
• Study participants should bediagnosed with allergic
rhinitis using appropriate diagnostic methods including clinical
symptoms characteristic of allergic rhinitis with a positive
radioallergosorbent test (RAST) or skin prick test (SPT).
Intervention and comparison
• Any trial should be pragmatic and consider the use of saline
irrigation as an adjunct to pharmacological treatments (such
as intranasal steroids and antihistamines).
• In adults in primary care, a trial of saline irrigation
compared with intranasal corticosteroids could be considered.
• Investigators should consider the volume, tonicity,
alkalinity, temperature and frequency of administration of
the saline irrigation used.
• If people with seasonal allergic rhinitis are included within
the trial, it should be conducted at a time of the year when
symptoms are expected to occur. All trials should be completed
for a sufficient duration to determine whether continued use of
saline nasal irrigation has additional benefits or harms. Studies
should consider investigating the effect of longer-term use of
nasal saline (e.g. more than six months).
Outcomes
• Studies should focus on outcomes that are important to
people with allergic rhinitis and use validated instruments to
measure these, in particular using standard, validated, patient-
reported disease severity scores and disease-specific health-related
quality of life scores. People may find dichotomised outcomes
easiest to interpret; for example, the percentage of participants
achieving a minimal clinically important difference (MCID) or
improvement for that outcome. Such MCIDs or cut-off points
should be included in the study protocol and clearly outlined in
the methods section.
• Adverse effects should be defined at the start of the trial
and methods for reporting these should be clearly stated in the
protocol.
• Symptom scores should include both nasal and ocular
symptoms (such as eye redness and eye itching) as many people
will experience these with allergic rhinitis.
• The duration of the trial needs to be carefully considered.
The current evidence only includes trials that had up to a three-
month treatment duration. There are still unanswered questions
about the benefits and harms of long-term use of nasal saline for
persistent allergic rhinitis.
• Trials and other high-quality studies should use consistent
outcomes and adhere to reporting guidelines, such as
CONSORT, so that results can be compared across future trials.
The development of a standardised set of outcomes, or core
outcome set, for allergic rhinitis, agreed by researchers, clinicians
and patients, will facilitate this process.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Chairattananon 2013
Methods 2-arm, non-blinded, parallel-groupRCT, with 8weeks duration of treatment and follow-
up
Participants Location: Bangkok, Thailand
Setting of recruitment and treatment: secondary care: Department of Allergy and
Immunology, Paediatric Department
Sample size: 48
• Number randomised: 25 in saline, 23 in control
• Number completed: 22 in saline, 20 in control
Participant (baseline) characteristics:
• Age: 9.7 ± 2.78 years
• Gender: male 24 (57.1%)/female 17 (42.9%)
• Main diagnosis: allergic rhinitis
• Type of allergic rhinitis: not reported
• Severity of allergic rhinitis: mild to moderate
• Type of allergic trigger: common aeroallergen (common aeroallergen: house dust
mite, cockroach, cat, dog, grass, moulds)
• Other important effect modifiers, if applicable: none reported
Inclusion criteria: aged between 5 and 15 years with:
(1) clinical diagnosis of allergic rhinitis (ARIA guideline)
(2) positive skin prick test to one or more of common aeroallergens, house dust mite,
cockroach, cat, dog, grass, moulds) and/or specific IgE to aeroallergens
(3) combined daily total nasal symptom score and medication score (CSM) at randomi-
sation between 3 to 9 (mild to moderate symptoms)
Exclusion criteria:
(1) Use of intranasal steroids more than 3 times per week for 2 weeks prior to enrolment
(2) Use of nasal irrigation for at least 1 month or more than 3 times per week for 1
month prior to entry
(3) Uncontrolled asthma, sinusitis, severe nasal septum deviation, intolerance to nasal
saline irrigation, severe symptoms need to be treat with intranasal corticosteroid
Interventions Intervention (n = 25): isotonic saline nasal irrigation, 90 mL per nostril twice per day
for 8 weeks. Irrigation was done via a Hashi® Nasal Rinser
Comparator group (n = 23): no saline solution
Use of additional interventions (common to both treatment arms): participants were
prescribed cetirizine and pseudoephedrine as needed
Outcomes Outcomes of interest in the review:
Primary outcomes:
1. Health-related quality of life, using disease-specific health-related quality of life
score. Thai allergic rhinoconjunctivitis patients (RCQ-36) (36 questions measured on
a 0 to 4 scale, higher = worse quality of life) measured at baseline and week 2, 4 and 8.
Personal communication with the authors indicated that only 35 items were used to
construct an overall score, which had a range of 0 to 140.
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Chairattananon 2013 (Continued)
2. Disease severity, as measured by a visual analogue scale to assess the severity of
overall nasal symptoms, ranging from 0 to 10 (higher score = better symptoms).
Measured weekly from baseline to 8 weeks.
3. Significant adverse effects: epistaxis
Secondary outcomes: none reported
Other outcomes reported by the study:
• Combined daily total nasal symptoms score and medication score (CSM)
• Nasal mucociliary clearance
• Use of antibiotics
Funding sources No information provided
Declarations of interest No information provided
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”The computer generated random
numbers with block randomization in two
groups were used.“
Comment: adequate information about
randomisation schedule
Allocation concealment (selection bias) Unclear risk Comment: no information about alloca-
tion concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: the study was not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: it does not appear that the out-
come assessors were blinded to treatment
group
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: 6 participants (14.3%) did not
finish the trial. These were evenly split be-
tween the groups (3 participants in each
group) and reasons were provided
Selective reporting (reporting bias) Unclear risk Comment: no protocol was identified on
ClinicalTrials.gov or the Thai registry of
clinical trials, although a trial protocol is
mentioned in the results
One outcome was presented in the re-
sults section, but was not mentioned in the
methods (e.g. use of antibiotics)
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There is a difference between the previ-
ously published abstract and the full paper
with regards to the quality of life instru-
ment used. There is no overall range given
for the quality of life instrument used
Other bias (Non validated instruments) Unclear risk Comment: there is a link to a paper for the
quality of life instrument (RCQ-36) but
the scoring system appears to be different
and no explanation is given as to why a 0
to 4 scale (rather than a 1 to 5 scale) is used
Other bias Low risk Comment: no other sources of bias were
identified
Chen 2014
Methods 3-arm, non-blinded, parallel-group RCT, with 12-week duration of treatment and fol-
low-up
Participants Location: Shanghai, China
Setting of recruitment and treatment: secondary care: Department of Otolaryngology
at Shanghai Children Hospital
Sample size: 61
• Number randomised: 17 in intranasal steroids group, 18 in seawater group, 26
in intranasal steroids PLUS seawater group
• Number completed: no dropouts were reported
Participant (baseline) characteristics:
• Age: mean 6 years (range 2 to 15 years)
• Gender: 38% female/62% male
• Main diagnosis: allergic rhinitis (moderate to severe) caused by house dust mites
and mould
• Type of allergic rhinitis: (persistent) not stated
• Severity of allergic rhinitis: moderate/severe
• Type of allergic trigger: house dust mites and mould
• Other important effect modifiers, if applicable: no information provided
Inclusion criteria: the diagnosis of allergic rhinitis was confirmed by history, physical
examination and skin prick tests for a battery of common allergens
Exclusion criteria: marked septum deviation, prior nasal surgery, nasal polyposis and
symptoms of infection
Interventions Intranasal steroid group (n = 17): 200 µg fluticasone propionate nasal spray (Flonase,
GlaxoSmithKline UK) daily for 4 weeks, followed by administration of 100 mg daily
for 4 weeks and 50 mg daily for another 4 weeks
Seawater saline group (n = 18): 4 to 6 sprays of seawater, twice a day for nasal irri-
gation from a commercial positive-pressure nasal irrigation applicator (Nasal Cleaner;
physiological seawater, Nantong Apon Medical Appliance Co., China). Treatment for
12 weeks
Intranasal steroid PLUS seawater saline group (n = 26): both interventions as above
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for 12 weeks
Use of additional interventions (common to both treatment arms): no information
provided
Outcomes Outcomes of interest in the review:
Primary outcomes:
1. Disease severity, as measured by a patient-reported symptom score. Nasal
symptoms were: (1) nasal itching, (2) rhinorrhoea, (3) nasal obstruction and (4)
sneezing. The intensity of these 4 symptoms was rated on a 4-point scale: 0 = no
symptoms, 1 = slight symptoms, 2 = mild symptoms and 3 = severe symptoms. Total
scores ranged from 0 to 12 and represented the sums of scores for the 4 symptoms
Other outcomes reported by the study:
• Nasal signs (1 = turbinate hypertrophy with little nasal blockage, 2 = nasal
congestion with nasal blockage and 3 = nasal congestion with total nasal blockage
limiting nasal breathing)
• Nasal secretions of the eosinophilia
Funding sources “This study was supported by a Project of the Shanghai Committee of Science and Technology,
China (Grant No. 12411952407).”
Declarations of interest No information provided
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: ”…randomly assigned…“
Comment: unclear methods of randomisa-
tion. Some concern that there were more
participants in the combination group
compared with the other treatment groups
but because of the small sample size it is
difficult to know if this is by chance. There
is no information about the baseline char-
acteristics of the participants in the text
Allocation concealment (selection bias) Unclear risk Comment: there is no information regard-
ing allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: this was an open study and no
blinding was completed
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: there was no blinding and
the main outcome was a patient-reported
symptom score and so some bias in the re-
sults may have occurred. People who were
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in the combined group will have known
they were receiving ’double’ treatment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: no withdrawals were reported.
However, there is not enough information
to determine if all of the participants in-
cluded in the trial completed, or if there
were some lost to follow-up
Selective reporting (reporting bias) High risk Comment: no protocol could be identified
on ClinicalTrials.gov or the Chinese clini-
cal trials registry (chictr.org.cn). The out-
comes reported in the methods section are
presented although only in graphical form.
No standard deviations for the symptom
scores are provided. Precise P values are not
provided
Other bias (Non validated instruments) Unclear risk Comment: it is unclear whether the symp-
tom scoring system used is validated. The
paper provides a table with a reference to
an external paper but there is no related ref-
erence in the bibliography, so it is not pos-
sible to check
Other bias Unclear risk Comment: no other sources of bias were
identified
Cordray 2005
Methods 3-arm, single-blinded, parallel-group RCT, with 7-day duration of treatment and follow-
up
Participants Location: Oklahoma, USA
Setting of recruitment and treatment: primary care: family practice
Sample size: 21
• Number randomised: unclear - 21
• Number completed: 5 in Dead Sea saline, 5 in intranasal corticosteroids, 5 in
control (normal saline)
Participant (baseline) characteristics:
• Age: 35.2 ± 16.05 (range: 20 to 74 years)
• Gender (M/F): 3/12 (80% female)
• Main diagnosis: seasonal allergic rhinitis
• Type of allergic rhinitis: (intermittent - data extractor interpretation)
• Severity of allergic rhinitis: not reported
• Type of allergic trigger: pollen and Alternaria
• Other important effect modifiers, if applicable: none reported
Inclusion criteria: 18 years of age and experienced at least 2 of the 6 symptoms (nasal
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stuffiness, watery/itchy eyes, rhinorrhoea, sneezing, postnasal drainage and itchy throat/
cough) at presentation and had to have a positive skin puncture test for seasonal allergies
Exclusion criteria: chronic sinusitis, nasal polyposis, a deviated nasal septum or history
of nasal septal perforation and recent nasal or sinus surgery; the use of an antihistamine,
cromolyn, decongestant, or a topical or systemic corticosteroid within the preceding 2
weeks or an immunotherapeutic agent within the preceding 2 years
Interventions Dead Sea saline (n = 5): intranasal hypertonic Dead Sea saline spray, 2 sprays into each
nostril 3 times daily for 7 days. No volume given
Intranasal corticosteroid group (n = 5): aqueous triamcinolone spray (110 µg into
each nostril once daily) for 7 days
‘Control’ normal saline group (n = 5): nasal saline spray, 2 sprays into each nostril 3
times daily for 7 days
Use of additional interventions (common to both treatment arms): none stated. The
use of antihistamines was not allowed during treatment
Outcomes Outcomes of interest in the review:
Primary outcomes:
1. Health-related quality of life, using Rhinoconjunctivitis Quality of Life
Questionnaire (RQLQ), mean composite score (range: 0 to 6, lower = better quality of
life) at 7 days
Other outcomes reported by the study:
None reported
Funding sources No information provided
Declarations of interest No information provided
Notes The RQLQ is a validated instrument containing 28 questions regarding 7 domains:
activities, sleep, practical problems, nasal symptoms, eye symptoms and other symptoms.
For each domain, participants rate themselves as to how much their symptoms have
affected them during the previous week on a scale of 0 to 6 (0 = no effect on quality of
life)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: ”Patients were randomised…“
Comment: no information regarding the
process for randomisation. 21 people were
enrolled in the study and 15 people were
randomised. No information given about
the baseline characteristics per group
Allocation concealment (selection bias) Unclear risk Comment: no information regarding the
processes used for allocating the partici-
pants to groups and whether the investigat-
ing clinicians could have influenced this
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: ”…single-blind, placebo controlled
study….“
Comment: although the paper states that
the trial was single-blind, it provides no
information regarding who was blinded
and how this was maintained given the in-
tranasal steroid intervention had different
a different frequency of administration to
the saline groups
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: there is a lack of information
regarding who was blinded and how the
blindingwasmaintained given the different
intervention regimens
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: ”During the study, 6 of the 21 par-
ticipants withdrew“
Comment: 6/21 (28.6%) of participants
withdrew. The overall reasons for dropping
out were listed but as the paper did not give
the number randomised to each group or
the numbers withdrawing from each group
there may be bias
Selective reporting (reporting bias) High risk Comment: no protocol for the trial was
identified on ClinicalTrials.gov. Although
the results present the values for the re-
sults before and after treatment, no stan-
dard deviations are provided and no infor-
mation regarding the difference between
groups was included
Reporting of adverse effects was not com-
pleted well. The paper reports that 2 par-
ticipants withdrew due to adverse reactions
but no information was provided regarding
what the events were, nor which groups the
participants were allocated to
Other bias (Non validated instruments) Low risk Quote: ”The RQLQ is a reliable, validated
instrument with strong discriminative prop-
erties“
Other bias Unclear risk Comment: there is a general lack of in-
formation provided in the paper regarding
how the interventions were applied (tonic-
ity, volume of saline sprays), the process
of randomisation, numbers randomised to
each group, the numbers dropping out
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from each group and how that would have
affected the results, the baseline character-
istics for each group
Di Berardino 2017
Methods 2-arm, non-blinded, single-centre, parallel-group RCT, with 2 periods of 6 days each,
one during low pollen season (1 to 7 April) and one during peak pollen season (27 April
to 3 May), duration of treatment and follow-up (duration of pollen season)
Participants Location: Italy
Setting of recruitment and treatment: unclear setting: University of Milan
Sample size: 40
• Number randomised: 20 in saline group, 20 in no saline group
• Number completed: 20 in saline group, 20 in no saline group
Participant (baseline) characteristics:
• Age: 26.0 ± 6.1 years
• Gender: M (%)/F (%): 16 (40%)/24 (60%)
• Main diagnosis: allergic rhinoconjunctivitis
• Type of allergic rhinitis: seasonal (intermittent)
• Severity of allergic rhinitis: not stated
• Type of allergic trigger: grass pollen
• Other important effect modifiers, if applicable: 0% asthma (exclusion criteria)
Inclusion criteria: (a) a typical clinical history of seasonal allergic rhinoconjunctivitis,
and (b) marked positivity of the skin-prick test results (wheal > 5 mm) to grass pollen
extracts in a hydroglyceric solution titrated at 30,000 biologic units/mL according to the
established guidelines
Exclusion criteria: (a) the coexistence of nasal polyposis and/or bronchial asthma, (b)
sensitisation to other allergens, (c) previous specific immunotherapy, (d) chronic use of
nasal decongestants or corticosteroids and (e) smoking
Interventions Intervention (n = 20): atomised hypertonic phosphate-buffered solution, at pH 6.1
(Atomix; Tred,Milan, Italy), one puff (0.13mL) in both nostrils 3 times per day, duration
= 6 days in low pollen season (1 to 7 April) and 6 days in the peak pollen season (27
April to 3 May)
Comparator group (n = 20): no saline
Use of additional interventions (common to both treatment arms): antihistamines
when needed (cetirizine 10 mg once a day). Participants were asked to record the fre-
quency of administration and dosage as well
Outcomes Outcomes of interest in the review:
Primary outcomes:
1. Disease severity, as measured by patient-reported symptom scores on a diary card.
The intensity of the following symptoms was recorded daily: itching, sneezing,
discharge and obstruction. Scores reported on a scale of 0 to 2 (0 = no symptoms; 1 =
tolerable symptoms; 2 = intolerable symptoms). The daily symptoms were summed
into a symptoms scores for the week.
Secondary outcomes: none listed
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Other outcomes reported by the study:
Mucociliary clearance, ocular symptoms, consumption of antihistamines
Funding sources ”No external funding sources reported.”
Declarations of interest “The authors have no conflicts of interest to declare pertaining to this article.”
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”The patients were randomly divided
into two groups according to the randomiza-
tion tables.“
Comment: adequate sequence generation
Allocation concealment (selection bias) Unclear risk Comment: there is no information regard-
ing the allocation concealment in this study
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: it does not appear that the par-
ticipants or healthcare professionals in this
study were blinded to treatment group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: it does not appear that outcome
assessors in this study were blinded to treat-
ment group
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: it does not appear that any par-
ticipantwhowas randomised failed to com-
pete the study
Selective reporting (reporting bias) Low risk Comment: no protocol was mentioned in
the paper or found on ClinicalTrials.gov or
the European Clinical Trials Registry
How the nasal symptom score was mea-
sured and summarised is not well described
in the paper and no overall range of scores
is given in the paper. However, these data
were provided by personal communication
with the authors
Other bias (Non validated instruments) Unclear risk Comment: it is not clear if the instrument
used to measure the nasal symptoms was
validated. It is a different scale to those used
in other papers
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Other bias Low risk Comment: no other risk of bias identified
Garavello 2003
Methods 2-arm, non-blinded, parallel-groupRCT, with 6weeks duration of treatment and follow-
up
Participants Location: Italy
Setting of recruitment and treatment: secondary care: Department of Otolaryngology,
San Gerardo Hospital
Sample size: 20
• Number randomised: 10 in intervention (saline), 10 in comparison (no saline)
• Number completed: 10 in intervention (saline), 10 in comparison (no saline)
Participant (baseline) characteristics:
• Age: 6 to 12 years
• Gender: 8 (40%) male/12 (60%) female
• Main diagnosis: seasonal allergic rhinitis
• Type of allergic rhinitis: seasonal (intermittent)
• Severity of allergic rhinitis: not given
• Type of allergic trigger: Parietaria pollen
• Other important effect modifiers, if applicable: not given (people with asthma
were excluded)
Inclusion criteria: (1) typical anamnesis for seasonal allergic rhinitis for at least 2 years;
(2) positive prick tests to Parietaria pollen extracts in a hydroglyceric solution titrated at
20.00 biological units (BU)/ml; (3) positive RAST to Parietaria pollens of at least class
2
Exclusion criteria: presence of symptoms of asthma, urticaria or eczema, a clinically
relevant sensitisation to other allergens and the use of specific immunotherapy within
the past 2 years
Interventions Intervention (n = 10): hypertonic saline solution (3%), room temperature, 2.5 mL in
each nostril administered by disposable syringe, 3 times daily for 6 weeks
Comparator group (n = 10): no saline solution
Use of additional interventions (common to both treatment arms): participants were
allowed to use oral antihistamines as rescue medications. The use was recorded and
presented as an outcome
Outcomes Outcomes of interest in the review:
Primary outcomes:
1. Disease severity, as measured by patient-reported symptom scores on a diary card.
The intensity of the following symptoms were recorded daily: rhinorrhoea, nasal
obstruction, nasal itching and sneezing. Scores reported on a scale of 0 to 4 (0 = none;
1 = slight, 2 = mild, 3 = moderate, 4 = severe). A daily total score (range: 0 to 16) was
reported, which was the sum of scores of the 4 symptoms. Daily scores were averaged
to calculate a ”mean daily rhinitis score“ per participant for each week. Measured at 4
weeks and 6 weeks.
Secondary outcomes: none reported
Other outcomes reported by the study:
45Saline irrigation for allergic rhinitis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Garavello 2003 (Continued)
• Use of oral antihistamines as rescue medication
Funding sources No information provided
Declarations of interest No information provided
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”…randomization was performed
according to a computer-generated list un-
known to the physicians.“
Comment: adequate generation of ran-
domised schedule
Allocation concealment (selection bias) Low risk Quote: ”…randomization was performed
according to a computer-generated list un-
known to the physicians.“
Comment: clinicians were unaware of the
randomisation schedule during randomisa-
tion
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: participants were not blinded
to treatment
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: participants were not blinded
to treatment. Given the main outcome was
participant-reported this may have influ-
enced the results
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: all randomised participants
completed the trial
Selective reporting (reporting bias) Low risk Comment: no protocol available on Clin-
icalTrials.gov or European Clinical Trial
Registry
All outcomes listed in the methods section
are reported in the results section
Other bias (Non validated instruments) Unclear risk Comment: it is unclear whether the symp-
tom scoring system is a validated scale
Other bias Low risk Comment: no other sources of bias were
identified
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Methods 2-arm, non-blinded, parallel-group RCT, with 7-week duration of treatment and follow-
up
Participants Location: Italy
Setting of recruitment and treatment: not stated
Sample size: 44
• Number randomised: 22 in saline, 22 in no saline
• Number completed: 20 in saline, 20 in no saline
Participant (baseline) characteristics:
• Age: 9.1 ± 2.5 years (range 5 to 14)
• Gender (F/M): 25 (62.5%)/15 (37.5%) (from Table 1) or 20 (50%)/20 (50%) (in
results section text)
• Main diagnosis: allergic rhinoconjunctivitis
• Type of allergic rhinitis: seasonal allergic rhinoconjunctivitis (intermittent)
• Severity of allergic rhinitis: not given
• Type of allergic trigger: grass pollen
• Other important effect modifiers, if applicable:
◦ Bronchial asthma: 0% (exclusion criteria)
◦ Duration of disease (years): Group A: 1.5 years ± 0.7; Group B: 1.6 ± 0.7
years
Inclusion criteria: 1) typical anamnesis for seasonal allergic rhinoconjunctivitis; 2)
marked positivity of the skin prick tests (≥ 2 plus) to grass pollen extracts in a hydro-
glyceric solution titrated at 20,000 biological units
Exclusion criteria: 1) presence of nasal polyposis and/or bronchial asthma; b) sensitisa-
tion to other allergens and c) previous specific immunotherapy
Interventions Intervention (n = 22): nasal rinsing 3 times daily. Each rinsing consisted of 3 sprays per
nostril (1 spray = x50 µL) nebulised at a mass median aerodynamic diameter of about
18 µm. Solution was hypertonic saline solution (NaCl 3%, 925 ± 30 mosm/kg, pH 7.
45 ± 0.2) in a bottle fitted with an atomiser for paediatric use
Treatment time 7 weeks
Comparator group (n = 22): no saline treatment
Use of additional interventions (common to both treatment arms): oral antihis-
tamines were allowed when needed; the intake of antihistamines was reported
Outcomes Outcomes of interest in the review:
Primary outcomes:
1. Disease severity, as measured by patient-reported symptom score. Daily record of
4 allergic symptoms (nasal discharge, nasal blockage, eye redness, eye itching) was kept
during the trial. Each symptom was recorded on a scale of 0 to 3 (0 = none, 3 = severe).
A total (ranging from 0 to 16 - see Notes section below) representing the sum of the
scores of these 4 symptoms was used to calculate a mean daily rhinitis score per
participant for each week of the pollen season. Measured at 4 weeks and 7 weeks.
Secondary outcomes:
1. Other local adverse effects: local irritation/discomfort
2. Other local adverse effects: Eustachian tube dysfunction
Other outcomes reported by the study:
Mean number of daily antihistamine treatments per participant per week
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Funding sources No information provided
Declarations of interest No information provided
Notes The study authors reported in the paper that the range for the disease severity scale was
from 0 to 16. However, it is unclear whether this is a reporting error as the total range
for 4 symptoms each measured on a 0 to 3 scale should be 0 to 12. We contacted the
authors to clarify this but no response was received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”Patients were…randomly assigned
to the active or control group according to ran-
domisation tables.“
Comment: references Garavello 2003 for
methods
Allocation concealment (selection bias) Low risk Quote: ”This randomization was per-
formed according to a computer-gener-
ated list unknown to the physicians.…“
(Garavello 2003)
Comment: references Garavello 2003 for
methods
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: blindingwas not possible in this
trial
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: outcomes were assessed by par-
ticipants/carers who were not blinded to
treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: 4/44 (9.1%) participants did
not complete the trial and the dropouts
were balanced between groups (2 in each
group) with reasons provided
Plausible effect size among missing out-
comes is not enough to have a clinically rel-
evant impact on observed effect size
Selective reporting (reporting bias) Low risk Comment: no protocol available for the
trial through ClinicalTrials.gov or Euro-
peanClinical TrialsRegistry. The outcomes
as described in the methods section are
recorded in the results section. They are
recorded in the same way as other similar
papers (Garavello 2003), which reduces the
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chance of selective outcome reporting.
Other bias (Non validated instruments) Unclear risk Comment: a summary symptom score of 4
elements is included (nasal discharge, nasal
blockage, ocular itching and ocular redden-
ing), each measured on a scale of 0 to 3. It
is not clear if this is a validated score
Other bias Low risk Comment: no other biases identified
Garavello 2010
Methods 2-arm, non-blinded, parallel-groupRCT, with 6weeks duration of treatment and follow-
up
Participants Location: Italy
Setting of recruitment and treatment: secondary care: ENT clinic, outpatient
Sample size: 52
• Number randomised: 26 in intervention (saline), 26 in comparison (no saline)
• Number completed: 22 in intervention (saline), 23 in comparison (no saline)
Participant (baseline) characteristics:
• Age: Group 1: 23.9 ± 5.4 years; Group 2: 24.4 ± 5.8 years
• Gender: 100% female
• Main diagnosis: pregnant women affected by Parietaria pollen allergic rhinitis for
at least 5 years
• Type of allergic rhinitis: intermittent (seasonal)
• Severity of allergic rhinitis: not reported
• Type of allergic trigger: Parietaria pollen
• Other important effect modifiers, if applicable: not stated
Inclusion criteria: (1) typical anamnesis for seasonal allergic rhinitis; (2) marked posi-
tivity of the prick tests (≥ 2 plus) to Parietaria pollen extracts and assessed according to
the already known guidelines, and (3) uncomplicated pregnancy with expected delivery
date after the pollen season
Exclusion criteria: (1) coexistence of nasal polyposis and/or bronchial asthma; (2) sen-
sitisation to other allergens, and (3) previous specific immunotherapy
Interventions Intervention (n = 26): 20 mL (10 mL in each nostril) sterile, room temperature, hyper-
tonic saline solution (NaCl 3%, 925 ± 30 mosm/kg, pH 7.45 ± 0.2) administered using
a disposable syringe, 3 times a day
Instructed to energetically breathe in during administration. Treatment continued for 6
weeks
Comparator group (n = 26): no local therapy
Use of additional interventions (common to both treatment arms): oral antihis-
tamines when needed. Participants were asked to record the relative intake. Choice of
preparation and dose was left to participants
Outcomes Outcomes of interest in the review:
Primary outcomes:
1. Disease severity, as measured by patient-reported symptoms. The following
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symptoms were recorded daily: rhinorrhoea, obstruction, nasal itching and sneezing.
Scores reported on a scale of 0 to 4 (0 = none; 1 = slight; 2 = mild; 3 = moderate; 4 =
severe). A daily total score was reported, which was the sum of scores of the 4 symptoms
(range = 0 to 16). Daily scores were averaged to calculate a ”mean daily rhinitis score“
per participant for each week of the pollen season. Measured at 4 weeks and 6 weeks.
Secondary outcomes:
1. Other local adverse effects: local irritation/discomfort
2. Other local adverse effects: Eustachian tube dysfunction
Other outcomes reported by the study:
The mean number of antihistamines assumption per participant per week for each week
of the pollen season; nasal resistance
Funding sources No information provided
Declarations of interest No information provided
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”randomly assigned to the active or
control group according to randomization ta-
bles.“
Comment: adequate randomisation
Allocation concealment (selection bias) Low risk Quote: ”Sealed opaque envelopes containing
the treatment allocation were opened after
randomization just before the initiation of the
study period. The allocation sequence was pre-
pared by one of the authors (E.S.). Another
author (W.G.) enrolled and assigned patients
to the treatment groups.“
Comment: adequate allocation conceal-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: ”Women and physicians were not
blinded to treatment allocation.“
Comment: blinding was not possible due
to the nature of the interventions used in
the trial
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: blinding of participants was not
possible and the main outcome measures
were patient reported, which may lead to
bias in the outcomes
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: 7/52 participants (13%) did
not complete the trial. This was balanced
between the treatment groups. The reasons
for non-completion were given and were
balanced. Plausible effect size among miss-
ing outcomes is not enough to have a clini-
cally relevant impact on observed effect size
Selective reporting (reporting bias) Low risk Comment: no protocol was identified on
ClinicalTrials.gov or the European Clinical
Trials Registry. The outcomes as reported
in the methods section are reported in the
results. Adverse effects are not well reported
in the paper
Other bias (Non validated instruments) Unclear risk Comment: it is unclear if the rating scale
to measure symptoms was validated
Other bias Low risk Comment: no sources of ’other’ bias were
identified
Li 2009
Methods 3-arm, non-blinded, parallel-group RCT, with 12-week duration of treatment and fol-
low-up
Participants Location: China
Setting of recruitment and treatment: not stated
Sample size: 26
• Number randomised: 12 in steroids + saline, 6 in steroids alone group and 8 in
saline alone
• Number completed: 12 in steroids + saline, 6 in steroids alone group and 8 in
saline alone
Participant (baseline) characteristics:
• Age: mean: 11 years, range: 8 to 15 years
• Gender: not stated
• Main diagnosis: allergic rhinitis
• Type of allergic rhinitis: persistent allergic rhinitis
• Severity of allergic rhinitis: moderate/severe
• Type of allergic trigger: house dust mite and mould
• Other important effect modifiers, if applicable: none stated
Inclusion criteria: the diagnosis of allergic rhinitis was confirmed by history, physical
examination and skin prick test with a battery of common allergens. All participants
presented with nasal oedema and vicious secretion
Exclusion criteria: marked septum deviation, prior nasal surgery, nasal polyposis and
symptoms of infection
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Interventions Steroid only group (n = 6): 256 µg budesonide nasal spray daily for 4 weeks, followed
by 128 µg and 64 µg daily for 4 weeks. Total treatment time = 12 weeks
Saline only group (n = 8): 500mLof normal saline (0.9% sodium chloride solution) was
used twice a day for nasal irrigation with a commercial positive-pressure nasal irrigation
applicator
Steroid PLUS saline (n = 12): both the ’saline’ and ’steroid’ treatments
Use of additional interventions (common to both treatment arms): all participants
had a 10 mg loratadine tablet daily for 2 weeks in combination with other managements
Outcomes Outcomes of interest in the review:
Primary outcomes:
1. Disease severity, as measured weekly by patient-reported symptom score. Each
symptom (sneezing/itching, rhinorrhoea, nasal congestion and postnasal drip/snorting)
was measured on a 0 to 3 scale (0 = no symptom). These were added to give a total score
with a range of 0 to 12 (0 = least severe). Measured weekly at week 0, 2, 4, 8 and 12.
2. Significant adverse effects: epistaxis
Secondary outcomes:
1. Other local adverse effects: local irritation/discomfort
2. Other local adverse effects: Eustachian tube dysfunction
Other outcomes reported by the study:
Nasal signs (combined score of colour of nasal turbinates, nasal secretions, swelling of
turbinates and retropharyngeal inflammation),
mucociliary clearance and concentration of soluble intercellular adhesion molecule
Funding sources “National Natural Science Fund (No. 30572025, No. 30700935) and the Natural Science
Fund of Jiangsu Province (No. BK2007610).”
Declarations of interest No information provided
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: ”randomised“
Comment: although the methods section
uses the word ”randomised“ the abstract
uses ”divided“ and there is no information
about the methods to be able to determine
how randomisation was completed
The groups have unequal numbers of par-
ticipants (6, 8 and 12) and there is a lack
of baseline demographics to be able to de-
termine whether they were similar
Allocation concealment (selection bias) High risk Comment: there is no information regard-
ing allocation concealment. As the abstract
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uses the word ”divided“ and there are un-
equal numbers of participants in each arm
there is a concern that selection bias may
have occurred
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: the study was not blinded, al-
though it is unlikely that the study could
have been blinded given the nature of the
intervention
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: it would not have been possi-
ble to blind the patient-reported outcome
(symptom score). However, the other out-
comes (signs, mucociliary clearance etc.)
could have been blinded as they were not
participant-assessed. The paper does not
indicate that this occurred
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: it appears that everyone that en-
tered the study completed it
Selective reporting (reporting bias) Low risk Comment: no protocol for the trial was
identified on ClinicalTrials.gov or on the
Chinese Registry of Clinical Trials
All outcomes reported in the methods sec-
tion of the protocol are presented in the re-
sults
Other bias (Non validated instruments) Unclear risk Comment: it is unclear if the rating scale
used to measure symptoms was validated.
The paper mentioned relating to the scale
is not a validation paper
Other bias Low risk Comment: no further causes of bias were
identified
Lin 2017
Methods 2-arm, non-blinded, single-centre, parallel-group RCT, with 30-day duration of treat-
ment and follow-up
Participants Location: China
Setting of recruitment and treatment: university hospital ENT clinic
Sample size: 50
• Number randomised: 25 in saline group, 25 in steroids group
• Number completed: 23 in saline group, 22 in steroids group
Participant (baseline) characteristics:
• Mean age (range): 47.3 (18 to 75)
• Gender (F/M): 24 (53%) /21 (47%)
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• Main diagnosis: allergic rhinitis with cough
• Type of allergic rhinitis: persistent (ARIA 2010 guidelines)
• Severity of allergic rhinitis: not stated
• Type of allergic trigger: house dust mite
• Other important effect modifiers, if applicable:
◦ Asthma: 0% (exclusion criteria)
Inclusion criteria: cough for ≥ 8 weeks, reporting nasal secretions at the back of the
throat, having elevated specific immunoglobulin E levels to house dust mite and having
persistent allergic rhinitis according to the ARIA guidelines
Exclusion criteria: asthma and gastroesophageal reflux disease (GERD)
Interventions Intervention (n = 23): saline, topical nasal-pharyngeal irrigation 200 mL, ”normal“
(isotonic) saline with a temperature of 40°C, twice daily (in the morning and evening),
pumping a 100 mL solution from a saline solution bag hung on a drip stand overhead
into each nostril and allowing it to run out of the mouth. Treatment duration = 30 days
Comparator group (n = 22): topical nasal spray of fluticasone propionate 100 µg twice
daily (one spray of 50 µg in each nostril in themorning and evening). Treatment duration
= 30 days
Use of additional interventions (common to both treatment arms): during the whole
study period, the participants were instructed not to use any other drugs
Outcomes Outcomes of interest in the review:
Primary outcomes:
1. Health-related quality of life, using Mini Rhinoconjunctivitis Quality of Life
Questionnaire (Mini-RQLQ) at 20 days (Mini-RQLQ range = 0 to 84; lower = better
quality of life)
2. Disease severity, as measured by visual analogue scale of total nasal symptom score
(including nasal obstruction, rhinorrhoea, sneezing and nasal pruritus) at 30 days
3. Adverse effects: epistaxis
Secondary outcomes:
1. Other adverse effects
Other outcomes reported by the study:
Cough symptom score, Leicester cough questionnaire, capsaicin cough challenge,
lung function test, assessment of inflammatory mediators (histamine, leukotriene C4,
prostaglandin D2 and the major basic protein from nasal lavage fluid)
Funding sources ”This work was supported by the National Natural Science Foundation (grant 81371076)
, and the Shanghai Suburb Tertiary Hospital Clinical Capacity Building Project (grant
SHDC12015905)”
Declarations of interest “The authors have no conflicts of interest to declare pertaining to this article”
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote: ”A 30-day treatment regimen was
assigned in accordance with an indepen-
dently generated random code to one of the
following groups…“
Comment: independently generated ran-
dom code
Allocation concealment (selection bias) Unclear risk Comment: there is no information about
allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: participants and healthcare
professionals were not blinded to the treat-
ment group. There may have been a dif-
ference in treatment between the 2 groups
with the saline group required to attend
clinic as an outpatient for their treatment
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: it does not appear that the
people assessing the outcomes (partici-
pants and/or healthcare professionals) were
blinded to the treatment group
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: 45/50 participants (90%) com-
pleted the trial. The loss to follow-up was
similar between the groups (88%and 92%)
but it is not clear what the reasons for loss
to follow-up in each group were
Selective reporting (reporting bias) Low risk Comment: no protocol was identified on
ClinicalTrials.gov or on Chinese Clinical
Trials Registry. A protocol number was pro-
vided in the paper (2014-179), but it was
not possible to find the protocol. The out-
comes as listed in themethods are presented
in full in the results section
Other bias (Non validated instruments) Low risk Comment: the outcomes relevant to this re-
view (mini-RQLQ) and VAS for total nasal
symptoms were both validated in this pop-
ulation and references are given to the rel-
evant validation papers
Other bias Unclear risk Comment: no other sources of bias found
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Methods 3-arm, single-blinded, multicentre, parallel-group RCT, with 4 weeks duration of treat-
ment and follow-up
Participants Location: Italy, 2 sites (Milan and Naples)
Setting of recruitment and treatment: secondary care: 2 paediatric hospitals
Sample size: 240
• Number randomised: 80 in hypertonic saline, 80 in ’normal’ saline, 80 in no
saline treatment
• Number completed: 80 in hypertonic saline, 80 in ’normal’ saline, 60 in no
saline treatment
Participant (baseline) characteristics:
• Age: 6.7 years (range: 5 to 9 years)
• Gender: M: 61.2%, F: 38.8%
• Main diagnosis: children with seasonal allergic rhinitis
• Type of allergic rhinitis: seasonal (intermittent)
• Severity of allergic rhinitis: not reported
• Type of allergic trigger: grass pollen including orchard and rye grass
• Other important effect modifiers, if applicable: 0% asthma (exclusion criteria)
Inclusion criteria: children aged 5 to 9 years with seasonal grass pollen-related allergic
rhinitis diagnosed on the basis of their history (seasonal allergic rhinitis in the period of
grass pollen antigen circulation for at least 1 year with documented rhinorrhoea, obstruc-
tion, nasal itching and sneezing), positive skin test reactions to pollen extracts, including
orchard and rye grass (Lofarma Allergens, Milano, Italy), and a physical examination at
the time of enrolment
Exclusion criteria: congenital or acquired immunodeficiency, cancer, autoimmune dis-
ease, congenital or early onset chronic diseases capable of modifying respiratory function
(such as cystic fibrosis or bronchodysplasia), nasal septum deviation or craniofacial mal-
formations, asthma, the use of systemic or local steroids or antihistamines in the previous
month, the use of immunotherapy in the previous 2 years
Interventions Intervention 1 (n = 80): hypertonic saline (2.7% sodium chloride solution) at room
temperature, irrigation using bulb syringe, 20 mL per nostril at a low positive pressure,
2 times per day (morning and evening). Duration of treatment was approximately 10
seconds. Total treatment time = 4 weeks
Intervention 2 (n = 80): ’normal’ saline (0.9% sodium chloride solution) at room
temperature, irrigation using bulb syringe, 20 mL per nostril at a low positive pressure,
2 times per day (morning and evening). Duration of treatment was approximately 10
seconds. Total treatment time = 4 weeks
Comparator group (n = 80): no saline treatment
Use of additional interventions (common to both treatment arms): children were
allowed to use an oral antihistamine (loratadine 5 mg once a day if they weighed < 30
kg, 10 mg once a day if they weighed > 30 kg) as a rescue treatment to control rhinitis
symptoms when required, but not intranasal steroids
Outcomes Outcomes of interest in the review:
Primary outcomes:
1. Disease severity, as measured by patient-reported symptom score; 3 nasal
symptoms (nasal itching, nasal obstruction and sneezing) were assessed by children in
front of doctor at 4 weeks. Rhinorrhoea was assessed by doctor. Nasal symptoms were
measured using a 4-point scale (1 = no symptoms, 2 = mild, 3 = moderate, 4 = severe).
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Nasal score was calculated as the mean of the sum of scores of each nasal symptom.
2. Significant adverse effects: epistaxis
Secondary outcomes:
1. Other local adverse effects: local irritation/discomfort
2. Other local adverse effects: Eustachian tube dysfunction
Other outcomes reported by the study:
Turbinate swelling, degree of adenoidal hypertrophy, diagnosis of OME, use of rescue
medication, compliance and satisfaction
Funding sources No information provided
Declarations of interest “All authors report no conflicts of interest relevant to this article.”
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”The enrolled children were ran-
domly assigned I: I :I to receive… on the basis
of a computer-generated randomization list
in blocks of six.“
Comment: adequate randomisation meth-
ods
Allocation concealment (selection bias) Unclear risk Quote: ”…the treatment assignments were
made by a single investigator in each center
(SB and MC).“
Comment: unclear how allocation conceal-
mentwasmaintained, although itwas com-
pleted by one investigator
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: ”The bottles were unlabelled and sim-
ilar in appearance.“
Comment: although efforts were made to
ensure blinding of the 2 saline solutions,
this is not the comparison of interest for
this review. It was not possible to blind all
of the treatment groups as one was a ’no
saline treatment’
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: ”The parents were instructed not to
discuss the assignmentwith the only investiga-
tors responsible for the clinical and instrumen-
tal follow-up (PM and AV), who remained
blinded to the group assignment until the end
of the study.“
Comment: this would be low risk for the
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Marchisio 2012 (Continued)
outcomes that were assessed by physician,
but not for those outcomes that were as-
sessed by participants (e.g. nasal symptoms)
, which are of interest in this review
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there do not seem to be any par-
ticipants lost to follow-up in either of the
saline groups. In the ’no saline treatment’
group 20/80 of the participants (25%) did
not complete the study. Reasons for this
are provided. The main reason was because
of the use of intranasal steroids. Including
these participants is likely to have made the
’no saline treatment’ group appear more ef-
fective than it was
Selective reporting (reporting bias) Low risk Comment: no protocol for the study was
identified on ClinicalTrials.gov or Euro-
pean Clinical Trials Registry. All outcomes
as stated in the methods section were re-
ported in the results
Other bias (Non validated instruments) Unclear risk Comment: it is not clear if the methods
used to evaluate the nasal scores were vali-
dated
The investigators allowed participants to
score 3 nasal symptoms (nasal itching, nasal
obstruction and sneezing) and let doctors
score rhinorrhoea, which is different to
other Total Nasal Symptom Scores mea-
sured in other papers
Other bias Low risk Comment: no other sources of bias were
identified
Ning 2011
Methods 3-arm, (no blinding described), single-centre, parallel-group RCT, with 2 weeks PLUS
the length of pollen season duration of treatment and follow-up
Participants Location: China
Setting of recruitment and treatment: secondary care: outpatient clinic, Department
of Otorhinolaryngology, Peking University People’s Hospital, Beijing
Sample size: 30
• Number randomised: 10 in budesonide group, 10 in saline group, 10 in control
(no saline treatment) group
• Number completed: 10 in budesonide group, 10 in saline group, 10 in control
(no saline treatment) group
Participant (baseline) characteristics:
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Ning 2011 (Continued)
• Age: mean 38.9 years, range 18 to 72
• Gender: 13 (43%) male, 17 (57%) female
• Main diagnosis: allergic rhinitis
• Type of allergic rhinitis: persistent (ARIA 2001)
• Severity of allergic rhinitis: moderate to severe (according to ’Diagnostic and
treatment principle for allergic rhinitis and a recommended scheme’ (2004, Lan Zhou,
China))
• Type of allergic trigger: mugwort pollen
• Other important effect modifiers, if applicable: not reported
Inclusion criteria: diagnosis of mugwort main trigger allergic rhinitis with confirmation
in the clinic, according to 2004 ChineseMedical Association ENT conference diagnostic
criteria
Exclusion criteria: glucocorticoid contraindication
Interventions Intranasal steroid (n = 10): budesonide, 64 µg given morning and evening via nasal
puff per side. (Daily dose of 256 µg). Treatment started 2 weeks prior to the pollen season
(dates estimated from the dates of the pollen season the previous year) and continued
for the duration of the pollen season
Saline group (n = 10): same administration method and frequency of administration
as budesonide. No information about tonicity or dose of saline administered. Treatment
duration = 2 weeks PLUS duration of pollen season
No saline treatment (n = 10): no intervention given
Use of additional interventions (common to both treatment arms): no information
Outcomes Study outcomes:
Primary outcomes:
1. Disease severity, as measured by nasal symptom scores (diagnostic and treatment
principle for allergic rhinitis and a recommended scheme (2004, Lan Zhou, China)). 4
symptoms were measured (sneezing, rhinorrhoea, blocked nose/congestion and itchy
nose), measured on a 3-point scale (1 to 3), higher = worse symptoms. Measured at end
of treatment. Not clear but likely to be approximately 6 weeks treatment.
Secondary outcomes: none reported
Other outcomes reported by the study:
Time of onset of symptoms (early in the pollen season, middle, late)
Number of attacks
Ratio of participants who relapsed in each group
Funding sources Ministry of Science and Technology of the People’s Republic China, National 15
Priority Areas Funding ”Allergic Rhinitis Diagnosis and Prevention Research“ No:
2007BA118B115
Declarations of interest No information provided
Notes Translated from Chinese by Aidan Tan and Minsai Cai
Risk of bias
Bias Authors’ judgement Support for judgement
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Ning 2011 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote: ”Participants were randomised into
three groups“
Comment: no further details given
Allocation concealment (selection bias) Unclear risk Comment: there is no description about
the allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: placebo with saline was given
when compared to the intranasal steroid
group, but the paper does not state whether
the participants and healthcare profession-
als were blinded to treatment group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: no description of blinding of
assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: all 30 participants were fol-
lowed up during the treatment. Nasal
symptom scores, attack time of each par-
ticipant and the ratio of participants who
underwent relapse were all reported in the
results
Selective reporting (reporting bias) Low risk Comment: no protocol was identified on
ClinicalTrials.gov or the Chinese Clinical
Trials Registry
All of the outcomes listed in the methods
section were reported in the results section
Other bias (Non validated instruments) Unclear risk Comment: the study used the 2004 Chi-
nese Medical Association ENT conference
allergic rhinitis diagnostic criteria/guide-
lines. It is not clear if this is a validated scale
Other bias Low risk No other sources of bias were identified
Rogkakou 2005
Methods 2-arm, non-blinded, parallel-group RCT, with 4-week duration of treatment and follow-
up
Participants Location: Italy
Setting of recruitment and treatment: secondary care: Allergy and Respiratory Diseases
Department, University of Genoa
Sample size: 14
• Number randomised: 7 in antihistamine PLUS saline, 7 in antihistamine alone
• Number completed: 7 in antihistamine PLUS saline, 7 in antihistamine alone
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Rogkakou 2005 (Continued)
Participant (baseline) characteristics:
• Age: 32.5 ± 4.2 (range 18 to 60 years)
• Gender: male 6 (43%)/female 8 (57%)
• Main diagnosis: persistent allergic rhinitis
• Type of allergic rhinitis: persistent
• Severity of allergic rhinitis: not stated
• Type of allergic trigger: house dust mites and/or Parietaria
• Other important effect modifiers, if applicable: not reported
Inclusion criteria: age between 18 and 65 years with clinical history of persistent allergic
rhinitis (symptoms present 4 days or more a week) for at least 1 year and a positive skin
prick test (mean wheal diameter > 3 mm) or RAST (at least class II) for house dust
mites or/and Parietaria. They also had to be symptomatic during the run-in period (total
symptom score > 6)
Exclusion criteria: anatomical abnormalities of the nasal cavity or relevant associated
diseases (i.e. vasomotor rhinitis, glaucoma, uveitis, infections, malignancies)
People with asthma requiring continuous inhaled steroids and pregnant women
Interventions Intervention (n = 7): hypertonic saline (Iperclean® UCB Pharma) 4 times a day. No
volume given. Treatment duration = 4 weeks
Comparator group (n = 7): no saline
Use of additional interventions (common to both treatment arms): cetirizine, orally,
10 mg/day. Treatment duration = 4 weeks
Outcomes Outcomes of interest in the review:
Primary outcomes:
1. Health-related quality of life, using disease-specific health-related quality of life
score. Rhinasthma® questionnaire (30-item questionnaire evaluating physical,
psychological, practical aspects of life). Each item is scored on a 5-point Likert scale (1
= not at all, 5 = very much). The highest score is 100, higher = worse quality of life.
Measured at 4 weeks.
2. Disease severity, patient-reported on a diary card and reported as a ”daytime
symptoms“ score. Score measured the following symptoms on a scale of 0 to 3 (0 =
none, 3 = severe): rhinorrhoea, itching, sneezing, stuffy nose, watery eyes, itching,
conjunctival hyperemia, palpebral oedema. The sum of the symptom scores for each
week of the study was calculated.
Secondary outcomes: none reported
Other outcomes reported by the study:
Night-time symptoms, acoustic rhinometry
Funding sources No information provided
Declarations of interest No information provided
Notes Rhinasthma®questionnaire results presented the domains of ’lower airways (LA)’, ’upper
airways (UA)’ and ’respiratory allergy impact’ (RAI) separately, but only the results for
’global impact’, which is a synthetic score covering the entire questionnaire, were used
for this review
Risk of bias
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Rogkakou 2005 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”…patients were randomized
through a computer-generated list...“
Comment: adequate sequence generation
Allocation concealment (selection bias) Unclear risk Comment: no information is provided
about allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: this was an open study. Partici-
pants andpersonnel were aware of the treat-
ment group to which they had been allo-
cated
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: the primary outcomes are par-
ticipant-reported and the participants were
not blinded to the treatment group
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: it does not appear that any of
the randomised participants dropped out
of the study or were lost to follow-up
Selective reporting (reporting bias) High risk Comment: there was no protocol for the
study found on ClinicalTrials.gov or the
European Clinical Trials Registry
The outcomes set out in the methods sec-
tion were well reported in the results sec-
tion, although measures of variation were
not provided for the quality of life outcome
Other bias (Non validated instruments) Unclear risk Comment: the paper provides a reference
for the Rhinasthma® quality of life score,
which indicates that this scoring system has
good overall psychometric properties
No information is provided, however, for
the validation of the symptom scoring
Other bias Low risk Comment: no other risks of bias were iden-
tified
Wu 2014
Methods 3-arm, non-blinded, single-centre, parallel-group RCT with 3-month duration of treat-
ment and follow-up
Participants Location: China
Setting of recruitment and treatment: not stated; treatment carried out in outpatients,
Guangzhou
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Wu 2014 (Continued)
Sample size: 61
• Number randomised: 17 in steroids group, 21 in saline group, 23 in saline AND
steroids group
• Number completed: 17 in steroids group, 21 in saline group, 23 in saline AND
steroids group
Participant (baseline) characteristics:
• Age: range 5 to 50 years
• Gender: 24 (39.3%) male, 37 (60.7%) female
• Main diagnosis: allergic rhinitis
• Type of allergic rhinitis: not reported
• Severity of allergic rhinitis: not reported
• Type of allergic trigger: not reported
• Other important effect modifiers, if applicable: none reported
Inclusion criteria: allergic rhinitis diagnosed with a skin prick test
Exclusion criteria: (1) use of antihistamines or steroid medications (orally or nasally) in
past 4 weeks, (2) chronic progressive respiratory problems, (3) severe systemic illness, (4)
nasal growths/previous trauma/obvious nasal septum deformity, (5) previous sinusitis,
(6) upper or lower respiratory illness, (7) alcoholic/drug abuse/poor habit history
Interventions Steroids group (n = 17): budesonide, intranasal steroid spray, 64 µg/spray, 1 spray twice
day (in morning and at night). Treatment duration = 3 months
Saline group (n = 21): normal saline (no concentration information), 75 mL, twice a
day (in morning and at night). Treatment duration = 3 months
Steroids PLUS saline group (n = 23): both of the above interventions, using the steroid
spray after the nasal irrigation. Treatment duration = 3 months
Additional treatments: no information provided
Outcomes Outcomes of interest in the review:
Primary outcomes:
1. Health-related quality of life, Rhinoconjunctivitis Quality of Life Questionnaire
(RQLQ), measured at 3 months. It is not clear how the overall score was constructed; it
may be the sum of scores for the individual domains.
2. Patient-reported symptoms using a visual analogue scale of 0 to 10, to assess
symptoms of nasal obstruction, itching, sneezing, nasal discharge, eye itching, eye
swelling, tearing, eye pain, coughing and difficulty breathing (0 = lowest impact of
symptoms, 10 = highest impact of symptoms, lower = better). Measured at 3 months.
Other outcomes reported by the study:
• Fractional exhaled nitric oxide, as an indicator of lower respiratory inflammation
Funding sources “National Priority Research Theme Respiratory Disease funded (No: 2007DA780154F090)
”
Declarations of interest No information provided
Notes The RQLQ is a validated instrument containing 28 questions regarding 7 domains:
activities, sleep, practical problems, nasal symptoms, eye symptoms and other symptoms.
For each domain, participants rate themselves as to how much their symptoms have
affected them during the previous week on a scale of 0 to 6 (0 = no effect on quality of
life)
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Wu 2014 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”participants were randomly allo-
cated to groups…“
Comment: no further description given;
cannot tell how randomisation sequence
was done
Allocation concealment (selection bias) Unclear risk Comment: no description of allocation
concealment was given
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: no statement on blinding was
given
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: ”...standardised collection form was
used for demographics and outcomes“
Comment: no statement on blinding was
given. Single statement as above, regarding
how data were collected
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: ”All participants tolerated the treat-
ment well, with no adverse events and com-
pleted the period of treatment“
Comment: none of the participants with-
drew from the trial or were lost to follow-
up
Selective reporting (reporting bias) Low risk Comment: no protocol available from
ClinicalTrials.gov or the Chinese Clinical
Trials Registry
All of the outcomes listed in the methods
section were reported in the results section
Other bias (Non validated instruments) Unclear risk Comment: RQLQ is validated for this
group of people. It appears that there is a
MandarinChinese version of this question-
naire but it is not known whether this has
been validated. No reference to the valida-
tion was provided in the paper
Visual analogue scales were used for pa-
tient-reported symptoms
Other bias Low risk Comment: no other sources of bias identi-
fied
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Yasar 2013
Methods 3-arm, non-blinded, parallel-group RCT, with 8-week duration of treatment and follow-
up
Participants Location: Cumhuriyet University, Turkey
Setting of recruitment and treatment: secondary care: paediatric allergy and ENT
department
Sample size: 60
• Number randomised: 20 in intranasal antihistamine, 20 in nasal steroid, 20 in
isotonic saline
• Number completed: 20 in intranasal antihistamine, 20 in nasal steroid, 20 in
isotonic saline
Participant (baseline) characteristics:
• Age: 9.8 ± 2.6 years (range: 7 to 16 years)
• Gender: females 23 (38.3%)/males 37 (61.7%)
• Main diagnosis: allergic rhinitis
• Type of allergic rhinitis: persistent and intermittent
• Severity of allergic rhinitis: mild, moderate and severe
• Type of allergic trigger: not given
• Other important effect modifiers, if applicable: not reported
Inclusion criteria: participants with histories of allergic rhinitis with skin prick test, nasal
smear, Phadiatop, total IgE and complete blood count tests used to confirm diagnosis
Exclusion criteria: septal deviation, nasal polyp and adenoid pads, and people with
rhinosinusitis who had received treatment in the past
Interventions Antihistamine (n = 20): 2 puffs of azelastine in each nostril per day (1 puff = 0.14 mg)
. Duration of treatment = 8 weeks
Intranasal steroid (n = 20): 2 puffs of mometasone furoate in each nostril per day (1
puff = 200 µg). Duration of treatment = 8 weeks
Nasal saline (n = 20): 2 puffs of isotonic sea water nasal saline spray (STERIMAR) in
each nostril per day. Duration of treatment = 8 weeks
Use of additional interventions (common to both treatment arms): not listed
Outcomes Outcomes of interest in the review:
Primary outcomes: no primary outcomes of interest were reported
Secondary outcomes: no secondary outcomes of interest were reported
Other outcomes reported by the study:
Nasal cavity volumes measured using acoustic rhinometry
Funding sources ”The authors received no financial support for the research and/or authorship of this article.”
Declarations of interest “The authors declared no conflicts of interest with respect to the authorship and/or publication
of this article”
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Yasar 2013 (Continued)
Random sequence generation (selection
bias)
High risk Comment: it is unclear if the participants
were randomised to study group in this
trial. The paper states that the participants
were ”classified“ into 3 groups. Randomisa-
tion was not mentioned. Although baseline
characteristics for the age and gender were
given and did not differ between groups,
other baseline characteristics were not pro-
vided
Allocation concealment (selection bias) Unclear risk Comment: there is no information in the
paper to detail how the participants were
allocated to the treatment groups
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: participants and healthcare
professionals were not blinded to treatment
group, despite the treatments being admin-
istered in the same way and on the same
regimen
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: there is no information regard-
ing the blinding of outcome assessors to
the treatment group. This would have been
feasible to complete
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there do not appear to be any
participants who were not analysed in the
results of the trial
Selective reporting (reporting bias) Low risk Comment: there was only one outcome
that wasmeasured, whichwas nasal volume
estimated using acoustic rhinometry. This
was reported in full in the results section
Other bias (Non validated instruments) Low risk Comment: the only outcome reported was
not an outcome of interest in this review
Other bias Low risk Comment: noother source of potential bias
in the study was identified
ARIA: Allergic Rhinitis and its Impact on Asthma guidelines
ENT: ear, nose and throat
F: female
M: male
OME: otitis media with effusion
RAST: radioallergosorbent test
RCT: randomised controlled trial
RQLQ: Rhinoconjunctivitis Quality of Life Questionnaire
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VAS: visual analogue scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bachmann 2000 POPULATION: chronic rhinosinusitis not allergic rhinitis
Barberi 2016a STUDY DESIGN: single-arm study; no comparison group
Barberi 2016b STUDY DESIGN: single-arm study; no comparison group
Barbieri 2002 INTERVENTION: thermal water, not saline solution
ChiCTR-INR-16009778 2016 COMPARISON: both treatment groups received saline solution; the study compared hydrogen-
rich saline with ’normal’ saline nasal irrigation
Chowdary 2017 POPULATION: the included population was ’allergic rhinitis’ but this was not confirmed with
skin prick testing or
radioallergosorbent test (RAST)
Chusakul 2012 COMPARISON: both treatment groups received saline solution; the study compared buffered
and un-buffered saline solutions
Del Giudice 2011 COMPARISON: both treatment groups received saline solution; the study compared irrigation
with ischia thermal water with irrigation with isotonic saline
Heatley 2001 POPULATION: chronic rhinosinusitis not allergic rhinitis
Jan 2013 STUDY DESIGN: single-arm study; no comparison group
Lin 2014 COMPARISON: both treatment groups received saline solution; the study compared the use of
saline solutions at 3 different temperatures (15°C, 25°C and 40°C)
Malizia 2017 COMPARISON: both treatment groups received saline solution; the study compared buffered
hypertonic saline versus normal saline solution
Mora 2002 INTERVENTION: thermal water, not saline solution
NCT01248325 2010 COMPARISON: treatment in comparison arm was Luffa Operculate, which is not a standard
treatment for allergic rhinitis
The status of this study on the ClinicalTrials.gov website was last updated in November 2010
NCT01326247 2011 COMPARISON: both treatment groups received saline solution; the study compared ”hyper-
mineral chloride sodium water“ with 0.9% nasal saline solution
The ClinicalTrials.gov website indicates that this study has been completed and a reference for the
full paper is provided
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(Continued)
NCT02729012 2016 COMPARISON: both treatment groups received saline solution; the study compared hypertonic
(3%) saline solution with 0.9% saline solution
The ClinicalTrials.gov website indicates that this study has been completed; no study results are
posted and there is no reference to the full paper
Nguyen 2014 STUDY DESIGN: single-arm study; no comparison group
Polasek 1987 POPULATION: the majority of participants had chronic rhinosinusitis not allergic rhinitis
COMPARISON: both treatment groups received saline solution; the study compared Prorhinel®
with isotonic saline solution
Rabago 2002 POPULATION: chronic rhinosinusitis not allergic rhinitis
Satdhabudha 2012 COMPARISON: both treatment groups received saline solution; the study compared buffered
and un-buffered saline solutions
Shoseyov 1998 POPULATION: chronic rhinosinusitis not allergic rhinitis
Singh 2016 Hypertonic seawater saline versus intranasal normal saline; the study compared hypertonic seawater
saline versus intranasal normal saline
TCTR20150923001 2015 COMPARISON: both treatment groups received saline solution; the study compared 1.8% and
0.9% nasal saline solutions
The trial record was last updated in September 2015; the status of the study was ’active, not
recruiting’ at this time point
TCTR20160120001 2016 COMPARISON: both treatment groups received saline solution; the study compared 3 different
treatment arms; 2 different solutions of 0.9% nasal saline and one 1.8% saline solution
The trial record was last updated in May 2016; the status of the study was ’recruiting’ at this time
point
TCTR20160913003 2016 COMPARISON: both treatment groups received saline solution; the study compared hypotonic
nasal saline irrigation with ’normal’ isotonic saline irrigation
Tomooka 2000 STUDY DESIGN: single-arm study; no comparison group
Ural 2009 COMPARISON: both treatment groups received saline solution; the study compared isotonic
with hypertonic saline
Valencia Chavez 2015 COMPARISON: both treatment groups received saline solution; the study compared seawater
diluted to 0.9% with 0.9% isotonic nasal saline solution
Xiong 2014 INTERVENTION: no saline solution was used: the ’active’ treatment group received tap water;
the control group received no nasal irrigation
68Saline irrigation for allergic rhinitis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Characteristics of studies awaiting assessment [ordered by study ID]
Hausfeld 2007
Methods Randomised controlled trial
Participants 103 participants (aged 19 to 82) with allergic and/or vasomotor rhinitis
Interventions All participants received triamcinolone acetonide nasal spray (intranasal steroid spray)
Group 1: ENTSOL® spray - buffered hypertonic saline nasal spray
Group 2: no saline nasal spray
Treatment duration = 3 to 6 weeks
Outcomes Septal irrigation
Notes Tried to contact the authors for more information but no response was received
ENTSOL® gel (buffered hypertonic saline nasal gel) was given to participants in either group who were experiencing
nasal irritation
Krcmova 2011
Methods Randomised controlled trial
Participants 30 adult (14 to 79 years) allergic patients with diagnosis of persistent allergic rhinitis
Interventions All participants received oral antihistamine
Group 1: saline solution (PantheNose spray)
Group 2: no saline solution
Intranasal steroids were allowed if symptoms worsened
Treatment duration = 4 to 6 weeks
Outcomes Use of steroid treatment, quality of life for activities, sleep, other, practical problems, nasal problems, eye problems,
feelings, 10-point VAS (symptoms?)
Notes 1 further translation from Czech required
Lee 2017
Methods Randomised controlled trial
Participants 20 children with allergic rhinitis and asthma
Interventions Group 1: daily isotonic saline nasal irrigation for 12 weeks
Group 2: control group
All participants received montelukast or inhaled ciclesonide, and levocetirizine as adjuvant treatment
Outcomes Rhinitis Control AssessmentTest (RCAT), AsthmaControl Test (ACT), forced expiratory volume in 1 second (FEV1)
, provocative concentration of methacholine causing a 20% fall in FEV1 (PC20) and oral fractional exhaled nitric
oxide (FeNO)
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Lee 2017 (Continued)
Notes Attempted to contact the author but no response was received
Manole 2013
Methods Unclear - no mention of randomisation in the abstract
Participants 92 participants between 8 and 18 years with allergic rhinitis
Interventions All participants received oral desloratadine (antihistamine)
Group 1: hypertonic saline irrigation
Group 2: no saline irrigation
Treatment duration = 7 days
Outcomes Daily symptom diary card
Acoustic rhinometry, radiography (Water’s projection), patient-reported scales of general discomfort, nasal airway
obstruction, agreeableness of the irrigation
Notes Attempted to contact the author but no response received
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D A T A A N D A N A L Y S E S
Comparison 1. Saline versus no saline treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Disease severity score (up to 4
weeks)
6 407 Std. Mean Difference (IV, Random, 95% CI) -1.32 [-1.84, -0.81]
1.1 Children 4 322 Std. Mean Difference (IV, Random, 95% CI) -1.07 [-1.39, -0.74]
1.2 Adults 2 85 Std. Mean Difference (IV, Random, 95% CI) -2.06 [-3.80, -0.32]
2 Disease severity score (4 weeks
to 6 months)
5 167 Std. Mean Difference (IV, Random, 95% CI) -1.44 [-2.39, -0.48]
2.1 Children 3 102 Std. Mean Difference (IV, Random, 95% CI) -1.06 [-2.13, 0.01]
2.2 Adults 2 65 Std. Mean Difference (IV, Random, 95% CI) -2.02 [-3.79, -0.25]
3 Health-related quality of life 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Up to 4 weeks 1 42 Mean Difference (IV, Fixed, 95% CI) -3.32 [-11.35, 4.71]
3.2 4 weeks to 6 months 1 42 Mean Difference (IV, Fixed, 95% CI) -2.06 [-8.38, 4.26]
Comparison 2. Saline versus no saline treatment (adjuvant to intranasal steroids or oral antihistamines)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Disease severity score (up to 4
weeks)
2 32 Std. Mean Difference (IV, Fixed, 95% CI) -0.60 [-1.34, 0.15]
1.1 Steroids as adjuvant
treatment
1 18 Std. Mean Difference (IV, Fixed, 95% CI) -0.32 [-1.31, 0.67]
1.2 Antihistamines as adjuvant
treatment
1 14 Std. Mean Difference (IV, Fixed, 95% CI) -0.95 [-2.08, 0.17]
2 Disease severity score (4 weeks
to 6 months))
2 58 Std. Mean Difference (IV, Fixed, 95% CI) -0.32 [-0.85, 0.21]
2.1 Steroids as adjuvant
treatment
2 58 Std. Mean Difference (IV, Fixed, 95% CI) -0.32 [-0.85, 0.21]
3 Health-related quality of life (4
weeks to 6 months)
2 54 Std. Mean Difference (IV, Random, 95% CI) -1.26 [-2.47, -0.05]
3.1 Steroids as adjuvant
treatment
1 40 Std. Mean Difference (IV, Random, 95% CI) -0.78 [-1.43, -0.13]
3.2 Antihistamines as adjuvant
treatment
1 14 Std. Mean Difference (IV, Random, 95% CI) -2.05 [-3.43, -0.67]
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Comparison 3. Saline versus steroids
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Disease severity score (up to 4
weeks)
1 14 Mean Difference (IV, Fixed, 95% CI) 1.06 [-1.65, 3.77]
2 Disease severity score (4 weeks
to 6 months)
3 97 Std. Mean Difference (IV, Random, 95% CI) 1.26 [-0.92, 3.43]
3 Health-related quality of life 2 83 Std. Mean Difference (IV, Random, 95% CI) 0.01 [-0.73, 0.75]
4 Adverse effects 1 45 Risk Ratio (M-H, Fixed, 95% CI) 0.07 [0.00, 1.24]
Comparison 4. Subgroup comparison - volume
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Disease severity score (up to 4
weeks)
6 407 Std. Mean Difference (IV, Random, 95% CI) -1.32 [-1.84, -0.81]
1.1 Very low-volume 3 100 Std. Mean Difference (IV, Random, 95% CI) -0.96 [-1.39, -0.52]
1.2 Low-volume 2 265 Std. Mean Difference (IV, Random, 95% CI) -2.07 [-3.73, -0.42]
1.3 High-volume 1 42 Std. Mean Difference (IV, Random, 95% CI) -0.92 [-1.56, -0.28]
2 Disease severity score (4 weeks
to 6 months)
5 167 Std. Mean Difference (IV, Random, 95% CI) -1.44 [-2.39, -0.48]
2.1 Very low-volume 3 80 Std. Mean Difference (IV, Random, 95% CI) -1.33 [-2.22, -0.44]
2.2 Low-volume 1 45 Std. Mean Difference (IV, Random, 95% CI) -2.91 [-3.77, -2.05]
2.3 High-volume 1 42 Std. Mean Difference (IV, Random, 95% CI) -0.41 [-1.02, 0.21]
Comparison 5. Subgroup comparison - tonicity
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Disease severity score (up to 4
weeks)
6 407 Std. Mean Difference (IV, Random, 95% CI) -1.45 [-2.13, -0.78]
1.1 Physiologic (0.9% saline) 2 152 Std. Mean Difference (IV, Random, 95% CI) -0.82 [-1.18, -0.47]
1.2 Hypertonic (> 0.9%
saline)
5 255 Std. Mean Difference (IV, Random, 95% CI) -1.72 [-2.62, -0.82]
2 Disease severity score (4 weeks
to 6 months)
4 147 Std. Mean Difference (IV, Random, 95% CI) -1.52 [-2.70, -0.33]
2.1 Physiologic (0.9% saline) 1 42 Std. Mean Difference (IV, Random, 95% CI) -0.41 [-1.02, 0.21]
2.2 Hypertonic (> 0.9%
saline)
3 105 Std. Mean Difference (IV, Random, 95% CI) -1.91 [-3.14, -0.68]
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Analysis 1.1. Comparison 1 Saline versus no saline treatment, Outcome 1 Disease severity score (up to 4
weeks).
Review: Saline irrigation for allergic rhinitis
Comparison: 1 Saline versus no saline treatment
Outcome: 1 Disease severity score (up to 4 weeks)
Study or subgroup Saline Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Children
Garavello 2003 10 5.98 (4.07) 10 11.97 (4.79) 12.7 % -1.29 [ -2.27, -0.31 ]
Garavello 2005 20 7.91 (3.3) 20 10.07 (3.73) 17.4 % -0.60 [ -1.24, 0.03 ]
Marchisio 2012 160 1.93 (0.98) 60 3.1 (0.7) 21.6 % -1.28 [ -1.60, -0.96 ]
Chairattananon 2013 22 -7.77 (0.86) 20 -6.5 (1.75) 17.3 % -0.92 [ -1.56, -0.28 ]
Subtotal (95% CI) 212 110 69.0 % -1.07 [ -1.39, -0.74 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 3.99, df = 3 (P = 0.26); I2 =25%
Test for overall effect: Z = 6.42 (P < 0.00001)
2 Adults
Garavello 2010 22 7.51 (1.7) 23 12.22 (1.41) 14.2 % -2.97 [ -3.84, -2.10 ]
Di Berardino 2017 20 13 (10) 20 29.6 (16.5) 16.8 % -1.19 [ -1.87, -0.51 ]
Subtotal (95% CI) 42 43 31.0 % -2.06 [ -3.80, -0.32 ]
Heterogeneity: Tau2 = 1.42; Chi2 = 9.99, df = 1 (P = 0.002); I2 =90%
Test for overall effect: Z = 2.32 (P = 0.020)
Total (95% CI) 254 153 100.0 % -1.32 [ -1.84, -0.81 ]
Heterogeneity: Tau2 = 0.30; Chi2 = 20.17, df = 5 (P = 0.001); I2 =75%
Test for overall effect: Z = 5.00 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.21, df = 1 (P = 0.27), I2 =17%
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Analysis 1.2. Comparison 1 Saline versus no saline treatment, Outcome 2 Disease severity score (4 weeks
to 6 months).
Review: Saline irrigation for allergic rhinitis
Comparison: 1 Saline versus no saline treatment
Outcome: 2 Disease severity score (4 weeks to 6 months)
Study or subgroup Saline Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Children
Chairattananon 2013 22 -7.7 (2.07) 20 -6.85 (2.03) 21.5 % -0.41 [ -1.02, 0.21 ]
Garavello 2003 10 5.38 (5.35) 10 9.18 (5.44) 19.4 % -0.67 [ -1.58, 0.23 ]
Garavello 2005 20 3.54 (2.34) 20 9.96 (3.47) 20.3 % -2.13 [ -2.92, -1.34 ]
Subtotal (95% CI) 52 50 61.2 % -1.06 [ -2.13, 0.01 ]
Heterogeneity: Tau2 = 0.75; Chi2 = 11.88, df = 2 (P = 0.003); I2 =83%
Test for overall effect: Z = 1.93 (P = 0.053)
2 Adults
Garavello 2010 22 6.33 (1.09) 23 10.4 (1.6) 19.8 % -2.91 [ -3.77, -2.05 ]
Ning 2011 10 6 (2.06) 10 8 (1.33) 19.1 % -1.10 [ -2.06, -0.15 ]
Subtotal (95% CI) 32 33 38.8 % -2.02 [ -3.79, -0.25 ]
Heterogeneity: Tau2 = 1.41; Chi2 = 7.57, df = 1 (P = 0.01); I2 =87%
Test for overall effect: Z = 2.24 (P = 0.025)
Total (95% CI) 84 83 100.0 % -1.44 [ -2.39, -0.48 ]
Heterogeneity: Tau2 = 1.01; Chi2 = 27.83, df = 4 (P = 0.00001); I2 =86%
Test for overall effect: Z = 2.94 (P = 0.0032)
Test for subgroup differences: Chi2 = 0.83, df = 1 (P = 0.36), I2 =0.0%
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Analysis 1.3. Comparison 1 Saline versus no saline treatment, Outcome 3 Health-related quality of life.
Review: Saline irrigation for allergic rhinitis
Comparison: 1 Saline versus no saline treatment
Outcome: 3 Health-related quality of life
Study or subgroup Saline Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 4 weeks
Chairattananon 2013 22 16.64 (7.52) 20 19.96 (16.86) 100.0 % -3.32 [ -11.35, 4.71 ]
Subtotal (95% CI) 22 20 100.0 % -3.32 [ -11.35, 4.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
2 4 weeks to 6 months
Chairattananon 2013 22 14.42 (9.03) 20 16.48 (11.58) 100.0 % -2.06 [ -8.38, 4.26 ]
Subtotal (95% CI) 22 20 100.0 % -2.06 [ -8.38, 4.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.81), I2 =0.0%
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Analysis 2.1. Comparison 2 Saline versus no saline treatment (adjuvant to intranasal steroids or oral
antihistamines), Outcome 1 Disease severity score (up to 4 weeks).
Review: Saline irrigation for allergic rhinitis
Comparison: 2 Saline versus no saline treatment (adjuvant to intranasal steroids or oral antihistamines)
Outcome: 1 Disease severity score (up to 4 weeks)
Study or subgroup
Saline +
pharmaco-
logical
No saline +
pharmacolog
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Steroids as adjuvant treatment
Li 2009 12 3.38 (2.26) 6 4.13 (2.14) 56.6 % -0.32 [ -1.31, 0.67 ]
Subtotal (95% CI) 12 6 56.6 % -0.32 [ -1.31, 0.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
2 Antihistamines as adjuvant treatment
Rogkakou 2005 7 4.2 (6.5) 7 17.5 (17.3) 43.4 % -0.95 [ -2.08, 0.17 ]
Subtotal (95% CI) 7 7 43.4 % -0.95 [ -2.08, 0.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.66 (P = 0.098)
Total (95% CI) 19 13 100.0 % -0.60 [ -1.34, 0.15 ]
Heterogeneity: Chi2 = 0.68, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 1.57 (P = 0.12)
Test for subgroup differences: Chi2 = 0.68, df = 1 (P = 0.41), I2 =0.0%
-10 -5 0 5 10
Favours saline + pharma Favours pharma alone
76Saline irrigation for allergic rhinitis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.2. Comparison 2 Saline versus no saline treatment (adjuvant to intranasal steroids or oral
antihistamines), Outcome 2 Disease severity score (4 weeks to 6 months)).
Review: Saline irrigation for allergic rhinitis
Comparison: 2 Saline versus no saline treatment (adjuvant to intranasal steroids or oral antihistamines)
Outcome: 2 Disease severity score (4 weeks to 6 months))
Study or subgroup Saline + pharma Pharma alone
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Steroids as adjuvant treatment
Li 2009 12 3.49 (2.45) 6 4.52 (2.21) 28.8 % -0.41 [ -1.40, 0.58 ]
Wu 2014 23 1.47 (0.7) 17 1.71 (0.97) 71.2 % -0.29 [ -0.92, 0.35 ]
Total (95% CI) 35 23 100.0 % -0.32 [ -0.85, 0.21 ]
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.19 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Saline versus no saline treatment (adjuvant to intranasal steroids or oral
antihistamines), Outcome 3 Health-related quality of life (4 weeks to 6 months).
Review: Saline irrigation for allergic rhinitis
Comparison: 2 Saline versus no saline treatment (adjuvant to intranasal steroids or oral antihistamines)
Outcome: 3 Health-related quality of life (4 weeks to 6 months)
Study or subgroup Saline + pharma Pharma alone
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Steroids as adjuvant treatment
Wu 2014 23 27.35 (12.73) 17 38.47 (15.63) 61.9 % -0.78 [ -1.43, -0.13 ]
Subtotal (95% CI) 23 17 61.9 % -0.78 [ -1.43, -0.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.34 (P = 0.019)
2 Antihistamines as adjuvant treatment
Rogkakou 2005 7 7.7 (2.2431) 7 15.5 (4.5153) 38.1 % -2.05 [ -3.43, -0.67 ]
Subtotal (95% CI) 7 7 38.1 % -2.05 [ -3.43, -0.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.91 (P = 0.0036)
Total (95% CI) 30 24 100.0 % -1.26 [ -2.47, -0.05 ]
Heterogeneity: Tau2 = 0.51; Chi2 = 2.67, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 2.04 (P = 0.041)
Test for subgroup differences: Chi2 = 2.67, df = 1 (P = 0.10), I2 =63%
-4 -2 0 2 4
Favours saline + pharma Favours pharma alone
78Saline irrigation for allergic rhinitis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.1. Comparison 3 Saline versus steroids, Outcome 1 Disease severity score (up to 4 weeks).
Review: Saline irrigation for allergic rhinitis
Comparison: 3 Saline versus steroids
Outcome: 1 Disease severity score (up to 4 weeks)
Study or subgroup Saline Steroids
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Li 2009 8 5.19 (3.04) 6 4.13 (2.14) 100.0 % 1.06 [ -1.65, 3.77 ]
Total (95% CI) 8 6 100.0 % 1.06 [ -1.65, 3.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours saline Favours steroids
Analysis 3.2. Comparison 3 Saline versus steroids, Outcome 2 Disease severity score (4 weeks to 6 months).
Review: Saline irrigation for allergic rhinitis
Comparison: 3 Saline versus steroids
Outcome: 2 Disease severity score (4 weeks to 6 months)
Study or subgroup Saline Steroids
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Li 2009 8 6.15 (3.28) 6 4.52 (2.21) 32.5 % 0.53 [ -0.55, 1.61 ]
Lin 2017 23 4.97 (0.39) 22 3.43 (0.5) 33.2 % 3.38 [ 2.45, 4.32 ]
Wu 2014 21 1.6 (0.9) 17 1.71 (0.97) 34.3 % -0.12 [ -0.76, 0.52 ]
Total (95% CI) 52 45 100.0 % 1.26 [ -0.92, 3.43 ]
Heterogeneity: Tau2 = 3.48; Chi2 = 37.14, df = 2 (P<0.00001); I2 =95%
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Saline versus steroids, Outcome 3 Health-related quality of life.
Review: Saline irrigation for allergic rhinitis
Comparison: 3 Saline versus steroids
Outcome: 3 Health-related quality of life
Study or subgroup Saline Steroids
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Lin 2017 23 23.8 (4.7) 22 21.8 (5.7) 51.6 % 0.38 [ -0.21, 0.97 ]
Wu 2014 21 32.52 (14.92) 17 38.47 (15.63) 48.4 % -0.38 [ -1.03, 0.26 ]
Total (95% CI) 44 39 100.0 % 0.01 [ -0.73, 0.75 ]
Heterogeneity: Tau2 = 0.19; Chi2 = 2.89, df = 1 (P = 0.09); I2 =65%
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours saline Favours steroids
Analysis 3.4. Comparison 3 Saline versus steroids, Outcome 4 Adverse effects.
Review: Saline irrigation for allergic rhinitis
Comparison: 3 Saline versus steroids
Outcome: 4 Adverse effects
Study or subgroup Saline Steroids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lin 2017 0/23 6/22 100.0 % 0.07 [ 0.00, 1.24 ]
Total (95% CI) 23 22 100.0 % 0.07 [ 0.00, 1.24 ]
Total events: 0 (Saline), 6 (Steroids)
Heterogeneity: not applicable
Test for overall effect: Z = 1.81 (P = 0.070)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Subgroup comparison - volume, Outcome 1 Disease severity score (up to 4
weeks).
Review: Saline irrigation for allergic rhinitis
Comparison: 4 Subgroup comparison - volume
Outcome: 1 Disease severity score (up to 4 weeks)
Study or subgroup Saline Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Very low-volume
Di Berardino 2017 20 13 (10) 20 29.6 (16.5) 16.8 % -1.19 [ -1.87, -0.51 ]
Garavello 2003 10 5.98 (4.07) 10 11.97 (4.79) 12.7 % -1.29 [ -2.27, -0.31 ]
Garavello 2005 20 7.91 (3.3) 20 10.07 (3.73) 17.4 % -0.60 [ -1.24, 0.03 ]
Subtotal (95% CI) 50 50 46.9 % -0.96 [ -1.39, -0.52 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 2.11, df = 2 (P = 0.35); I2 =5%
Test for overall effect: Z = 4.33 (P = 0.000015)
2 Low-volume
Garavello 2010 22 7.51 (1.7) 23 12.22 (1.41) 14.2 % -2.97 [ -3.84, -2.10 ]
Marchisio 2012 160 1.93 (0.98) 60 3.1 (0.7) 21.6 % -1.28 [ -1.60, -0.96 ]
Subtotal (95% CI) 182 83 35.8 % -2.07 [ -3.73, -0.42 ]
Heterogeneity: Tau2 = 1.32; Chi2 = 12.84, df = 1 (P = 0.00034); I2 =92%
Test for overall effect: Z = 2.46 (P = 0.014)
3 High-volume
Chairattananon 2013 22 -7.77 (0.86) 20 -6.5 (1.75) 17.3 % -0.92 [ -1.56, -0.28 ]
Subtotal (95% CI) 22 20 17.3 % -0.92 [ -1.56, -0.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.81 (P = 0.0049)
Total (95% CI) 254 153 100.0 % -1.32 [ -1.84, -0.81 ]
Heterogeneity: Tau2 = 0.30; Chi2 = 20.17, df = 5 (P = 0.001); I2 =75%
Test for overall effect: Z = 5.00 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.72, df = 2 (P = 0.42), I2 =0.0%
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Analysis 4.2. Comparison 4 Subgroup comparison - volume, Outcome 2 Disease severity score (4 weeks to
6 months).
Review: Saline irrigation for allergic rhinitis
Comparison: 4 Subgroup comparison - volume
Outcome: 2 Disease severity score (4 weeks to 6 months)
Study or subgroup Saline Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Very low-volume
Garavello 2003 10 5.38 (5.35) 10 9.18 (5.44) 19.4 % -0.67 [ -1.58, 0.23 ]
Garavello 2005 20 3.54 (2.34) 20 9.96 (3.47) 20.3 % -2.13 [ -2.92, -1.34 ]
Ning 2011 10 6 (2.06) 10 8 (1.33) 19.1 % -1.10 [ -2.06, -0.15 ]
Subtotal (95% CI) 40 40 58.8 % -1.33 [ -2.22, -0.44 ]
Heterogeneity: Tau2 = 0.41; Chi2 = 6.06, df = 2 (P = 0.05); I2 =67%
Test for overall effect: Z = 2.93 (P = 0.0033)
2 Low-volume
Garavello 2010 22 6.33 (1.09) 23 10.4 (1.6) 19.8 % -2.91 [ -3.77, -2.05 ]
Subtotal (95% CI) 22 23 19.8 % -2.91 [ -3.77, -2.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.64 (P < 0.00001)
3 High-volume
Chairattananon 2013 22 -7.7 (2.07) 20 -6.85 (2.03) 21.5 % -0.41 [ -1.02, 0.21 ]
Subtotal (95% CI) 22 20 21.5 % -0.41 [ -1.02, 0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
Total (95% CI) 84 83 100.0 % -1.44 [ -2.39, -0.48 ]
Heterogeneity: Tau2 = 1.01; Chi2 = 27.83, df = 4 (P = 0.00001); I2 =86%
Test for overall effect: Z = 2.94 (P = 0.0032)
Test for subgroup differences: Chi2 = 21.64, df = 2 (P = 0.00), I2 =91%
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Analysis 5.1. Comparison 5 Subgroup comparison - tonicity, Outcome 1 Disease severity score (up to 4
weeks).
Review: Saline irrigation for allergic rhinitis
Comparison: 5 Subgroup comparison - tonicity
Outcome: 1 Disease severity score (up to 4 weeks)
Study or subgroup Saline Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Physiologic (0.9% saline)
Chairattananon 2013 22 -7.77 (0.86) 20 -6.5 (1.75) 14.6 % -0.92 [ -1.56, -0.28 ]
Marchisio 2012 80 2.55 (0.7) 30 3.1 (0.7) 15.7 % -0.78 [ -1.21, -0.35 ]
Subtotal (95% CI) 102 50 30.3 % -0.82 [ -1.18, -0.47 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 4.50 (P < 0.00001)
2 Hypertonic (> 0.9% saline)
Di Berardino 2017 20 13 (10) 20 29.6 (16.5) 14.4 % -1.19 [ -1.87, -0.51 ]
Garavello 2003 10 5.98 (4.07) 10 11.97 (4.79) 12.4 % -1.29 [ -2.27, -0.31 ]
Garavello 2005 20 7.91 (3.3) 20 10.07 (3.73) 14.6 % -0.60 [ -1.24, 0.03 ]
Garavello 2010 22 7.51 (1.7) 23 12.22 (1.41) 13.1 % -2.97 [ -3.84, -2.10 ]
Marchisio 2012 80 1.3 (0.7) 30 3.1 (0.7) 15.2 % -2.55 [ -3.10, -2.01 ]
Subtotal (95% CI) 152 103 69.7 % -1.72 [ -2.62, -0.82 ]
Heterogeneity: Tau2 = 0.91; Chi2 = 31.99, df = 4 (P<0.00001); I2 =87%
Test for overall effect: Z = 3.73 (P = 0.00019)
Total (95% CI) 254 153 100.0 % -1.45 [ -2.13, -0.78 ]
Heterogeneity: Tau2 = 0.70; Chi2 = 46.25, df = 6 (P<0.00001); I2 =87%
Test for overall effect: Z = 4.23 (P = 0.000024)
Test for subgroup differences: Chi2 = 3.26, df = 1 (P = 0.07), I2 =69%
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Analysis 5.2. Comparison 5 Subgroup comparison - tonicity, Outcome 2 Disease severity score (4 weeks to
6 months).
Review: Saline irrigation for allergic rhinitis
Comparison: 5 Subgroup comparison - tonicity
Outcome: 2 Disease severity score (4 weeks to 6 months)
Study or subgroup Saline Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Physiologic (0.9% saline)
Chairattananon 2013 22 -7.7 (2.07) 20 -6.85 (2.03) 26.2 % -0.41 [ -1.02, 0.21 ]
Subtotal (95% CI) 22 20 26.2 % -0.41 [ -1.02, 0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
2 Hypertonic (> 0.9% saline)
Garavello 2003 10 5.38 (5.35) 10 9.18 (5.44) 24.2 % -0.67 [ -1.58, 0.23 ]
Garavello 2005 20 3.54 (2.34) 20 9.96 (3.47) 25.0 % -2.13 [ -2.92, -1.34 ]
Garavello 2010 22 6.33 (1.09) 23 10.4 (1.6) 24.6 % -2.91 [ -3.77, -2.05 ]
Subtotal (95% CI) 52 53 73.8 % -1.91 [ -3.14, -0.68 ]
Heterogeneity: Tau2 = 1.00; Chi2 = 12.57, df = 2 (P = 0.002); I2 =84%
Test for overall effect: Z = 3.04 (P = 0.0023)
Total (95% CI) 74 73 100.0 % -1.52 [ -2.70, -0.33 ]
Heterogeneity: Tau2 = 1.30; Chi2 = 27.61, df = 3 (P<0.00001); I2 =89%
Test for overall effect: Z = 2.51 (P = 0.012)
Test for subgroup differences: Chi2 = 4.60, df = 1 (P = 0.03), I2 =78%
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Table 1. Summary of study characteristics
Population Intervention Compar-
ison
Study ID N Severity Intermit-
tent/ per-
sistent
Allergen Tonicity Volume1 Adminis-
tration
methods
Adjuvant Treat-
ment du-
ration
Chairat-
tananon
48
Children
Mild/
moderate
Not
stated
House
dustmite,
’Normal’/
isotonic
90 mL
(high)
2
times per
If needed:
cetirizine
8 weeks No saline
treatment
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Table 1. Summary of study characteristics (Continued)
2013
(Thai-
land)
(persis-
tent)
cock-
roach,
cat, dog,
grass,
moulds
saline day using
Hashi®
Nasal
Rinser
and pseu-
doephedrine
Chen
2014
(China)
61
Children
Moder-
ate/severe
Persistent House
dust
mites and
mould
Hyper-
tonic (sea
water)
Not given 4 to 6
sprays, 2
times per
day
200 µg
flutica-
sone pro-
pionate
nasal
spray
daily
4 weeks Steroids
alone
Cordray
2005
(USA)
21
Adults
Not
stated
Seasonal
(inter-
mittent)
Pollen
and Al-
ternaria
1. Hyper-
tonic
Dead
Sea saline
spray
Not given 2 sprays,
3 times
per day
None 7 days Aqueous
triamci-
nolone
spray
(110 µg
into
each nos-
tril once
daily)
2. Nor-
mal saline
spray
Not given 2 sprays,
3 times
per day
None 7 days Aqueous
triamci-
nolone
spray
(110 µg
into
each nos-
tril once
daily)
Di
Be-
rardino
2017
(Italy)
40
Adults
(allergic
rhinocon-
junctivi-
tis)
Not
stated
Seasonal
(inter-
mittent)
Grass
pollen
Hyper-
tonic (%
not
given)
0.15 mL
(very low)
2
times per
day, using
a nasal
aerosol
spray
Rescue
antihis-
tamines
6 days No saline
treatment
Garavello
2003
(Italy)
20
Children
Not
stated
Seasonal
(inter-
mittent)
Parietaria
pollen
Hyper-
tonic
(3%)
2.5 mL
(very low)
3 times
per day,
using dis-
posable
syringe
Rescue
antihis-
tamines
6 weeks No saline
treatment
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Table 1. Summary of study characteristics (Continued)
Garavello
2005
(Italy)
52
Children
(allergic
rhinocon-
junctivi-
tis)
Not
stated
Seasonal
(inter-
mittent)
Grass
pollen
Hyper-
tonic
(3%)
0.15 mL
(very low)
3
times per
day, spray
from bot-
tle fitted
with an
atomiser
Not
reported
7 weeks No saline
treatment
Garavello
2010
(Italy)
44
Adults
(pregnant
women)
Not
stated
Seasonal
(inter-
mittent)
Parietaria
pollen
Hyper-
tonic
(3%)
10 mL
(low)
3 times
per day,
using dis-
posable
syringe
Rescue
antihis-
tamines
6 weeks No saline
treatment
Li 2009
(China)
26
Children
Moder-
ate/severe
Persistent House
dust
mites and
mould
’Normal’
(0.9%)
500 mL
(high)
2
times per
day using
positive-
pressure
nasal irri-
gation ap-
plicator
256 µg
budes-
onide
nasal
spray
daily
4 weeks Steroids
alone
2
times per
day using
positive-
pressure
nasal irri-
gation ap-
plicator
None 4 weeks Steroids
alone
Lin 2017
(China)
50
Adults
(aller-
gic rhini-
tis with
chronic
cough)
Not
stated
Persistent House
dust
mites
’Normal’
(0.9%)
100 mL
(high)
Nasal
pharyn-
geal irri-
gation
(pump-
ing saline
solu-
tion from
a solution
bag hung
on a drip
stand
over-
head into
each nos-
Not
stated
4 weeks Steroids
alone
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Table 1. Summary of study characteristics (Continued)
tril and
allowing
it to run
out of the
mouth)
Marchi-
sio
2012
(Italy)
220
Children
Not
stated
Seasonal
(inter-
mittent)
Grass
pollen in-
cluding
or-
chard and
rye grass
1. Hyper-
tonic (2.
7%)
20 mL
(low)
2
times per
day, irri-
gation us-
ing bulb
syringe
Rescue
antihis-
tamines
4 weeks No saline
treatment
2. ’Nor-
mal’ (0.
9%)
20 mL
(low)
2
times per
day, irri-
gation us-
ing bulb
syringe
Rescue
antihis-
tamines
4 weeks No saline
treatment
Ning
2011
(China)
30
Adults
Moder-
ate/severe
Persistent Mugwort
pollen
Not
stated
Not
stated: 1
’puff ’
(very low)
2
times per
day, using
a nasal
aerosol
spray
Not
reported
2 weeks No saline
treatment
Not
reported
2 weeks Budes-
onide,
128 µg
per nos-
tril per
day
Rogkakou
2005
(Italy)
14
Adults
Not
stated
Persistent House
dust
mites
and/or
Parietaria
Hyper-
tonic (%
not
given)
Not given Not given Ceti-
rizine,
orally, 10
mg/day
4 weeks Antihis-
tamines
alone
Wu 2014
(China)
61
Adults
Not
stated
Not
stated
Not
stated
’Normal’
(% not
given)
75 mL
(high)
2
times per
day, no
method
given
Budes-
onide, in-
tranasal
steroid
spray, 64
µg/spray,
1 spray
twice day
(in morn-
ing and at
night)
3 months Steroids
alone
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2
times per
day, no
method
given
None 3 months Steroids
alone
Yasar
2013
(Turkey)
60
Children
Mild,
mod-
erate and
severe
Persis-
tent and
seasonal
Not
stated
Not
stated
Not
stated
”2 puffs“
(very low)
2 ’puffs’
per nos-
tril per
day, using
a nasal
aerosol
spray
Mometa-
sone
furoate (2
puffs in
each nos-
tril per
day)
8 weeks Steroids
alone
1Volume reported as per nostril per application. The volume categories were defined as: VERY LOW: less than 5 ml per nostril per
application; LOW: between 5 ml to 59 ml per nostril per application; HIGH: ≥ 60 ml per nostril per application.
Table 2. Summary of patient-reported disease severity scores
Study ID Symptoms measured Score for each symptom Summation (total
range)
Notes
Chairattananon 2013 ’Nasal symptoms’ Visual analogue scale Completed once at endof
study (0 to 10)
Lower score = worse
symptoms
Chen 2014 1. Nasal itching
2. Rhinorrhoea
3. Nasal obstruction
4. Sneezing
0 to 3 scale
(0 = no symptoms, 3 = se-
vere symptoms)
Total scores represented
the sums of scores for the
4 symptoms (range: 0 to
12)
No measures of vari-
ance presented and insuf-
ficient details to impute
them
Authors were contacted
but no response was re-
ceived.
Cordray 2005 Not measured
Di Berardino 2017 1. Nasal itching
2. Nasal discharge
3. Nasal obstruction
4. Sneezing
0 to 2 scale (0 = no
symptoms, 2 = intolera-
ble symptoms)
Daily scores for each
symptom were added to-
gether then summed for
each day of the 7-day trial
period (range: 0 to 56)
-
Garavello 2003 1. Nasal itching
2. Rhinorrhoea
3. Nasal obstruction
4. Sneezing
0 to 4 scale (0 = no symp-
toms, 4 = worst symp-
toms)
Daily scores for each
symptom were summed.
The daily scores were av-
eraged to calculate ’mean
daily rhinitis score’ per
participant for each week
-
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Table 2. Summary of patient-reported disease severity scores (Continued)
(range: 0 to 16)
Garavello 2005 1. Nasal discharge
2. Nasal blockage
3. Eye redness
4. Eye itching
0 to 3 scale (0 = none, 3
= severe)
Daily scores for each
symptom were summed.
The daily scores were
averaged to calculate a
’mean daily rhinitis score’
per participant for each
week of the pollen season
(probable range: 0 to 12,
see notes section)
Paper reports that the to-
tal range was 0 to 16. Au-
thors were contacted for
clarificationbut therewas
no response
Garavello 2010 1. Nasal itching
2. Rhinorrhoea
3. Nasal obstruction
4. Sneezing
0 to 4 scale (0 = none; 1 =
slight; 2 = mild; 3 =mod-
erate; 4 = severe)
Daily scores for each
symptom were summed.
The daily scores were
averaged to calculate a
’mean daily rhinitis score’
per participant for each
week of the pollen season
(range: 0 to 16)
-
Li 2009 1. Sneezing/itching
2. Rhinorrhoea
3. Nasal congestion
4. Postnasal drip/snort-
ing
0 to 3 scale (0 = no symp-
tom)
In-
dividual symptom scores
were summed to give a to-
tal score (range: 0 to 12)
-
Lin 2017 1. Nasal obstruction
2. Rhinorrhoea
3. Sneezing
4. Nasal pruritis
Visual analogue scale Completed once at endof
study (0 to 10)
Lower score = less severe
symptoms
Marchisio 2012 1. Nasal itching
2. Rhinorrhoea
3. Nasal obstruction
4. Sneezing
1 to 4 (1 = no symptoms,
4 = severe)
Nasal score was calcu-
lated as the mean of the
sum of scores of each
nasal symptom (range: 1
to 4)
Rhinorrhoea was assessed
by physician
Ning 2011 1. Sneezing
2. Rhinorrhoea
3. Blocked nose/conges-
tion
4. Itchy nose
1 to 3 (higher = worse
symptoms)
Symptom score was cal-
culated as the sum of
the individual symptoms
(range: 4 to 12)
-
Rogkakou 2005 1. Rhinorrhoea
2. Itching
3. Sneezing
4. Stuffy nose
5. Watery eyes
4-point scale (0 = none, 3
= severe)
The sum of the symptom
scores for each week of
the study was calculated
(range: 0 to 24)
Night-time
symptom scores were also
reported by participants
but not presented in this
review
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Table 2. Summary of patient-reported disease severity scores (Continued)
6. Itching
7. Conjunctival hyper-
aemia
8. Palpebral oedema
Wu 2014 1. Nasal obstruction
2. Itching
3. Sneezing
4. Nasal discharge
5. Eye itching
6. Eye swelling
7. Tearing
8. Eye pain
9. Coughing
10. Difficulty breathing
0 to 10 (0 = least symp-
toms, 10 = most symp-
toms)
The method for combin-
ing is not clear. The re-
sults are likely to be an
average of the individual
symptoms (range: 0 to
10)
-
A P P E N D I C E S
Appendix 1. Search strategies
CENTRAL (CRS Web) MEDLINE (Ovid) Embase (Ovid) Web of Science (Web of
Knowledge)
1 MESH
DESCRIPTOR Rhinitis AND
CENTRAL:TARGET
2MESHDESCRIPTORCon-
junctivitis AND CENTRAL:
TARGET
3 (rhinit* or Rhinoconjunctivi-
tis or conjunctivitis):AB,EH,
KW,KY,MC,MH,TI,TO
AND CENTRAL:TARGET
4#1OR#2OR#3ANDCEN-
TRAL:TARGET
5 MESH DESCRIPTOR Al-
lergens EXPLODE ALL AND
CENTRAL:TARGET
6 MESH DESCRIPTOR
pollen EXPLODE ALL AND
CENTRAL:TARGET
7 MESH DESCRIPTOR Hy-
1 Rhinitis/
2 Conjunctivitis/
3 (rhinit* or Rhinoconjunctivi-
tis or conjunctivitis).ab,kf,ti
4 1 or 2 or 3
5 exp Allergens/
6 exp Pollen/
7 exp Hypersensitivity/
8 (allerg* or hypersensitivit* or
perennial or nonseason* or sea-
son* or pollen* or dust or hair*
or dander or mite*).ab,kf,ti
9 5 or 6 or 7
10 4 and 9
11 exp Rhinitis, Allergic/
12 exp Conjunctivitis, Allergic/
13 (hayfever or ”hay fever“ or
pollenosis or pollinosis or SAR
1 rhinitis/
2 conjunctivitis/
3 (rhinit* or Rhinoconjunctivi-
tis or conjunctivitis).ab,kw,ti
4 1 or 2 or 3
5 exp allergen/
6 exp pollen/
7 exp hypersensitivity/
8 (allerg* or hypersensitivit* or
perennial or nonseason* or sea-
son* or pollen* or dust or hair*
or dander or mite*).ab,kw,ti
9 5 or 6 or 7 or 8
10 4 and 9
11 exp allergic rhinitis/
12 exp allergic conjunctivitis/
13 (hayfever or ”hay fever“ or
pollenosis or pollinosis or SAR
#1 TOPIC:
(rhinit* or Rhinoconjunctivitis
or conjunctivitis)
Indexes=SCI-EXPANDED,
CPCI-S Timespan=All years
#2 TOPIC: (allerg* or hyper-
sensitivit* or perennial or non-
season* or season* or pollen* or
dust or hair* or dander ormite*)
Indexes=SCI-EXPANDED,
CPCI-S Timespan=All years
#3 #2 AND #1
Indexes=SCI-EXPANDED,
CPCI-S Timespan=All years
#4 TOPIC: (hayfever or ”hay
fever“ or pollenosis or polli-
nosis)
Indexes=SCI-EXPANDED,
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(Continued)
persensitivity EXPLODE ALL
AND CENTRAL:TARGET
8 (allerg* or hypersensitivit* or
perennial or nonseason* or sea-
son* or pollen* or dust or hair*
or dander
or mite*):AB,EH,KW,KY,MC,
MH,TI,TO ANDCENTRAL:
TARGET
9 #5 OR #6 OR #7 OR #8
AND CENTRAL:TARGET
10 #4 AND #9 AND CEN-
TRAL:TARGET
11 MESH DE-
SCRIPTOR Rhinitis, Allergic
EXPLODE ALL AND CEN-
TRAL:TARGET
12
MESH DESCRIPTOR Con-
junctivitis, Allergic EXPLODE
ALL AND CENTRAL:TAR-
GET
13 (hayfever or ”hay fever“
or pollenosis or pollinosis or
SAR or PAR):AB,EH,KW,KY,
MC,MH,TI,TO AND CEN-
TRAL:TARGET
14 #10 OR #11 OR #12 OR
#13 AND CENTRAL:TAR-
GET
15 MESH DESCRIPTOR So-
lutions AND CENTRAL:
TARGET
16MESHDESCRIPTORHy-
pertonic Solutions ANDCEN-
TRAL:TARGET
17 MESH DESCRIP-
TOR Saline Solution, Hyper-
tonic EXPLODE ALL AND
CENTRAL:TARGET
18MESHDESCRIPTOR Iso-
tonic So-
lutions EXPLODE ALL AND
CENTRAL:TARGET
19 MESH DE-
SCRIPTOR Sodium Chloride
EXPLODE ALL AND CEN-
TRAL:TARGET
20
or PAR).ab,kf,ti
14 10 or 11 or 12 or 13
15 Solutions/
16 Hypertonic Solutions/
17 exp Saline Solution, Hyper-
tonic/
18 exp isotonic solutions/
19 exp Sodium Chloride/
20 exp Mineral Waters/
21 exp seawater/
22 exp Hypotonic Solutions/
23 (saline or ”sodium chloride“
or saltwater or hypertonic* or
hypotonic* or isotonic* or hy-
persaline or ”sea water“ or sea-
water or ((salt* or thermal or
mineral or sulfur* or bromic or
iodic* or bromide or iodine or
bromine) and (water* or solu-
tion*))).ab,kf,ti
24 15 or 16 or 17 or 18 or 19
or 20 or 21 or 22 or 23
25 Therapeutic Irrigation/
26 exp Nasal Lavage/
27 exp Administration, Inhala-
tion/
28 exp Administration, In-
tranasal/
29 exp Nasal Sprays/
30 exp Buffers/
31 (douch* or spray* or lavag*
or wash* or rinse* or rinsing or
irrigat* or pulsed or nebulise* or
aerosol* or buffer* or atomis* or
atomiz* or (squeeze and bottle)
).ab,kf,ti
32 (intranasal or inhalation* or
irrigator).ab,kf,ti.
33 25 or 26 or 27 or 28 or 29
or 30 or 31 or 32
34 24 and 33
35 (sterimar or NeilMed or
nasaline or navage or marimer
or physiomer or Emcur or ”sim-
ply saline“ or ”nasal mist“ or ayr
or salex or ”otrovin saline“ or
ISCS or Prorhinel or SSBI).ab,
kf,ti
or PAR).ab,kw,ti
14 10 or 11 or 12 or 13
15 ”solution and solubility“/
16 exp hypertonic solution/
17 exp sodium chloride/
18 exp isotonic solution/
19 exp mineral water/
20 exp sea water/
21 exp hypotonic solution/
22 (saline or ”sodium chloride“
or saltwater or hypertonic* or
hypotonic* or isotonic* or hy-
persaline or ”sea water“ or sea-
water or ((salt* or thermal or
mineral or sulfur* or bromic or
iodic* or bromide or iodine or
bromine) and (water* or solu-
tion*))).ab,kw,ti
23 15 or 16 or 17 or 18 or 19
or 20 or 21 or 22
24 lavage/
25 exp nasal lavage/
26 exp inhalational drug ad-
ministration/
27 exp intranasal drug admin-
istration/
28 exp nose spray/
29 exp buffer/
30 (douch* or spray* or lavag*
or wash* or rinse* or rinsing or
irrigat* or pulsed or nebulise* or
aerosol* or buffer* or atomis* or
atomiz* or (squeeze and bottle)
).ab,kw,ti
31 (intranasal or inhalation* or
irrigator).ab,kw,ti.
32 24 or 25 or 26 or 27 or 28
or 29 or 30 or 31
33 23 and 32
34 (sterimar or NeilMed or
nasaline or navage or marimer
or physiomer or Emcur or ”sim-
ply saline“ or ”nasal mist“ or ayr
or salex or ”otrovin saline“ or
ISCS or Prorhinel or SSBI).ab,
kw,ti
35 ((nasal or intranasal or sinus
or nose or sinonasal) adj3 (irri-
CPCI-S Timespan=All years
#5 #4 OR #3
Indexes=SCI-EXPANDED,
CPCI-S Timespan=All years
#6 TOPIC: ((saline or ”sodium
chloride“ or saltwater or hy-
pertonic* or hypotonic* or iso-
tonic* or hypersaline or ”seawa-
ter“ or seawater or ((salt* or
thermal or mineral or sulfur* or
bromic or iodic* or bromide or
iodine or bromine) and (water*
or solution*))))
Indexes=SCI-EXPANDED,
CPCI-S Timespan=All years
#7 TOPIC: ((douch* or spray*
or lavag* or wash* or rinse*
or rinsing or irrigat* or pulsed
or nebulise* or aerosol* or
buffer* or atomis* or atomiz* or
(squeeze and bottle)))
Indexes=SCI-EXPANDED,
CPCI-S Timespan=All years
#8 TOPIC: ((intranasal or in-
halation* or irrigator))
Indexes=SCI-EXPANDED,
CPCI-S Timespan=All years
#9 #8 OR #7
Indexes=SCI-EXPANDED,
CPCI-S Timespan=All years
#10 #9 AND #6
Indexes=SCI-EXPANDED,
CPCI-S Timespan=All years
#11 TOPIC: ((sterimar or
NeilMed or nasaline or nav-
age or marimer or physiomer
or Emcur or ”simply saline“
or ”nasal mist“ or ayr or salex
or ”otrovin saline“ or ISCS or
Prorhinel or SSBI))
Indexes=SCI-EXPANDED,
CPCI-S Timespan=All years
#12 TOPIC: ((nasal or in-
tranasal or sinus or nose or
sinonasal) NEAR/3 (irrigation*
or rinsing or rinse* or wash* or
lavage or douch* or hygiene))
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MESH DESCRIPTOR Min-
eral Waters EXPLODE ALL
AND CENTRAL:TARGET
21MESHDESCRIPTORSea-
water EXPLODE ALL AND
CENTRAL:TARGET
22MESHDESCRIPTORHy-
potonic Solutions EXPLODE
ALL AND CENTRAL:TAR-
GET
23 (saline or ”sodium chloride“
or saltwater or hypertonic* or
hypotonic* or isotonic* or hy-
persaline or ”sea water“ or sea-
water or ((salt* or thermal or
mineral or sulfur* or bromic or
iodic* or bromide or iodine or
bromine) and (water* or solu-
tion*))):AB,EH,KW,KY,MC,
MH,TI,TO ANDCENTRAL:
TARGET
24 #15 OR #16 OR #17 OR #
18 OR #19 OR #20 OR #21
OR #22 OR #23 AND CEN-
TRAL:TARGET
25
MESH DESCRIPTOR Ther-
apeutic Irrigation AND CEN-
TRAL:TARGET
26 MESH DESCRIPTOR
Nasal Lavage EXPLODE ALL
AND CENTRAL:TARGET
27MESHDESCRIPTOR Ad-
ministration, Inhalation EX-
PLODE ALL AND CEN-
TRAL:TARGET
28MESHDESCRIPTOR Ad-
ministration, Intranasal EX-
PLODE ALL AND CEN-
TRAL:TARGET
29 MESH DESCRIPTOR
Nasal Sprays EXPLODE ALL
AND CENTRAL:TARGET
30 MESH DESCRIPTOR
Buffers EXPLODE ALL AND
CENTRAL:TARGET
31 ((douch* or spray* or lavag*
or wash* or rinse* or rinsing
or irrigat* or pulsed or nebu-
36 ((nasal or intranasal or sinus
or nose or sinonasal) adj3 (irri-
gation* or rinsing or rinse* or
wash* or lavage or douch* or hy-
giene)).ab,kf,ti
37 exp Mineral Waters/tu
[Therapeutic Use]
38 34 or 35 or 36 or 37
39 14 and 38
gation* or rinsing or rinse* or
wash* or lavage or douch* or hy-
giene)).ab,kw,ti
36 33 or 34 or 35
37 14 and 36
Indexes=SCI-EXPANDED,
CPCI-S Timespan=All years
#13 #12 OR #11 OR #10
Indexes=SCI-EXPANDED,
CPCI-S Timespan=All years
#14 #13 AND #5
Indexes=SCI-EXPANDED,
CPCI-S Timespan=All years
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lise* or aerosol* or buffer* or
atomis* or atomiz* or (squeeze
and bottle))):AB,EH,KW,KY,
MC,MH,TI,TO AND CEN-
TRAL:TARGET
32 ((intranasal or inhalation*
or irrigator)):AB,EH,KW,KY,
MC,MH,TI,TO AND CEN-
TRAL:TARGET
33 #25 or #26 or #27 or #28 or
#29 or #30 or #31 or #32 AND
CENTRAL:TARGET
34 #24 and #33 AND CEN-
TRAL:TARGET
35 ((sterimar or NeilMed or
nasaline or navage or marimer
or physiomer or Emcur or
”simply saline“ or ”nasal mist“
or ayr or salex or ”otrovin
saline“ or ISCS or Prorhinel
or SSBI)):AB,EH,KW,KY,MC,
MH,TI,TO ANDCENTRAL:
TARGET
36 ((nasal or intranasal or sinus
or nose or sinonasal) ADJ3 (ir-
rigation* or rinsing or rinse* or
wash* or lavage or douch* or hy-
giene)):AB,EH,KW,KY,MC,
MH,TI,TO ANDCENTRAL:
TARGET
37
MESH DESCRIPTOR Min-
eral Waters EXPLODE ALL
WITHQUALIFIERTUAND
CENTRAL:TARGET
38 #34 or #35 or #36 or #37
AND CENTRAL:TARGET
39 #14 and #38 AND CEN-
TRAL:TARGET
CINAHL (EBSCO) ICTRP ClinicalTrials.gov LILACS
S37 S14 AND S36
S36 S32 OR S33 OR S34 OR
S35
S35 (MH ”Mineral Water/
TU“)
S34 TX (nasal or intranasal or
sinus or nose or sinonasal) N3
(irrigation* or rinsing or rinse*
rhinit* AND saline OR rhinit*
AND salt AND water
OR hayfever AND saline OR
hayfever AND salt AND water
via CRS Web
1 (rhinit* or Rhinoconjunctivi-
tis or conjunctivitis or hayfever
or ”hay fever“ or pollenosis or
pollinosis or SAR or PAR):AB,
EH,KW,KY,MC,MH,TI,TO
AND INSEGMENT
(TW:rhinit* OR TW:rinit OR
TW:hayfever
OR TW:”hay fever” OR TW:
pollinosis OR TW:pollenosis)
AND (TW:salin* OR TW: wa-
ter* OR TW: Agua*)
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or wash* or lavage or douch* or
hygiene)
S33 TX (sterimar or NeilMed
or nasaline or navage or
marimer or physiomer or Em-
cur or ”simply saline“ or ”nasal
mist“ or ayr or salex or ”otrovin
saline“ or ISCS or Prorhinel or
SSBI)
S32 S23 AND S31
S31 S24 OR S25 OR S26 OR
S27 OR S28 OR S29 OR S30
S30 TX (intranasal or inhala-
tion* or irrigator)
S29 TX (douch* or spray* or
lavag* or wash* or rinse* or rins-
ing or irrigat* or pulsed or neb-
ulise* or aerosol* or buffer* or
atomis* or atomiz* or (squeeze
and bottle))
S28 (MH “Buffers+”)
S27 (MH “Administration, In-
tranasal+”)
S26 (MH “Administration, In-
halation+”)
S25 (MH “Nasal Lavage+”)
S24 (MH “Therapeutic Irriga-
tion”)
S23 S15 OR S16 OR S17 OR
S18 OR S19 OR S20 OR S21
OR S22
S22 TX saline or ”sodium chlo-
ride“ or saltwater or hyper-
tonic* or hypotonic* or iso-
tonic* or hypersaline or ”seawa-
ter“ or seawater or ((salt* or
thermal or mineral or sulfur* or
bromic or iodic* or bromide or
iodine or bromine) and (water*
or solution*))
S21 (MH “Hypotonic Solu-
tions+”)
S20 (MH ”Mineral Water“)
S19 (MH “Sodium Chlo-
ride+”)
S18 (MH “isotonic
solutions+”)
S17 (MH “Saline Solution, Hy-
pertonic+”)
2 (saline or ”sodium chloride“
or saltwater or hypertonic* or
hypotonic* or isotonic* or hy-
persaline or ”sea water“ or sea-
water or ((salt* or thermal or
mineral or sulfur* or bromic or
iodic* or bromide or iodine or
bromine) and (water* or solu-
tion*))):AB,EH,KW,
KY,MC,MH,TI,TO AND IN-
SEGMENT
3 (sterimar or NeilMed or
nasaline or navage or marimer
or physiomer or Emcur or ”sim-
ply saline“ or ”nasal mist“ or ayr
or salex or ”otrovin saline“ or
ISCS or Prorhinel or SSBI):AB,
EH,KW,KY,MC,MH,TI,TO
AND INSEGMENT
4 (nasal or intranasal or si-
nus or nose or sinonasal)
AND (irrigation* or rinsing
or rinse* or wash* or lavage
or douch* or hygiene):AB,EH,
KW,KY,MC,MH,TI,T AND
INSEGMENT
5 #2 OR #3 OR #4
6 #1 AND #5
7 (nct*):AU AND INSEG-
MENT
8 #6 AND #7
via Clincialtrials.gov
( rhinitis OR hayfever OR
Rhinoconjunctivitis OR pol-
lenosis OR pollinosis OR ”hay
fever“ ) AND ( saline OR salt
AND water OR “sodium chlo-
ride” OR saltwater OR hyper-
tonic OR hypotonic OR iso-
tonic OR hypersaline OR ”sea
water“ OR seawater OR steri-
mar OR NeilMed OR nasaline
OR navage OR marimer OR
physiomer OR Emcur OR
”nasal mist“ OR ayr OR salex
OR ”otrovin saline“ OR ISCS
OR Prorhinel OR SSBI OR ir-
rigation OR rinsing OR rinse
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S16 (MH “Hypertonic Solu-
tions”)
S15 (MH “Solutions”)
S14 S10 OR S11 OR S12 OR
S13
S13 TX hayfever or ”hay fever“
or pollenosis or pollinosis or
SAR or PAR
S12 (MH “Conjunctivitis, Al-
lergic+”)
S11 (MH ”Rhinitis, Allergic,
Perennial“)OR (MH”Rhinitis,
Allergic, Seasonal“)
S10 S8 AND S9
S9 S4 OR S5 OR S6 OR S7
S8 S1 OR S2 OR S3
S7 TX allerg* or hypersensi-
tivit* or perennial or nonsea-
son* or season* or pollen* or
dust or hair* or dander ormite*)
S6 (MH “Hypersensitivity+”)
S5 (MH “Pollen+”)
S4 (MH ”Allergens+“)
S3 TX rhinit* or Rhinocon-
junctivitis or conjunctivitis
S2 (MH “Conjunctivitis”)
S1 (MH ”Rhinitis“)
OR wash OR lavage OR douch
OR douching OR hygiene OR
salt AND solution ) | Interven-
tional Studies
Appendix 2. Data extraction form
REF ID: Study title:
Date of extraction: Extracted by:
General comments/notes (internal for discussion):
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Flow chart of trial
Group A (Intervention) Group B (Comparison)
No. of people screened
No. of participants randomised - all
No. randomised to each group
No. receiving treatment as allocated
No. not receiving treatment as allocated
- Reason 1
- Reason 2
No. dropped out
(no follow-up data for any outcome avail-
able)
No. excluded from analysis1 (for all out-
comes)
- Reason 1
- Reason 2
1This should be the people who received the treatment and were therefore not considered ’dropouts’ but were excluded from all
analyses (e.g. because the data could not be interpreted or the outcome was not recorded for some reason)
Information to go into ’Characteristics of included studies’ table
Methods X arm, double/single/non-blinded, [multicentre] parallel-group/
cross-over/cluster-RCT, with x duration of treatment and x dura-
tion of follow-up
Participants Location: country, no. of sites etc.
Setting of recruitment and treatment:
Sample size:
• Number randomised: x in intervention, y in comparison
• Number completed: x in intervention, y in comparison
Participant (baseline) characteristics:
• Age:
• Gender:
• Main diagnosis: [as stated in paper]
• Type of allergic rhinitis: [persistent or intermittent as per
ARIA 2008 guidelines]
• Severity of allergic rhinitis: [mild or moderate/severe as per
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(Continued)
ARIA 2008 guidelines]
• Type of allergic trigger: [e.g. mites, pollens, animals, etc.]
• Other important effect modifiers, if applicable: (e.g.
comorbidity of asthma):
Inclusion criteria: [state diagnostic criteria used for allergic rhinitis,
polyps score if available]
Exclusion criteria:
Interventions Intervention (n = x): intervention name including tonicity,
method of administration [including volume], frequency of ad-
ministration, duration of treatment
Comparator group (n = y):
Use of additional interventions (common to both treatment
arms):
Outcomes Outcomes of interest in the review:
Primary outcomes:
• Disease severity, as measured by patient-reported symptom
score (such as the Total Nasal Symptom Score (TNSS)
questionnaire and visual analogue scales)
• Significant adverse effects: epistaxis
Secondary outcomes:
• Patient-reported individual symptom scores for the
following symptoms:
◦ nasal obstruction/blockage/congestion
◦ nasal discharge (anterior or posterior rhinorrhoea -
identify which one, or if both have been reported)
◦ nasal itching
◦ sneezing
• Health-related quality of life, using disease-specific health-
related quality of life scores, such as the Rhinoconjunctivitis
Quality of Life Questionnaire (RQLQ), Mini
Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ)
and Rhinitis Symptom Utility Index (RSUI)
• Health-related quality of life, using generic quality of life
scores, such as the SF-36, EQ-5D and other well-validated
instruments
• Other local adverse effects: local irritation/discomfort, aural
symptoms
• Endoscopic score (e.g. Lund-Mackay/Lund-Kennedy)
Other outcomes reported by the study:
• [List outcomes reported but not of interest to the review]
Funding sources ’No information provided’/’None declared’/State source of fund-
ing
Declarations of interest ’No information provided’/’None declared’/State conflict
Notes
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Quote: ”…“
Comment:
Allocation concealment (selection bias) Quote: ”…“
Comment:
Blinding of participants and personnel
(performance bias)
Quote: ”…“
Comment:
Blinding of outcome assessment (detection
bias)
Quote: ”…“
Comment:
Incomplete outcome data (attrition bias) Quote: ”…“
Comment:
Selective reporting (reporting bias) Quote: ”…“
Comment:
Other bias (see section 8.15)
Insensitive/non-validated instrument?
Quote: ”…“
Comment:
Other bias (see section 8.15) Quote: ”…“
Comment:
Findings of study: continuous outcomes
Results (continuous data table)
Outcome Group A Group B Other summary stats/Notes
Mean SD N Mean SD N Mean difference (95% CI), P values etc.
Disease-spe-
cific HRQL
(instrument
name/range)
Time point:
Generic
HRQL
(instrument
name/range)
Time point:
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(Continued)
Symptom
score (overall)
(instrument
name/range)
Time point:
Added total -
if scores re-
ported
separately for
each symptom
(range)
Time point:
Nasal
blockage/
obstruction/
congestion
(instrument
name/range)
Nasal
discharge (an-
terior or pos-
terior rhinor-
rhoea - specify
which one if it
is known)
(instrument
name/range)
Sneezing
(instrument
name/range)
Nasal itching
(instrument
name/range)
Endoscopic
score
(instrument
name/range)
Comments:
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Results (dichotomous data table)
Outcome Intervention Group A Group B Other summary
stats/notes
No. of people
with events
No. of people
analysed
No. of people
with events
No. of people
analysed
P values, RR
(95% CI), OR
(95% CI)
Epistaxis/
nosebleed
Nasal saline
Local irritation
(sore throat, oral
thrush, discom-
fort)
Nasal saline
Local adverse ef-
fects: Eustachian
tube dysfunction
Nasal saline
The following adverse effects will only be extracted if the comparison arm is one of the interventions indicated
Os-
teoporosis (min-
imum 6months)
INCS
Stunted growth
(children, mini-
mum 6 months)
INCS Can also be mea-
sured as average
height
Mood
disturbances
Oral steroids
Gastrointestinal
disturbances (di-
arrhoea, nausea,
vomiting, stom-
ach irritation)
Oral steroids
Antibiotics
Insomnia Oral steroids
Os-
teoporosis (min-
imum 6months)
INCS
Oral steroids
Skin irritation Antibiotics
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(Continued)
Anaphy-
laxis or other se-
rious allergic re-
actions such
as Stevens-John-
son syndrome
Antibiotics
An-
tihistamine and
decongestant ad-
verse
effects: somno-
lence, irritability,
insomnia, rhini-
tis medicamen-
tosa, prolonged
middle ear effu-
sion
Antihistamines/
decongestants
Comments:
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Kornkiat Snidvongs reviewed and edited the protocol. For the full review he screened abstracts, completed data extraction, reviewed
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We had initially stated that we would present the initial results by volume of saline solution. This was changed to show the primary
results by age of the participants within the study. This was because we felt it was more important to know whether the intervention
worked for the different population groups.
The published protocol contained conflicting statements on the inclusion of studies according to the duration of treatment and follow-
up. We modified the methods section to ensure consistency. There was no minimum duration of treatment and follow-up. Had results
been available after the completion of treatment we would have reported these as they may provide useful information regarding the
duration of effects of saline.
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